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ABSTRACT
The epidermal growth factor receptor (EGFR) is often aberrantly expressed in 
colorectal cancer, and several EGFR inhibitors have been approved for the treatment 
of cancer patients. However, the expression levels and prognostic significance of the 
EGFR reported for colorectal cancer varies between studies, and there has been no 
clear association between EGFR expression and response to the EGFR inhibitors. 
The aim of the present study was therefore to investigate the expression of the EGFR, 
HER-2, and IGF-IR in a panel of human colorectal tumour cell lines and their 
association with response to the EGFR and/or IGF-IR inhibitors. The expression 
pattern and clinical significance of the EGFR, EGFRvIII, phosphorylated EGFR, 
HER-2 and IGF-IR was also determined in the tumour specimens from 87 Dukes’ C 
colorectal cancer patients.
Overexpression of the EGFR, HER-2 and IGF-IR was found to be uncommon in 12 
human colorectal tumour cell lines. Of these, only DiFi cells overexpressed the 
EGFR, contained constitutively active EGFR and were highly sensitive to growth 
inhibition by anti-EGFR mAb ICR62 and the EGFR tyrosine kinase inhibitors (TKIs) 
gefitinib and erlotinib. While the anti-EGFR mAb and EGFR TKIs were found to 
have overlapping, but not identical modes of action, co-targeting the EGFR ligand 
binding domain and tyrosine kinase domain with a combination of mAb and TKI was 
not superior over targeting tumour cells with the single-agent in-vitro. In contrast, 
treatment with a combination of the EGFR inhibitors and an IGF-IR TKI was more 
effective than treatment with the single-agent.
Using three different anti-EGFR antibodies, >76% of 87 Dukes’ C colorectal cancer 
cases were found to be EGFR positive. Interestingly, 34% and 8% of the cases were 
also EGFRvIII and pEGFR positive, respectively. In addition, IGF-IR, EGFR, and 
HER-2 coexpression was found to be common (>62 %) in the 87 Dukes’ C patients. 
While EGFR, EGFRvIII, and HER-2 expression were predominantly cytoplasmic, 
60% of patients were found to express membranous IGF-IR. While no significant 
associations were found between patient survival and growth factor receptor 
expression, cytoplasmic expression of the EGFRvIII and coexpression of the IGF-IR, 
EGFR, and HER-2 was associated with improved response to radiotherapy.
Since there has been no clear association between EGFR expression and response to 
the EGFR inhibitors in clinical studies, the expression of IGF-IR has been associated 
with resistance to EGFR and HER-2 inhibitors in the experimental setting, and 
coexpression of the EGFR, EGFRvIII, IGF-IR and HER-2 was found to be common 
in colorectal cancer patients, these results provide a rationale for investigating the 
therapeutic benefit of co-targeting the IGF-IR, EGFR, and HER-2 in colorectal cancer 
patients and their potential as predictive factors for response to therapy with the 
EGFR inhibitors.
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CHAPTER ONE
Introduction
1.1 Background
Cancer is a major health problem, and is second only to heart disease as the leading cause 
of death in the western world (Jemal et <?/., 2005). At the beginning of the millennium, 
there were over 10 million new cancer cases, 6.2 million cancer deaths, and 22.4 million 
people living with cancer world-wide (Stewart & Kleihues, 2003). Data from the 
Surveillance, Epidemiology and End Results (SEER) program between 1992 and 2002 
ranks colorectal cancer the third most common cancer in men (after prostate and lung) 
and women (after breast and lung) in terms of incidence and mortality (Edwards et a l, 
2005), with lifetime probabilities for developing the disease being 1/17 and 1/18 
respectively (Gloeckler Ries et al, 2003). In the UK, colorectal cancer was accountable 
for 16,165 deaths in 2001 (Cancer Research UK, 2005). Therefore, there is a need for 
better preventative measures, or the identification of novel predictive factors or more 
specific therapeutic targets for this disease.
1.2 Cancer aetiology
The progression of a normal cell into a tumour cell (i.e. carcinogenesis) is a multi-step 
process, involving a series of genetic abnormalities (mutations) (Hanahan & Weinberg, 
2000). The accumulation of genetic mutations in human cancers may arise from the 
hereditary transfer of faulty DNA, via the sporadic mutation of genes over time, or due to 
mutations in DNA caused by chemical or viral carcinogens (Weinberg, 1994; Midgley & 
Kerr, 1999; Hanahan & Weinberg, 2000; Bronchud, 2002; Walker & Quirke, 2002).
1
Each of the acquired genetic mutations may confer a growth advantage on the cell, 
including self-sufhciency to growth signals, insensitivity to anti-growth signals, evasion 
of programmed cell death (apoptosis), limitless replicative potential, sustained 
angiogenesis, as well as tissue invasion and metastasis. These have been designated the 
hallmarks of human cancer (Hanahan & Weinberg, 2000).
1.2.1 Normal cell cycle regulation
The human body is composed of approximately 200 different types of cell. Cell division 
is essential for normal tissue growth and regeneration. While some cells (e.g. cells of the 
intestinal lining) divide continuously, other cells divide less frequently or lose their 
ability to divide and become specialised (Tortora & Grabowski, 2003).
Somatic cells undergo replication and division by traversing the tightly regulated cell 
cycle. As shown in Figure 1.1, the complete eukaiyotic cell cycle comprises G1 (Gapl),
5 (Synthesis), G2 (Gap2), and M (Mitosis) phase (Israels & Israels, 2001 ; Lui & Grandis, 
2002; Sandal, 2002; Tortora & Grabowski, 2003). Under normal physiological 
conditions, entry or exit from each of the 4 distinct phases of the mammalian cell cycle is 
tightly regulated by the Cyclin-dependent kinases (Cdk’s). In turn, the activity of the 
Cdk’s is regulated by the availability of the cyclin unit, (i.e. transcriptional regulation) 
phosphoiylation by the cdk-activating complex, dephosphoiylation by phosphatases, and 
by the cdk-inhibitors (e.g. p27^P'^) (Israels & Israels, 2001; Sandal, 2002; Vermeulen et 
al, 2003). In addition, a number of cell cycle checkpoints (e.g. R-point, G1 checkpoint, 
G2 checkpoint), prevent continuation of the cell cycle in the absence of growth factor and 
prevent the propagation of cells with genetic abnormalities (Israels & Israels, 2001; Lui
6  Grandis, 2002; Sandal, 2002).
New daughter cell
CDK4/6(CvolinD~)
Begin cycleMitosis (cell division) Growth factors, 
oncogenes, 
cyclins and CDKs
CDKl rCvclin A/B1
The cell cycle
Synthesis 
(doubling of 
DNA) -------
CDK2 ('Cvclin Tumor suppressor 
genes. CDK 
inhibitors
Restriction point 
(point of no re tu rn )----
CDK2 (Cvclin E)
Figure 1.1. The mammalian ceil cycle and its regulatory elements. Under normal 
physiological conditions, entry or exit from each of the 4 distinct phases of the 
mammalian cell cycle is tightly regulated by the availability and activation of the Cyclin- 
dependent kinases (Cdk’s), cdk-inhibitors, as well as the restriction point (R). Adapted 
from Sandal (2002).
Growth factors play a crucial role in cell cycle progression (Aaronson, 1991; Jones & 
Kazlauskas, 2000; Stull et al, 2002). A competent factor (e.g. EGF, PDGF, bFGF) 
drives cells out of GO through the early portion of G1 (GIE), and a progression factor 
(e.g. insulin, IGF-I) is then required to overcome the restriction point (R) in Gl. Once 
past the R-point cells can enter the S phase, and are committed to continue the cell cycle, 
even in the absence of growth factor (Aaronson, 1991 ; Jones & Kazlauskas, 2000; Stull et 
a/., 2002).
1.2.2 Loss of growth control in human cancer
As described above, the mutation of genes encoding proteins that regulate the cell cycle 
has been associated with the formation of human cancer (Weinberg, 1994; Hanahan & 
Weinberg, 2000; Kahlenberg et ah, 2003; Vermeulen et a/., 2003). Specifically, the 
predominant mutations identified in human cancers involve the gain-of-function of 
protooncogenes or the loss-of-fiinction of tumour suppressor genes (Weinberg, 1994; 
Hanahan & Weinberg, 2000; Kahlenberg et al, 2003).
The protooncogenes are a group of genes encoding proteins that are involved in normal 
growth and development and positively regulate the cell cycle. They encode proteins 
such as growth factors, growth factor receptors (e.g. ErbB), cytoplasmic enzymes (e.g. 
RaQ and transcription factors (e.g. Myc) (Weinberg, 1994; Sandal, 2002). A mutation in 
the protooncogene (i.e. oncogene formation) may result in the production of high level of 
a normal protein (e.g. EGF, EGFR) or the production of a constitutively active mutated 
protein (e.g. EGFRvIII, see below). Such changes in turn may lead to the activation of 
cell signal transduction pathways in the absence of a mitogenic signal and unregulated 
cell cycle progression (Weinberg, 1994; Shtutman et al, 1999; Sandal, 2002).
In contrast to the protooncogenes, tumour suppressor genes encode proteins that have a 
growth suppressing function. Mutation or loss of both alleles of the tumour suppressor 
gene (e.g. P53, RB, ARC) can result in the inability of the gene product to induce cell 
cycle arrest or apoptosis (Weinberg, 1994; Bhattachaiya & Boman, 1995; Goss & 
Groden, 2000; Lamlum et al, 2000; Sadot et a l, 2001). Consequently, protooncogene 
and tumour suppressor gene mutations have been demonstrated in a wide range of human 
malignancies, including colorectal cancer (Bhattachaiya & Boman, 1995; Shtutman et a l.
1999; Goss & Groden, 2000; Hanahan & Weinberg, 2000; Fodde et al, 2001; Kemp et 
a/., 2004).
1.3 Colorectal Cancer
Colorectal tumours are epithelial in origin, arising from the human colon wall and 
extending in to the deeper layers of the colon as the disease advances. The estimated 5- 
year survival rates range from 90% in patients with early (stage I) colorectal cancer, to 
less than 10% in patients with metastatic colorectal cancer (Venook, 2005a). While 
conventional forms of therapy are improving, the median survival of patients with 
metastatic colorectal cancer remains less than 2 years (Cohen et al, 2005) and there is a 
need for the identification of more specific targets for the therapeutic intervention of 
colorectal cancer.
1.3.1 Structure of the Colon
The large intestine is the terminal portion of the gastro-intestinal tract. As illustrated in 
Figure 1.2, the large intestine is divided in to the colon, rectum, and anal canal. The main 
functions of the large intestine are to drive the contents of the colon to the rectum, the 
absorption of water, ions, and vitamins, and defecation (Tortora & Grabowski, 2003). 
The colon is divided in to ascending, transverse, descending, and sigmoid sections 
(Figure 1.2). As shown in Figure 1.3, histogically, the principle regions of the large 
intestine are the mucosa, submucosa, musculaiis, and serosa.
The mucosa consists of a simple columnar epithelium, connective tissue, and smooth 
muscle. The epithelium consists mainly of absorptive (water absorption) and goblet cells 
(mucus secretion for lubrication of colonic contents), which are located in long, tubular
glands that extend the full thickness of the mucosa. The submucosa consists of 
connective tissue that binds the mucosa to the muscularis, and contains many blood and 
lymphatic vessels. The muscularis consists of an external layer of longitudinal smooth 
muscle and an internal layer of circular smooth muscle. The serosa is a serous membrane 
composed of connective tissue and epithelium (Tortora & Grabowski, 2003).
13.2 The development of colorectal cancer: from adenoma to carcinoma
Human colorectal cancers develop from a stem cell in the colonic ciypt of the colonic 
mucosa, either through the inheritance of a genetic defect or due to DNA damage by a 
currently unknown mechanism (Walker & Quirke, 2002; please also see section 1.3.4). 
However, it is widely accepted that the development of colorectal cancer follows the 
adenoma-carcinoma sequence in which colonic mucosa becomes hyperproliferative, 
undergoes adenomatous change, dysplasia, and malignant transformation (Fodde et ah, 
2001; Audisio, 2002; Walker & Quirke, 2002).
As shown in Figure 1.4, during this process, the temporal accumulation of at least seven 
mutations can occur, including one in the KRAS oncogene, and six mutations that 
inactivate both alleles of the suppressor genes ARC, SMAD4, and P53 (Fodde et al, 
2001; Smith et al, 2002). It is suggested that the temporal order of these mutational 
events rather than their accumulation is important for the development of colorectal 
cancer. Consequently, it may take 20-40 years for carcinomas to develop from the 
earliest stages of the adenoma- carcinoma sequence, known as aberrant crypt foci (ACF), 
and sporadic colorectal cancers generally arise at a median age of 70-75 years (Fodde et 
al, 2001; Walker & Quirke, 2002). However, the majority of large bowel cancers arise 
from pre-existing adenomatous polyps or adenomas.
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Figure 1.2. The human large intestine. Diagram illustrating the human 
gastrointestinal tract and the major regions of the large intestine. Adapted from (National 
Cancer Institute., 2005).
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Figure 1.3. The histology of the colon. Haematoxylin and Eos in stained section of 
the human colon, showing the major histological regions (Histology Laboratory Index., 
2005)
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Figure 1.4. The adenoma-carcinoma sequence. The events of the adenoma- 
carcinoma sequence, showing the temporal order of mutational events (Fodde et al, 
2001).
Approximately 5% of adenomatous polyps are estimated to become malignant, and this 
may take 5 to 10 years (Midgley & Kerr, 1999)
1.3.3 Staging systems for the classification of human colorectal cancers
The progressive nature of cancer has lead to the development of staging systems to 
standardise the extent of the disease and administer the most appropriate treatment 
(Compton & Greene, 2004). The tumour, node, metastasis (TNM) staging system of the 
American Joint Committee on Cancer (AJCC) and the International Union Against 
Cancer (UICC), is now the recommended colorectal cancer staging system (Compton &
Greene, 2004). As described in Table 1.1, this system describes the extent of the tumour 
(T), nodal (N), and metastatic (M) involvement. However, the preceeding Dukes’ and 
Astler-Coller staging systems are still commonly used to classify colorectal tumours. The 
three systems are used to determine the stage of colorectal tumours, as shown in Table 
1.2 .
13.4 Risk factors for colorectal cancer
Incidence of colorectal cancer is not uniform across the globe, with high-risk regions 
comprising North America, Europe, and Australia and low-risk regions including Africa, 
Asia, and Latin America (Stewart & Kleihues, 2003). The geographical variation in 
incidence rates of colorectal cancer, the observation of changing incidence rates with 
geographical location in twin and migrant studies, and observation of diet in patients with 
a family history of colorectal cancer, emphasize the importance of environmental factors 
in colorectal cancer (Bruce et a l, 2000; Hemminki et al, 2001; Slattery et al, 2003; 
Baker et a l, 2005).
While smoking, high alcohol, and high fat (saturated and animal) consumption are 
associated with increased risk (Anderson et a l, 2003; Slattery et al, 2003; Terry et a l, 
2003; Mathew et al, 2004; Sanjoaquin et al, 2004), the frequent intake of fruit and 
vegetables, folate, calcium, vitamin D, and the n-3 essential fatty acids (eicosapentanoic 
acid and docosahexanoic acid) are associated with decreased risk of developing colorectal 
cancer (Pence, 1993; Brenner et al, 1998; Lamprecht & Lipkin, 2003; Slattery et a l, 
2003; Mathew et a l, 2004; Nagothu et aï., 2004; Sanjoaquin et a l, 2004).
Table 1.1. The TNM staging system for the classification of colorectal cancers.
The categories of the tumour, node, metastasis (TNM) staging system of the AJCC and 
the UICC. Adapted from (Compton & Greene, 2004).
CATEGORY DEFINITION
Primary tumour (T)
TX Primary tumour cannot be assessed
TO No evidence of primary tumour
Tis Carcinoma in situ
T1 Tumour invades the submucosa
T2 Tumour invades the muscularis propria
T3 Tumour invades through the muscularis propria
T4 Tumour directly invades olher organs or structures (T4a) 
or perforates the visceral peritoneum(T4b)
Regional lymph nodes (N)
NX Regional lymph nodes caimot be assessed
NO No regional lymph node metastasis
N1 Metastasis in one to three lymph nodes
N2 Metastasis in four or more lymph nodes
Distant metastasis (M)
MX Presence of distant metastasis carmot be assessed
MO No distant metastasis
Ml Distant metastasis
Table 12, Staging systems for the classification of colorectal cancers. The
tumour, node, metastasis (TNM), Dukes’, and Astler-Coller staging systems Adapted 
from (Compton & Greene, 2004).
Stage TNM Category Dukes’ Stage Aslter-Coller
0 Tis, NO, MO N/A N/A
I T1,N0,M0 A A
T2,N0,M0 B1
DA T3,N0,M0 B B2
IIB T4,N0,M0 B3
IIIA T1-T2,N1,M0 C Cl
m B T3-T4,N1,M0 C2
m e Any T, N2, MO C3
IV Any T, Any N, Ml N/A D
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While the majority of colorectal cancers do not have a recognised inheritable cause, 
approximately 2 -6 % of all colorectal cancer cases involve inheritable syndromes that may 
predispose to colorectal cancer (Kemp et a l, 2004). Dominant inheritance syndromes 
include familial adenomatous polyposis (FAP), hereditary non-polyposis colon cancer 
(HNPCC), peutz jeghers syndrome , and juvenile polyposis .
HNPCC is the most common of the hereditary syndromes, accounting for 1-5% of all 
colorectal cancers. It is caused by mutations in human DNA repair genes (e.g. hMSH2, 
hMLHl, hMSH6, PMSl, and PMS2). Failure by these genes to repair cellular DNA may 
lead to frame-shift mutations or aberrant proteins due to altered numbers of repeat 
sequences (Walker & Quirke, 2002; Kemp et ah, 2004). The second most common 
hereditary syndrome, FAP, accounts for less than 1% of all colorectal cancers. Unlike 
HNPCC, multiple adenomatous polyps develop in the colon during the second and third 
decades of life in patients with FAP. Because the number of pre-malignant polyps may 
reach thousands in some patients, the chance of developing cancer is near 1 0 0 % by the 
age of 40 years (Midgley & Kerr, 1999; Goss & Groden, 2000). In FAP, mutation in the 
tumour suppressor gene APC results in reduced binding and consequential nuclear 
accumulation of the T-cell-factor (TCF) transcriptional co- activator P-catenin. The p- 
catenin/ LEF-l/TCF pathway modulates the transcription of genes that encode proteins 
involved in tumour progression and the cell cycle, such as Myc and cyclin D1 (Figure 
1.5; Bhattacharya & Boman, 1995; Shtutman et ah, 1999; Goss & Groden, 2000; Sadot et 
al, 2001 ; Walker & Quirke, 2002).
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13.5 Treatment for Colorectal Cancer
Colorectal cancer patients can be treated by several approaches, with the degree of 
success depending on the stage of the disease. For early stage colon cancers, the surgical 
re-section of involved colon is highly effective, with cure rates of over 90% and 75% for 
Stage I (Dukes’ A) and Stage II (Dukes’ B) patients, respectively (Markowitz et al,
2002). However, metastatic colorectal cancer is present in 20% of patients and develops 
in 30% of patients with localised disease at diagnosis (Markowitz et al, 2002). While 
30% of patients have localised métastasés that can be removed by surgery, adjuvant 
therapy is usually required to destroy metastatic colon cancer in distant sites (Macdonald, 
1999; Longley et a l, 2003).
The agent 5-Fluorouricil (5-FU), which inhibits DNA synthesis, has been the standard 
regime for advanced colon cancers for over 40 years, and treatment with a post- surgical 
course of 5- FU can reduce the recurrence rate in node positive colorectal cancer patients 
from 60% to 40% (Markowitz et al, 2002; Venook, 2005a). However, the biological 
modulator leucovoiin and newer chemotherapeutic agents such as irinotecan, oxaliplatin, 
and capecitabine have been used as monotherapy or in combination with 5-FU treatment 
to improve patient survival (O'Connell et a l, 1997; Thirion et al, 2004; Venook, 2005a; 
Venook, 2005b). For example, in a meta-analysis of 3300 colorectal cancer patients, the 
response rate to 5-FU/leucovorin was 21% compared to 11% in patients receiving 5-FU 
alone (Thirion et a l, 2004).
The addition of the topoisomerase I inhibitor irinotecan to 5-FU/lecovorin treatment is 
designated the FOLFIRI regime. In a phase III trial, single-agent irinotecan resulted in a 
longer overall survival (i.e. 10.8 months) than infrisional 5-FU/leucovorin (i.e. 8.5
12
months) in 5-FU refractory metastatic colorectal cancer patients (Rougier et al., 1998). 
In another study, combining irinotecan with 5-FU/Leucovorin as a first-line treatment for 
colorectal cancer patients was more effective than 5-FU/leucovorin alone, and the 
combination was approved by the US FDA for the first-line treatment of metastatic 
colorectal cancer (Saltz et al, 2000).
The addition of the DNA cross-linker oxaliplatin to 5-FU/leucovorin treatment is 
designated the FOLFOX regime. Encouraging clinical trials led to the US FDA approval 
of oxaliplatin in combination with infrisional 5-FU/leucovorin as second-line therapy of 
metastatic colorectal cancer patients following treatment with irinotecan and 5- 
FU/leucovorin (Rothenberg et a l, 2003; Venook, 2005a). This regime has recently been 
approved for the first-line treatment of metastatic colorectal cancer patients (Venook, 
2005a). In addition, Capecitabine, an oral pro-drug of 5-FU, was approved in 2002 as 
monotherapy for the fist line treatment of metastatic colorectal cancer (Venook, 2005a).
In contrast to patients with tumours of the colon where distant métastasés require 
systemic treatment with chemotherapy, approximately 50% of rectal cancer recurrences 
are local and occur in the pelvis. Such local recurrences are amenable to treatment with 
radiotherapy (Midgley & Kerr, 1999; Markowitz et al, 2002). Several clinical studies 
have shown pre-operative radiotherapy to decrease local recurrence, decrease failure 
rates, and increase overall survival in rectal cancer patients (Gerard et a l, 1988; James et 
al, 1991; Midgley & Kerr, 1999). Consequently, the combination of chemotherapy and 
radiotherapy is the standard treatment for Stage II (Dukes’ B) and Stage III (Dukes’ C) 
rectal cancer tumours (Midgley & Kerr, 1999; Markowitz et al, 2002; Lidder & Hosie, 
2005).
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Despite improvements in adjuvant therapy, the outcomes of treatment for locally 
advanced and metastatic colorectal cancer remains disappointing with 5-year survival 
rates of less than 10% in patients with metastatic disease (Figueredo et a l, 2004; Baddi & 
Benson, 2005; Johnston, 2005; Venook, 2005a). There is therefore the urgent need to 
identify novel predictive markers and therapeutic targets in patients with colorectal 
cancer. In particular, aberrant expression of growth Actor receptors has been reported in 
a wide range of human malignancies, and in some cases this has been associated with a 
poor prognosis (Hanahan & Weinberg, 2000; Normarmo et a l, 2003). Recently, the anti- 
VEGF antibody bevacizumab has been approved for the first-line treatment of metastatic 
colorectal cancer patents in combination with 5-FU based regimes, and the anti-EGFR 
monoclonal antibody cetuximab has also been approved for treatment of colorectal cancer 
patients (Modjtahedi, 2005; Venook, 2005a). The EGFR inhibitors will be discussed in 
more detail in the later sections.
1.4 Growth factor receptors with tyrosine kinase activity
Tyrosine kinases are enzymes that transfer y-phosphate groups fi’om ATP to the hydroxyl 
group of protein tyrosine residues. The tyrosine kinases are vital for communication 
within an individual cell and between cells of multicellular organisms, relaying signals 
fi'om the extracellular environment to the nucleus of the cell (Blume-Jensen & Hunter,
2001). There are over 90 tyrosine kinase genes in the human genome, which can be 
divided in to receptor and non-receptor tyrosine kinases. There are 58 receptor tyrosine 
kinase genes, which can be grouped in to approximately 2 0  fiinctionally related 
subfamilies (Blume-Jensen & Hunter, 2001). The most recognised of these are the type 
I-in families of receptor tyrosine kinases, which are generally identified by the EGFR,
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IGF-TR, and PDGFR, respectively (Yarden & Ullrich, 1988; Ffackel et a l, 1999). The 
EGFR and IGF-IR are the main focus of this study and will be discussed in detail in the 
following sections.
1.4.1 The type-I growth factor receptor family
The type I growth factor receptor family comprises four members: ErbBl (EGFR/HERl); 
ErbB2 (HER2/Neu); ErbB3 (HER3); and ErbB4 (HER4). Each member, in their native 
state, is generally characterised by an extracellular domain with two cysteine rich regions 
for high-afifinity ligand binding, a transmembrane region, and an intracellular domain 
with tyrosine kinase activity (Yarden & Ullrich, 1988). The exceptions are ErbB2/HER2 
for which no ligand has yet been described, and ErbB3/HER3, which has impaired kinase 
function (Hackel et al, 1999). As will be described in more detail in the following 
sections, the various ErbB molecules are able to homodimerise with an identical ErbB 
molecule or heterodimerise with another member of the ErbB family to initiate a variety 
of cellular signalling processes. The results of experimental studies suggest that the three 
most commonly formed heterodimers are ErbB2/ErbB3, ErbB2/ErbB4, and 
ErbBl/ErbB4, with ErbB2 being the preferred dimérisation partner for the other ErbB 
molecules (Graus-Porta er a/., 1997;Normanno et a l, 2003).
The four ErbB molecules are important in normal mammalian development. Mice 
lacking the ErbB 1-4 molecules have been shown to die within 14 days of birth (Yarden, 
2001; Normanno et al, 2003; Casalini et al, 2004). However, expression of each of the 
ErbB molecules has been reported in malignancies from a range of human tissues 
(Normanno et a l, 2003). The ErbB molecules are responsible for mediating the 
biological effects of the EGF-family of ligands. These include the epidermal growth
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factor (EGF), transforming growth factor alpha (TGFa), heparin binding EGF (HB- 
EGF), amphiregulin (AR), betacellulin (BTC), epiregulin (EPI), and epigen (Cohen, 
1962; Anzano et al, 1982; Shoyab et al, 1989; Higashiyama et al, 1992; Shing et al, 
1993; Toyoda et a l, 1995; Strachan et al, 2001; Harris et al, 2003). In addition, the 
EGF-family of peptides also contains the neuregulin (NRG) subfamily (consisting of 
NRG-1, NRG-2, NRG-3 and NRG-4). The NRG-1 family also includes the heregulins 
(Normanno et al, 2003). As shown in Table 1.3, the different ErbB molecules vary in 
their ability to bind to the EGF-like ligands. The binding of the EGF-like ligands to their 
cognate receptors initiates a cascade of events that ultimately control cell growth and 
proliferation, angiogenesis, cell survival, and cellular differentiation (Beerli & Hynes, 
1996; Yarden, 2001; Arteaga, 2002; Normanno et a l, 2003).
1.4.2 The structure of the EGFR
The EGFR is a 170kDa transmembrane glycoprotein with tyrosine kinase activity. The 
EGFR gene is located across 110Kb on chromosome 7pl 1-13. It encodes an 1186 amino 
acid (aa) protein comprising a 622aa extracellular domain, a single pass alpha-helical 
transmembrane domain (approximately 22aa), and a 542aa intracellular domain. The 
extracellular domain consists of four domains LI, CRl, L2, and CR2. Ligand binding 
occurs between the beta-helical structures of the LI and L2 domains (Carpenter, 1987; 
Wells, 1999; Jorissen et a l, 2003). The intracellular region consists of three domains: a 
50aa juxtamembrane region Wiich can regulate EGFR kinase activity, receptor 
autophosphoiylation, and allow interaction with PKC, MAPK, and G proteins (Cochet et 
al, 1991; Northwood et al, 1991; Poppleton et al, 1999; Wells, 1999) a 250aa 
contiguous tyrosine kinase domain, and a 229aa carboxy- terminal tail. The cytoplasmic 
tail contains five tyrosine autophosphoiylation sites (three major at 1068,1148, and 1173
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Table 13. The ErbB receptors and their cognate ligands. Adapted from (Normanno 
gtaZ.,2003)
RECEPTOR LIGAND
EGFR/ErbBl Epidermal growth factor 
Transforming growth factor-a 
Amphiregulin 
Epiregulin 
Betacellulin 
Epigen
HB-EGF
HER-2/ErbB2 Unknown
HER-3/ErbB3 Neuregulin (NRG)-1 /heregulin (HRG) isoforms 
NRG-2a and p 
NRG-1/HRG isoforms
HER-4/ErbB4 NRG-2a and p 
NRG-3 
NRG-4 
Epiregulin 
Betacellulin 
HB-EGF
17
TGF-a EGF Epiregulin p-cellulin HB-EGF Amphiregulin
(1) (1) (1.4) (1) (1.4} (1) Ligands
Input
layer
Receptor
dimers
Adaptors
and
enzymesV a v l?rp2)fGAP
Ras-GTP
Signal-processing 
layer Cascades
Transcription
factors
Output Capo^osi  ^(proBferatio^^nglogenes^ ^ Maturation) (^Migrafion^^Adhesion^ ^  Invasion ^  ^ ifferentiatio^ 
layer
Figure 1.5. The EGF-like ligands and the multilayered EGFR signalling network.
The EGFR signalling network is highly complex. The input layer (A) contains receptors 
and ligands, and the cytosol (B) contains multiple layers of enzymes, adaptor proteins, 
second messengers and transcription factors. The output layer (C) includes a variety of 
biological outputs. Key; 1: EGFR/ErbB-1; 2: HER2/ErbB-2; 3: HER3/ErbB-3; 4: 
HER4/ErbB-4; Adapted from (Arteaga, 2002).
and two minor at 992 and 1086)(Downward et a l, 1984; Margolis et al, 1989; Walton et 
al, 1990), sites for c-Src phosphorylation (tyrosine 845), sites for EGFR recruitment in to 
clathrin coated pits for internalisation (e.g. tyrosine 974), as well as regions for the 
regulation of signal transducers and activators of transcription (STATs) (e.g. tyrosine 
954-tyrosine 974, and tyrosine 1114-glutamic acid 1172) (Carpenter, 1987; Chang et al, 
1993; Sato et al, 1995; Sorkin et al, 1996; Wells, 1999; Xia et al, 2002; Jorissen et al.
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2003). Activation of the EGFR is therefore the initiating event for the regulation of 
multiple signal transduction molecules (Figure 1.5).
1.4.3 The EGFR signalling network
The EGFR exists as an inactive monomer, however, the binding of ligand to the external 
domain of the EGFR induces receptor homodimerisation or heterodimerisation with 
another member of the EGFR family (Carpenter, 1987; Wells, 1999; Jorissen et al,
2003). This ultimately results in the activation of the intrinsic tyrosine kinase domain and 
tyrosine autophosphoiylation. This autophosphoiylation creates binding sites for Src- 
homology-2 (SH2) and phosphotyrosine-binding (PTB)-domain-containing proteins that 
include enzymes that are phosphoiylated and activated (Src, PLCy, PI3K), and adaptor 
molecules linking the receptor to downstream pathways (She, Grb2, Grb7, Nek) (Hackel 
et al, 1999; Schlessinger, 2000). The EGFR family member activation pathway 
however, is a multilayered network with two activation pathways dominating cell 
signalling. The major activation pathways of the EGFR include the Ras-Raf-MAPK 
pathway which is linked to cell proliferation, survival, and transformation, and the PI3K- 
pathway responsible for cell growth, proliferation, survival, and motility (Figure 1.5; 
Carpenter, 1987; Wells, 1999; Jorissen et al, 2003; Mendelsohn & Baselga, 2003).
In the MAPK pathway Grb2 interacts with phosphorylated EGFR tyrosines via its SH2 
domain, and the Grb2 (adaptor)/Sos (Ras exchange factor) complex activates Ras through 
GDP-GTP exchange, which in turn activates the serine/threonine kinase Raf-1. This 
phosphorylates and activates MEK, which in tum phosphorylates threonine 202/tyrosine 
204 on Erk-1 and Erk-2 (MAPK), allowing Erkl/2 nuclear translocation and the catalysis 
of phosphoiylation of a number of nuclear transcription factors (Hackel et al, 1999;
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Schlessinger, 2000; Jorissen et al, 2003). In addition, the Grb2/Sos complex can also be 
recruited to the cell membrane via She vriiich binds to the phosphoiylated EGFR via its 
PTB domain or by binding to the IRS-1 docking protein which is important for IGF-IR 
signalling (see section 1.9.1; Schlessinger, 2000).
The PI-3K molecule is composed of a p85 regulatoiy unit and a pi 10 phospolipid kinase. 
The EGFR only weakly binds the p85 subunit of PI-3K, and PI-3K forms a complex with 
phosphorylated EGFR via the docking protein Gabl. In addition, PI-3K may bind other 
receptors directly (e.g. HER3) or via IRS-1 (e.g. IGF-IR). Activated PI-3K 
phosphoiylates phosphatidylinositol (4) phosphate and phosphatidylinositol (4,5) bi­
phosphate. The resultant phosphatidylinositol (3, 4, 5) triphosphate in tum recmits a 
number of proteins, including the serine/ threonine kinase phosphoinositide-dependent 
kinase-1 (PDKl) and Akt (PKB) via the binding of their PH domains to membrane 
phospholipids. The Akt molecule is then activated by phosphoiylation at threonine 308 
and serine 473 by PDK. Activated Akt is released from the cell membrane and may then 
lead to decreased cellular apoptosis via phosphorylation (inactivation) of pro-apoptotic 
molecules such as BAD (Hackel et al, 1999; Schlessinger, 2000; Jorissen et a l, 2003).
However, EGFR activation can also lead to the recruitment of other signal transduction 
pathways. For example, phospholipase C gamma (PLCy) can bind to phosphoiylated 
tyrosines by its SH2 domain and catalyses the hydrolysis of phosphtidylinositol (4,5) 
biphosphate to yield the second messengers diacyl glycerol (DAG) and inositol 
triphosphate (EP3) leading to IP3 mediated calcium release from intracellular stores 
(affecting calcium dependent enzymes), and DAG assisted activation of PKC. In 
addition, EGFR activation can lead to ligand dependent- phosphorylation of the STATS,
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leading to ST AT homo-/ heterodimerisation, and translocation to the nucleus where they 
act as transcription factors (Hackel et al, 1999; Schlessinger, 2000; Jorissen et a l, 2003).
The EGFR activation pathway is therefore highly complex, and great signal diversity is 
achieved by the array of ligands with differing biological properties as well as the variety 
of ErbB homo- and hetero-dimeric complexes available (Figure 1.5). Indeed, the 
different ErbB homo-/heterodimers generate diverse and differing biological signals, due 
to the different adaptor proteins that they can recruit, and their different rates of 
internalisation and degradation. For example, the ErbB2/ErbB3 heterodimer has been 
shown to form the most potent ErbB signalling complex in terms of cell proliferation and 
transformation (Graus-Porta et a l, 1997; Normanno et a l, 2003). Unlike ErbBl, the 
ErbB2, ErbB3, and ErbB4 molecules have been shown to have impaired ligand induced 
endocytosis and degredation (Baulida et a l, 1996). Consequently, while EGF-induced 
ErbBl homodimers are targeted for lysosomal degredation, ErbBl/ErbB2 and 
ErbBl/ErbB3 heterodimers dissociate in the early endosome and are recycled to the cell 
surface where they can continue to signal (Lenferink et al, 1998). In addition, 
phosphoiylation of ErbBl and ErbB2 and their signal transduction via Grb2 or PI-3K has 
been shown to depend on their dimérisation partner (Olayioye et a l, 1998). For example, 
while ErbBl and ErbB2 can activate MAPK and Akt, and ErbBl homodimers associate 
with c-Cbl to initiate ubiquitination and consequent degradation, c-Cbl does not associate 
with ErbBl/ErbB2 heterodimers (Muthuswamy et a l, 1999).
Due to the complex nature of the EGFR signalling network, inhibition of the EGFR in 
cancer cells may depend upon multiple factors, including the availability of the various
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EGFR ligands, heterodimerisation with other ErbB molecules, as well as cross-talk with 
heterologous receptor systems (e.g. IGF-IR; please see Figure 1.6).
1.5 The role of the EGFR in human malignancies
The EGFR has an important fiinction in normal mammalian development. The targeted 
knockout of the EGFR in mice allows embryonic development suggesting that the EGFR 
may be dispensable for the proliferation of all cell types essential for normal 
physiological functions. However, mice lacking the EGFR only survive for 18 days, and 
although mice with impaired EGFR tyrosine kinase (TK) activity are viable and fertile, 
they have hair skin and eye abnormalities (Sibilia & Wagner, 1995; Threadgill et al, 
1995; Luetteke et a l, 1999). As shown in Figure 1.6, signalling via the EGFR may 
become deregulated in human malignancies via several mechanisms (Arteaga, 2002). 
The deregulation of EGFR activation in cancer may be a result of EGFR overexpression 
(Mayer et a l, 1993; Kopp et al, 2003), persistent activation by the EGFR ligands (i.e. via 
autocrine, paracrine or juxtacrine ligand) (Rubin Grandis et al, 1998; Espinoza et al,
2004), EGFR mutation (e.g. EGFRvIII) (Haley et al, 1989; Lal et al, 2002; Lammering 
et al, 2003), or heterodimerisation with other family members (e.g. the HER-2) and 
cross-talk with heterologous receptors (e.g. IGF-IR)(Lu et al, 2001; Camirand et al, 
2002; Wang et a l, 2002; Knowiden et al, 2003).
The biological consequence of EGFR activation include cell adhesion (Anklesaria et al, 
1990), increased angiogenesis (Yen et a l, 2002) increased proliferation, reduced 
apoptosis, and protection from radiation-induced cell death (Dent et al., 1999; Giralt et 
al, 2002; Wang et a l, 2002; Mendelsohn & Baselga, 2003; Herbst, 2004). These 
changes are among the hallmarks of human cancer (Hanahan & Weinberg, 2000).
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Figure 1.6. The mechanisms of EGFR deregulation in human cancer. The
principle ways that EGFR signalling may become deregulated, leading to cancer. S = 
substrate; K = tyrosine kinase; pY = phosphorylated tyrosine residue (Arteaga, 2002).
The expression of the EGFR has been reported in a range of human tumours, including 
breast (Pekonen et al, 1988; Foekens et al, 1989), head and neck (Hoffmann et al,
2001) NSCLC (Rusch et al, 1993; Kanematsu et al, 2003), gastric (Ghaderi et al,
2002), ovarian (Elie et al, 2004), and colorectal cancer (Goldstein & Arm in, 2001; 
Nicholson et al, 2001; McKay et al, 2002b). In addition, in some studies, EGFR 
expression been associated with advanced tumour stage (Niikura et a l, 1996; Ghaderi et 
al, 2002; Putti et a l, 2002; Espinoza et al, 2004; Spano et al, 2005), resistance to 
standard therapies (Dent et al, 1999; Ciardiello et al, 2000; Sirotnak et a l, 2000; Magne 
et al, 2001 ; Giralt et al, 2002; Milas et a l, 2004), and poor prognosis (Nicholson et al.
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2001). However, the percentage of patients expressing the EGFR differs between the 
studies reported in the literature, and there has been no clear correlation between EGFR 
expression and response to the EGFR inhibitors (Steele et al, 1990b; Nicholson et al, 
2001; McKay et al, 2002b; Ciardiello & Tortora, 2003; Kopp et a l, 2003; Ooi et al, 
2004; Italiano et a l, 2005; Modjtahedi, 2005; Spano et a l, 2005).
1.6 EGFR mutations in human malignancies
In addition to the wild-type EGFR, there are several known deletion mutant forms of the 
EGFR (Wells 1999). In contrast to the wild type EGFR, the type I mutant form of EGFR 
is structurally similar to the v-ErbB oncogene, has a deletion of the extracellular domain 
(due to translation initiation at amino acid 543) and is incapable of binding EGFR ligands 
(Humphrey et a l, 1988; Jorissen et al, 2003). The type II mutation has a deletion of 83 
amino acids in domain IV of the wild type EGFR, and is capable of binding EGF and 
TGFa and inducing tyrosine kinase activation (Humphrey et al, 1991). The type III 
deletion mutant form of the EGFR (EGFRvIII, A801EGFR, de2-7 EGFR) is the most 
commonly described EGFR variant. Characterised by a deletion of amino acids 6-273 
from the external domain of the wild type EGFR, the EGFRvIII is ligand-independent 
and has a constitutively active tyrosine kinase domain (Yamazaki et al, 1988; Haley et 
al, 1989; Yamazaki et al, 1990; Ekstrand et a l, 1995; Pedersen et a l, 2001).
The expression of EGFRvIII has been associated with a number of tumorigenic 
processes, including cell transformation, increased motility and invasion, and resistance 
to radiotherapy (Haley et a l, 1989; Lal et al, 2002; Lammering et a l, 2003). While the 
primary and secondary structure of the EGFRvIII intracellular domain is the same as the 
native receptor, and although EGFRvIII can bind Grb/Sos complexes implicating
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activation of the Ras-Raf-MAPK kinase pathway, low levels of Ras-GTP and MAPK 
activity in EGFRvIII expressing cells suggest this is unlikely to be the primary 
proliferative and transforming pathway of the EGFRvIII (Montgomery et al, 1995; 
Moscatello et a l, 1998; Pedersen et al, 2001). The EGFRvIII is however associated with 
constitutive activation of PI-3K (Moscatello et al, 1998) which has been shown to 
downregulate the cell cycle inhibitor p27 via the activation of the PI3-K/Akt pathway 
(Narita et a l, 2002). The EGFRvIII may therefore utilize a different pathway to activate 
signal transduction molecules Wren compared to the wild-type EGFR (Figure 1.5; 
Lorimer & Lavictoire, 2001).
Interestingly, like the wild-type EGFR, the EGFRvIII has also been shown to interact 
with other homologous and heterologous growth factor receptors, hr one study, the 
EGFRvIII was shown to heterodimerise with the HER-2 to elevate HER-2 
phosphorylation in MCF-7 breast cancer cells (Tang et a l, 2000). Similarly, in another 
study, IGF-1 (the principle ligand of the IGF-IR) was shown to increase the production of 
VEGF via the PI-3K pathway in NIH3T3 cells transfected with the EGFRvIII (Clarke et 
al, 2001). Expression of the EGFRvIII has been reported in 39% of NSCLC, 57% of 
high-grade gliomas, 8 6 % of low-grade gliomas, 6 6 % of pedriatic gliomas, 8 6 % of 
medullablastomas, 78% of breast carcinomas, 73% of ovarian carcinomas, as well as 
prostate and stomach cancers. The expression of the EGFRvIII however, is uncommon in 
non-malignant tissues (Moscatello et al, 1995; Olapade-Olaopa et a l, 2000; Pedersen et 
al, 2001; Olapade-Olaopa et al, 2004), making it an ideal target for therapy with 
EGFRvIII specific agents.
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Interestingly, several recent studies have detected the presence of mutations at exons 18- 
21 in the region encoding the tyrosine kinase domain of the EGFR. These mutations 
have been associated with an improved response to treatment with the EGFR tyrosine 
kinase inhibitors (TKIs) in some patients with NSCLC (Lynch et al, 2004; Paez et a l, 
2004; Pao et a l, 2004). In contrast to NSCLC, a recent study has reported that these 
activating EGFR mutations are rare in colorectal cancer and may not confer sensitivity to 
gefitinib and chemotherapy (Ogino et al, 2005). However, the prognostic significance 
and predictive value of the EGFR mutations in human colorectal tumours is unclear.
1.7 The expression and prognostic significance of the EGFR in colorectal cancer
In colorectal cancer, the expression of EGFR reported in the literature ranges fi*om 8 % to 
100% of the cases examined (Magnusson et al, 1989; Moorghen et al, 1990; Steele et 
al, 1990b; Ooi et al, 2004; Italiano et al, 2005; Spano et al, 2005). For example, Ooi 
and colleagues (2004), have shown EGFR expression in 8 % of244 stage I-IV (Dukes’ A- 
D) colorectal cancer patients using immunohistochemistiy (Ooi et a l, 2004). In contrast, 
Moorghen and colleagues (1990) found EGFR expression in 100% of 19 stage I-III 
colorectal cancer patients using ^^ I^-EGF ligand binding studies (Moorghen et a l, 1990).
In addition, the expression of the EGFR in colorectal cancer patients has been associated 
with a poor prognosis in some studies (Mayer et a l, 1993; Kopp et a l, 2003), while no 
such association has been found in other studies (Magnusson et a l, 1989; Goldstein & 
Armin, 2001; Lee et al, 2002; McKay et a l, 2002b; Khorana et a l, 2003; Spano et al, 
2005). The apparently conflicting evidence on the expression pattern and prognostic 
significance of the EGFR may stem fi-om the variety of methods used for determining 
receptor expression. Indeed, EGFR expression in colorectal cancer has been investigated
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using ligand (^^ I^-EGF) binding assays (Magnusson et a l, 1989; Kopp et a l, 2003), in- 
situ hybridisation (Komuta et a l, 1995; Ooi et al, 2004), PCR (Ge et a l, 2002), ELISA 
(Messa et al, 1998) and immunohistochemistiy (McKay et al, 2002b; Ooi et al, 2004; 
Italiano et a l, 2005; Spano et al, 2005). Interestingly, in a recent study involving 
NSCLC patients, the phosphorylation status of the EGFR (Tyr845), not overexpression of 
the EGFR, has been associated with a poor prognosis and the pathogenesis of NSCLC 
(Kanematsu et al, 2003). Consequently, further studies investigating the expression 
pattern and prognostic significance of the EGFR and the relative contribution of the 
EGFRvIII and phosphorylated EGFR (pEGFR) in EGFR positive colorectal cancers are 
warranted. This was one of the major aims of the present study.
In addition to the EGFR, aberrant expression of the ErbB-2 (HER-2), ErbB3, and ErbB4 
molecules have been demonstrated in a range of human cancers, including colorectal 
cancer (Normanno et a l, 2003). In particular, the expression of HER-2 has been reported 
in tumours from breast, pulmonary, gastric and colorectal cancer patients (Slamon et al, 
1987; Toikkanen et a l, 1992; Kay et al, 1994; Sun et al, 1995; Osako et al, 1998; 
Gharesi- Fard et a l, 2000; Koeppen et a l, 2001; Ghaderi et al, 2002; McKay et al, 
2002a; Essapen et a l, 2004). While the clinical significance of HER-2 expression has 
been established in breast cancer patients, with strong membranous HER-2 expression 
associated with poor prognosis and good response to the anti-HER-2 mAh trastuzumab, 
the clinical significance of HER-2 in colorectal cancer remains unclear (Slamon et al, 
1987; Toikkanen et al, 1992; Kay et a l, 1994; Sun et al, 1995; Osako et al, 1998; 
McKay et al, 2002a; Essapen et al, 2004). Since the EGFR can heterodimerise with the 
HER-2 and EGFR/HER-2 heterodimers are distinct from EGFR homodimers in terms of 
signal transduction, as well as rates of internalisation and degradation (Baulida et al,
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1996; Normanno et al, 2003), further studies investigating the coexpression pattern and 
prognostic significance of the EGFR and HER-2 in colorectal cancer patients are also 
warranted.
1.8 The EGFR as a biological target in cancer therapy
Since the early 1980s, a number of strategies have been developed for targeting the 
EGFR in human tumours. These include the use of ligand antagonists, tyrosine kinase 
inhibitors, antisense technology, antibodies to the receptor or its ligands, and EGFR- 
directed vaccine approaches (Modjtahedi et al, 1993a; Modjtahedi & Dean, 1994; 
McCormick, 2001; Espinoza-Delgado, 2002; Jansen & Zangemeister-Wittke, 2002; 
Wakeling, 2002; Mendelsohn & Baselga, 2003; Albanell & Gascon, 2005). Two of the 
most clinically advanced strategies are the monoclonal antibody (mAb) based therapies 
and the use of small molecule tyrosine kinase inhibitors (TKIs).
1.8.1 The anti-EGFR monoclonal antibodies
There are currently a number of anti-EGFR monoclonal antibodies (mAbs) that are at 
different stages of clinical development (Table 1.4). The mAh cetuximab is the most 
clinically advanced of the anti-EGFR antibodies. Cetuximab (IMC-C225) binds to the 
external domain of the EGFR and blocks the binding of EGF and TGFa to the EGFR, 
subsequently preventing ligand-induced tyrosine phosphoiylation of the receptor (Wu et 
al, 1995; Mendelsohn, 1997; Liu et al, 2000; Liu et al, 2001). Cetuximab has been 
shown to inhibit the growth of a number of EGFR expressing cell lines, and the results of 
several pieclinical studies suggest that cetuximab exerts its anti-tumour effects by 
inducing G1 arrest via up regulation of the cyclin-dependent kinase inhibitor p27^'^'\ 
reducing angiogenesis via interleukin- 8  (EL-8 ) downregulation, and via the induction of
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endothelial cell apoptosis (Fan et a l, 1994; Wu et al, 1995; Liu et al, 2001 ; Karashima 
et al, 2002; Mendelsohn & Baselga, 2003).
Several phase II clinical trials have shown that cetuximab is effective as a single agent 
and in combination with irinotecan for the treatment of EGFR expressing irinotecan 
refractory metastatic colorectal cancer patients (Cunningham et al, 2004; Saltz et al,
2004). Consequently, on February 12,2004, the U.S. FDA approved cetuximab for use in 
combination with irinotecan in the treatment of patients with EGFR expressing, 
metastatic colorectal cancer that are refractory to irinotecan-based chemotherapy 
(Modjtahedi, 2005; Vallbohmer & Lenz, 2005). However, in the phase II study by 
Cunningham and colleagues (2004), cetuximab as a single agent showed a response rate 
of only 10.8%, median response duration of 4.2 months, and a median time to disease 
progression of 1.5 months. While cetuximab in combination with irinotecan was slightly 
more effective, there was still only a response rate of only 22.9%, a median duration 
response of 5.7 months, and a median time to disease progression of 4.1 months 
(Curmingham et al, 2004). Additionally, the phase II trials by Curmingham and 
colleagues and Saltz and colleagues failed to show an association between EGFR 
expression and response to cetuximab (Cunningham et al, 2004; Saltz et a l, 2004; 
Albanell & Gascon, 2005).
In addition to cetuximab, a number of other antibodies have been developed against the 
EGFR (Table 1.4). These include mAh ABX-EGF, mAh EMD72000, mAh hR3, and the 
ICR antibodies, such as mAh ICR62 [reviewed in (Modjtahedi, 2005)]. The mAh ABX- 
EGF is a folly human IgG2 mAh that binds to the EGFR with high affinity (5xlO'^^M) 
and blocks the binding of EGF and TGFa to the EGFR (Yang et a l, 2001).
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Table 1.4. EGFR inhibitors in clinical development. Example of current anti- 
EGFR monoclonal antibodies (mAbs) and EGFR tyrosine kinase inhibitors (TKIs) under 
investigation and their developmental stage in clinical trials. Adapted from (Giaccone, 
2005)
Class Agent Sponsor Property/
Target
Clinical
Stage
For detail see
mAb Cetuximab Imclone/Bristol- 
Myers Squibb
Chimeric
IgGl
Licensed (Mendelsohn & 
Baselga, 2003; 
Imclone, 2006)
ABX-EGF Abgenix Fully human 
IgG2
III (Yang et a/., 2 0 0 1 ; 
Abgenix, 2005)
EMD72000 EMD
Pharmaceuticals
Humanised
IgGl
II (Venook, 2005b; 
EMD, 2006)
h-R3 MediGene Humanised
IgGl
II (Crombet et a l, 
2001,2003)
ICR62 Institute of 
Cancer Research 
(ICR)
RatIgG2b I (Modjtahedi et a l, 
1993d, 1996)
TKI Gefitinib AstraZeneca Reversible
EGFR
Licensed (Albanell & 
Gascon, 2005; 
Astrazeneca, 
2006)
Erlotinib Roche, OSI 
Pharmaceuticals 
and Genentech
Reversible
EGFR
Licensed (Albanell & 
Gascon, 2005; 
OSI, 2006)
CI-1033 Pfizer Irreversible
EGFR,
HER-2,
HER-4
II (Albanell & 
Gascon, 2005; 
Campos et al., 
2005)
EKB-569 Wyeth Irreversible
EGFR
II (Rowinsky, 2004; 
Tejpar et ah, 
2004)
GW-572016 Glaxo SmithKline Reversible
EGFR,
HER-2
II (Rowinsky, 2004; 
GlaxoSmithKline, 
2006)
BMS-
599626
Bristol- Myers 
Squibb
EGFR,
HER-2,
HER-4
I (Giaccone, 2005; 
Garland et ah, 
2005)
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ABX-EGF induces EGFR internalisation, inhibits ligand-induced tyrosine 
phosphoiylation of the EGFR and inhibits the growth in-vitro and in-vivo of a range of 
tumours (pancreatic, renal, breast, and prostate) expressing various levels of the EGFR 
(Yang et ah, 2001 ; Sridhar et al, 2003). In a recent press release reporting the results of a 
randomized Phase III trial involving 463 patients, ABX-EGF was found to be the first 
EGFR inhibitor to demonstrate improvement in progression-fiee survival as monotherapy 
for metastatic colorectal cancer, with a 46 percent decrease in tumour progression rate 
versus those who received best supportive care alone (Abgenix, 2005).
In contrast to chimeric and fiilly-human anti-EGFR mAbs cetuximab and ABX-EGF, 
respectively, mAb EMD 72000 (matuzumab) is a humanised anti-EGFR mAb. In a phase 
I dose-escalated trial, in common to cetuximab, EMD 72000 was shown to abrogate 
EGFR phosphorylation and MAPK activation, and increase levels of the cell cycle 
inhibitor p27^'^\ without alteration of total EGFR expression (Vanhoefer et a l, 2004; 
Modjtahedi, 2005). The mAh h-R3, is another humanised anti-EGFR mAh that inhibits 
tumour cell proliferation, and has pro-apoptotic and anti-angiogenic effects (Crombet- 
Ramos et al, 2002; Modjtahedi, 2005). In a phase I clinical trial with patients with 
advanced epithelial- derived tumours, no evidence of severe toxicity was observed after 
the administration of h-R3, secondary reactions were only mild (fevers, vomiting), and no 
anaphylactic or skin reactions were detected (Crombet et a l, 2003).
The mAh ICR62 is an IgG2b rat mAh that has been raised against the external domain of 
the EGFR on the human breast carcinoma cell line MDA-MB468. The mAh ICR62 binds 
to epitope C on the EGFR, blocks ligand binding to the EGFR and inhibits the growth in- 
vitro and in-vivo of EGFR overexpressing tumour cells (Modjtahedi et a l, 1993b;
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Modjtahedi et a l, 1994; Modjtahedi et ah, 1998b). In addition to binding wild type 
EGFR, mAb ICR62 has also been shown to bind to the EGFRvIII and inhibit the in-vivo 
growth and metastasis of EGFRvIII expressing tumours in athymie mice (Modjtahedi et 
al, 2003). The ability of mAh ICR62 to induce the regression of tumour xenografts is 
attributed to the ability of the Fc domain of the antibody to elicit host immunological 
fimctions, such as antibody-dependent cellular-cytotoxicity (Modjtahedi et al, 2003). 
The results of a phase I trial with mAh ICR62 in patients with un-resectable squamous 
cell carcinoma demonstrated good localisation of this antibody to metastatic lesions 24 
hours post ICR62 treatment (Modjtahedi et a l , 1996).
In addition to the mAh ICR62 and cetuximab that can bind to the wild-type EGFR and 
EGFRvIII, several monoclonal antibodies specific for the EGFRvIII have also been 
developed (e.g. YIO, Ua30:2, mAb806). These antibodies can induce internalisation of 
the EGFRvIII thereby reducing cell-surface expression of the EGFRvIII, and 
consequently reducing the transforming activity of such receptors (Wikstrand et a l, 1995; 
Sridhar et al, 2003). The EGFRvIII specific antibodies, either unarmed or armed with 
cytotoxic agents, radioisotopes and toxins, have shown a promising role for EGFRvIII- 
mediated glioma therapy by repressing the growth of EGFRvIII expressing xenografts, 
preventing cellular proliferation, DNA synthesis, and specifically killing EGFRvIII 
expressing cells (Wikstrand et al, 1995; Kuan et a l, 2000; Sridhar et al, 2003). Future 
clinical trials should unravel the therapeutic potential of the anti-EGFRvIII agents in 
cancer patients.
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1.8.2 The small molecule tyrosine kinase inhibitors
The small molecule tyrosine kinase inhibitors (TKIs) are a new generation of receptor 
specific drugs that compete with ATP for binding to the tyrosine kinase domain of the 
receptor. In contrast to anti-EGFR mAbs that target the external domain of the EGFR, the 
small molecule tyrosine kinase inhibitors target the internal domain of the EGFR. As 
shown in Table 1.4, of the EGFR TKIs, gefitinib (ZD 1839; Iressa); and erlotinib (OSI- 
774; Tarceva) are the most clinically advanced (Albanell & Gascon, 2005; Giaccone,
2005). Gefitinib has been shown to inhibit the tyrosine kinase of purified EGFR with 
IC50 values of 23 to 79nM (Gilmore et al, 2002). In pre-clinical studies, gefitinib has 
been shown to decrease EGFR, MAPK, and Akt phosphoiylation and inhibit the growth 
in-vitro and in-vivo of a range of cell lines (e.g. breast, colorectal, NSCLC) with high and 
low levels of EGFR expression (Anderson et al, 2001 ; Anido et al, 2003; Janmaat et a l, 
2003; Xu et al, 2003; Ono et al, 2004; Albanell & Gascon, 2005; Giaccone, 2005). In 
addition, gefitinib has also been shown to inhibit the growth of HER-2 expressing cells 
with low EGFR expression (Anderson et a l, 2001; Moasser et al, 2001; Moulder et al, 
2001; Anido et al., 2003; Hirata et a l, 2005). The anti-tumour activity of gefitinib has 
been associated with the induction of apoptosis, inhibition of growth factor production, 
and cell cycle arrest in G1 via upregulation of p27^‘^  ^and subsequent reduction in CDK2 
kinase activity (Ciardiello et a l, 2001; Janmaat et a l, 2003; Albanell & Gascon, 2005; 
Giaccone, 2005).
Several phase II trials (IDEAL 1 and IDEAL 2) have shown gefitinib to be effective in 
advanced NSCLC patients who had failed to respond to prior cisplatin based 
chemotherapy (Fukuoka et al, 2003; Kris et a l, 2003). Consequently, in July 2002, 
Iressa was approved in Japan and South Korea for the treatment of inoperable, recurrent
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NSCLC, and in May 2002 the USA FDA approved doses of250mg/d as monotherapy for 
patients with locally advanced and metastatic NSCLC (Wakeling, 2002; Mendelsohn & 
Baselga, 2003). However, in the studies by Kris and colleagues (2003) and Fukuoka and 
colleagues (2003), the overall response rate with 250mg/day gefitinib was only 12% and 
18.4%, respectively (Fukuoka et a l, 2003; Kris et al, 2003). Recently, two large phase 
III studies in NSCLC patients, INTACT-1 and INTACT-2, assessed the benefit of 
combining gefitinib with gemcitabine/cisplatin or paclitaxel/carboplatin based 
chemotherapies, respectively. However, there was no significant improvement in overall 
survival with the addition of gefitinib (Giaccone et al, 2004; Herbst et a l, 2004). In 
addition, there has been no clear association between EGFR expression and response to 
gefitinib in above pre-clinical and clinical studies.
Like gefitinib, erlotinib is a highly specific and reversible ATP-competitive inhibitor of 
the ErbBl tyrosine kinase, and inhibits EGFR autophosphoiylation with selectivity of 
more than 1000- times greater than other TKs, such as the IGF-IR TK or insulin 
receptor TK (Moyer et al, 1997). For example, erlotinib inhibits the activity of purified 
human EGFR tyrosine kinase with an IC50 of 2nM, and reduces EGFR 
autophosphoiylation in intact EGFR overexpressing HN5 cells with an I C 5 0  of 20nM 
(Moyer et al, 1997). In common with cetuximab and gefitinib, the anti-tumour activity 
of erlotinib has been associated with reduction of EGFR phosphoiylation, induction of 
cell cycle arrest in Gl, and the induction of apoptosis (Moyer et a l, 1997; Albanell & 
Gascon, 2005).
In the BR.21 phase IE trial, 150mg/day erlotinib was shown to have an overall response 
rate of 8.9% and increase median survival from 4.7 to 6.7 months when given as
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monotherapy in NSCLC patients who had failed 1 ^  or 2"^  line chemotherapy (Albanell & 
Gascon, 2005). Consequently, erlotinib has been approved by the US FDA for the 
treatment of NSCLC patients who have failed prior chemotherapy (Albanell & Gascon,
2005). However, the results of two large phase IE trials in advanced NSCLC (TRIBUTE 
and TALENT), in common with gefitinib in the INTACT-1 and INTACT-2 trials, failed 
to show a significant improvement in the survival of patients treated with 
paclitaxel/carboplatin or cisplatin/gemcitabine in combination with erlotinib (Giaccone, 
2005; Herbst et al, 2005). In addition to gefitinib and erlotinib, there are currently other 
small molecule EGFR inhibitors (e.g. Cl- 1033, EKB-569, BMS599626, GW2016) at 
different stages of clinical development, some of which can target both the EGFR and 
HER-2 (e.g. GW2016) or all members of the EGFR family (e.g. CI-1033) (Table 1.4; 
Wakeling, 2002; Albanell & Gascon, 2005; Giaccone, 2005; Modjtahedi, 2005).
While there has been improved survival in cancer patients treated with cetuximab, 
gefitinib, and erlotinib, treatment with the EGFR inhibitors is expensive and there has 
been no clear association between EGFR expression and response to the EGFR inhibitors 
in pre-clinical and clinical studies (Cunningham et al, 2004; Saltz et a l, 2004; Schrag,
2004). Interestingly, in several recent studies, mutation in exons 18 to 21 which code for 
the region close to the ATP binding pocket of the EGFR tyrosine kinase domain, have 
been associated with sensitivity to gefitinib in NSCLC patients (Lynch et a l, 2004; Paez 
et al, 2004; Pao et al, 2004; Pao et a l, 2005). These mutations, Wiich are more fi*equent 
in never smokers, patients with adenocarcinoma histology, women, and patients from 
East Asia, may be the Achilles heel of tumours by allowing the tumour to become 
dependent upon the EGFR for its survival (Gazdar et a l, 2004; Lynch et a l, 2004; Paez 
et al, 2004; Pao et al, 2004; Pao et al, 2005). In the study by Lynch and colleagues
35
(2004), cells harbouring such mutations were found to have double or triple magnitude of 
EGF induced EGFR activation, demonstrate EGFR activation for up to three hours, and 
are more sensitive to gefitinib induced inhibition of EGFR autophosphorylation (Lynch et 
al, 2004). However, these mutations may be less common in tumours fi*om other tissues, 
such as hepatocellular carcinomas and malignant gliomas, and are not found in all 
patients who have responded to gefitinib (Lynch et a l, 2004; Paez et a l, 2004; Pao et al, 
2004; Marie et al, 2005; Pao et a l, 2005; Su et al, 2005). More recently, in contrast to 
the EGFR tyrosine kinase mutations, tumour cells expressing the EGFRvIII were found 
to be more resistant to concentrations of gefitinib that were required to suppress EGFR 
phosphoiylation, EGFR mediated proliferation, and EGFR mediated anchorage- 
independent growth (Pedersen et a l, 2005). Consequently, there is an urgent need for 
further studies investigating the relative expression of wild-type EGFR and mutated 
EGFR in EGFR positive tumours and their association with response to the EGFR 
inhibitors (Ciardiello & Tortora, 2003; Mendelsohn & Baselga, 2003; Modjtahedi, 2005)
1.9 The IGF-IR System
In addition to the EGFR, the IGF-IR is another important growth factor receptor with 
tyrosine kinase activity that is often aberrantly expressed in human malignancies 
(Werner, 1998; Molina et al, 2000; Wemer et a l, 2000; LeRoith & Roberts, 2003). The 
IGF-IR system consists of the ligands IGF-I and IGF-II, the receptors IGF-IR and IGF- 
IIR (mannose-6 -phosphate receptor), and six IGF binding proteins (IGFBPl-6 ). In 
addition four lower affinity IGFBP related peptides, the insulin receptor related receptor 
(IRR), and IGFBP proteases have also been identified (Jones & Clemmons, 1995; 
Baserga gr a/., 1997).
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The mature TGF-T is a 70 amino acid protein and shares 62% homology in amino acid 
sequence to the mature IGF-II (67 amino acids). The insulin-like growth factors mediate 
a variety of processes under normal physiological conditions, in all stages of life, 
including preimplantation development, normal foetal and postnatal growth, bone 
development, hematopoiesis, and wound healing (Jones & Clemmons, 1995; Shimon & 
Shpilberg, 1995; Baserga et al., 1997; Ruan & Kleinberg, 1999; Yakar et a l, 2002; 
Georgiev et al, 2003). The importance of the IGF- ligands in mammalian cell growth 
has been demonstrated by disrupting normal gene expression in animal models. 
Inactivation of the IGF-I gene in mice results in embryonic growth deficiency and while 
some animals die shortly after birth, surviving animals reaching adulthood show retarded 
growth and infertility (Baker et a l, 1993). Disruption of the IGF-II gene is less severe, 
and although animals show retarded embryonic growth and a reduction in birth weight, 
animals are fertile and have normal relative postnatal growth rates (DeChiara et al, 
1990). However, the lack of a functional IGF-IR has severe implications on normal 
growth and development, and mice lacking the IGF-IR gene weigh only 45% of wild- 
type animals and die soon after birth (Liu et al, 1993).
1.9.1 The IGF-IR signalling network
While the major function of the IGF-IIR is to act as a scavenger to remove IGF-II fi*om 
the circulation, internalize it and target it for lysosomal degradation, the IGF-IR carries 
out the mitogenic functions of IGF-I and IGF-II (Jones & Clemmons, 1995; Baserga et 
al, 1997; Nakae et al, 2001). The IGF-IR is a 350kDa transmembrane tyrosine kinase, 
consisting of two alpha- and two beta-subunits which form a2(32 heterotetramers. The 
alpha-subunits are entirely extracellular chains, containing a cysteine-rich domain 
responsible for ligand binding. The transmembrane beta-subunits contain an
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extracellular, transmembrane, and intracellular domain. The intracellular region contains 
binding sites for the IRS-1 and She adaptor molecules (e.g. tyrosine 950), an ATP 
binding site (lysine 1003), sites required for ligand-mediated endocytosis (e.g. tyrosine 
1250), and a tyrosine kinase domain with three major phosphoiylation sites at tyrosine 
1131, 1135, and 1136 (Jones & Clemmons, 1995; Wemer et al, 1995; Baserga et al, 
1997; Nakae et a l, 2001).
In common with the EGFR, the major activation pathways of the IGF-IR include the PI- 
3K pathway and the MAPK pathway. However, in contrast to the EGFR, activation of 
the PI-3K and MAPK pathways by the IGF-IR are primarily mediated via IRS-1 and She 
(Baserga et a l, 1997). Binding of IGF-I or IGF-II to the IGF-IR alpha-subunits causes a 
conformational change in the intracellular domain of the IGF-IR beta- subunits and 
receptor tyrosine autophosphoiylation. This leads to the activation of IRS-1, which in 
turn activates the p85 subunit of PI-3K to initiate the PI-3K/Akt pathway (Myers et al, 
1993). The IRS-1 molecule can also activate the Ras-Raf-MAPK pathway via the 
recmitment of the Grb2/Sos complex (Baltensperger et a l, 1993). In addition, the IGF- 
IR can activate the MAPK pathway via the recmitment of the She adaptor molecule, and 
interaction of She with the IRS-1 homologues Gab-1 and Gab-2 can also lead to PI- 
3K/Akt activation (Jones & Clemmons, 1995; Blakesley et al, 1996; Baserga et al, 
1997; Butler et al, 1998; Molina et a l, 2000; LeRoith & Roberts, 2003). An illustration 
of IGF-IR induced MAPK and Akt activation is shown in Figure 1.7.
1.9.2 The IGF-IR in human malignancies
Deregulation of signalling via the IGF-IR and/or its ligands has been associated with the 
establishment and maintenance of the transformed phenotype, angiogenesis, invasion,
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Figure 1.7. The IGF-IR signalling network. Binding of IGF-I or IGF-II to the IGF- 
IR is able to activate a number of signal transduction molecules, including IRS-1 and She 
which can activate the MAPK and Akt pathways, ultimately leading to cellular 
proliferation and increased cell survival (Butler a/., 1998).
cell motility, métastasés, protection from micro-environmental stress, and resistance to 
apoptosis, chemotherapy and radiotherapy (Valentinis & Baserga, 1996; O'Connor et al., 
1997; Rubini et al, 1997; Perer et al, 2000; Peretz et al, 2002; Reinmuth et a l, 2002a; 
Reinmuth et a l, 2002b; Baserga et al, 2003; Sekharam et al, 2003). Consequently, a 
number of strategies targeting the IGF-IR have been developed, and blocking monoclonal 
antibodies (mAbs), small molecule tyrosine kinase inhibitors (TKIs), antagonistic 
peptides or anti-sense oligonucleotides have been shown to inhibit growth of a wide
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range of IGF-IR expressing tumour cells (e.g. breast, lung, multiple myeloma) both in- 
vitro and in-vivo, and to improve sensitivity of human tumour cell lines and xenografts to 
cytotoxic drugs and radiotherapy (Perer et al, 2000; Baserga, 2004; Hailey et al, 2002; 
Jackson-Booth et al, 2003; Maloney et al, 2003; Mitsiades et a l, 2004; Goetsch et al, 
2005; Min et al, 2005; Miyamoto et a l, 2005)
The expression of the IGF-IR has been reported in a range of human tumours, including 
cancer of the ovary, stomach, pancreas, lung, skin, endometrium, testicle, brain, breast 
(Peyrat et a l, 1988; All-Ericsson et a l, 2002; Del Valle et a l, 2002; Ouban et a l, 2003; 
Neuvians et a l, 2005), colon and rectum (Freier et al, 1999; Hakam et a l, 1999; Weber 
et al, 2002; Ouban et al, 2003; Peters et al, 2003). However, while the expression of 
IGF-IR has been associated with poor prognosis in some studies (Peiro et a l, 2003; 
Peters et a l, 2003), in other studies there has been no associations with survival (Hakam 
et al, 1999), or an association with improved prognosis (Peyrat & Bonneterre, 1992; 
Bhatavdekar et a l , 1995).
1.9.3 The IGF-IR in colorectal cancer
In colorectal cancer, IGF-IR expression has been associated with the development of 
colon adenocarcinomas (Kulik et al, 1997; Wemer, 1998; Freier et a l, 1999; Weber et 
al, 2002), the progression from adenoma to carcinoma (Hakam et a l, 1999), 
angiogenesis and métastasés in experimental systems (Freier et al, 1999; Reinmuth et a l, 
2002a; Reinmuth et a l, 2002b) as well as lung and liver métastasés in colorectal cancer 
patients (Hakam et al, 1999). However, other studies have demonstrated no difference in 
IGF- IR mRNA levels or IGF-IR expression by *^ I^GF-I binding studies between
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malignant and control tissues (Adenis et a l, 1995; Mishra et ah, 1998; Bustin et ah, 
2002).
The majority of immunohistochemical studies in the literature report the frequent 
expression of IGF-IR in colorectal cancer (Hakam et ah, 1999; Weber et ah, 2002; 
Ouban et a l, 2003; Peters et al, 2003). For example, IGF-IR expression was detected in 
91% and 96% of stage I-IV patients in two studies by Weber and colleagues (2002) and 
Hakam and colleagues (1999), respectively. However, in a recent study using a tissue 
microarray, IGF-IR expression was detected in only 2/68 (3%) of colorectal 
adenocarcinomas (Singer et al., 2004). In addition, the number of studies investigating 
the prognostic significance of the IGF-IR in colorectal cancer using 
immunohistochemistiy is limited (Hakam et a l, 1999) and warrants further investigation.
1.9.4 Crosstalk between the IGF-IR and EGFR
A number of recent studies have shown that the IGF-IR can crosstalk with other receptor 
systems, such as the EGFR, VEGFR, and HER-2, to enhance the malignant behaviour of 
tumour cells (Warren et a l, 1996; Lu et al, 2001; Chakravarti et al, 2002; Wang et a l, 
2002; Adams et a l, 2004). Indeed, the role of the IGF-IR as a progression fector for 
EGF-induced mitogenesis was first demonstrated over a decade ago, and more recent 
studies in MH-3T3 cells have also demonstrated that the IGF-IR may be essential for 
prolonged EGF- induced MAPK activation (Coppola et al, 1994; Swantek & Baserga, 
1999; Adams et a l, 2004). For example, both IGF-I and EGF have been demonstrated to 
induce expression of the early Gl D-type cyclins in mammary epithelial cells, but only 
IGF-I was found to up-regulate the E, A2, and B1 cyclins, required for traversal of the 
Gl-S checkpoint, S phase, and G2 phase of the cell cycle, respectively (Stull et a l, 2002)
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In other studies, IGF- IR activation has been shown to up-regulate the expression of the 
EGFR ligand TGFa in FET colorectal cancer cells and result in EGFR activation and re­
entry into the cell cycle, and continued IGF- IR signalling through the PI3K pathway has 
been shown to mediate resistance of glioma cells to the EGFR TKIs (Chakravarti et al, 
2002; Wang et a l, 2002). Indeed, IGF-IR expression has been associated with resistance 
to anti- EGFR and anti-HER-2 therapies in several experimental systems, and co­
targeting the IGF-IR with the EGFR or HER-2 may reduce the malignant behaviour of 
some tumours (Lu et a l, 2001 ; Camirand et a l, 2002; Jones et al, 2004; Steinbach et al, 
2004; Camirand et a l, 2005). For example, in one study, the simultaneous targeting of 
the HER-2 with trastuzumab and the IGF-IR via the expression of a dominant negative 
IGF-IR resulted in the synergistic growth inhibition of HER-2 overexpressing MCF- 
7/herl8 cells (Camirand et a l, 2002). In another study, enhanced anti-tumour activity 
was achieved using a bi-specific antibody which inhibited ligand binding and 
downstream signalling molecules of the MAPK and Akt pathways of both the EGFR and 
IGF-IR, respectively (Lu et al, 2004a).
As discussed in section 1.8, the tyrosine kinase inhibitors gefitinib, and erlotinib, and the 
monoclonal antibody cetuximab have been approved for the treatment of EGFR 
expressing cancer patients. In addition, clinical trials using the EGFR inhibitors have so 
far produced a response of a short duration in only a subpopulation of patients, and there 
has been no clear correlation between EGFR expression and response to the EGFR TKIs 
(please see section 1.8). However, there has been no study investigating the coexpression 
pattern and prognostic significance of EGFR, HER-2, and IGF-IR in colorectal cancer 
patients, and further studies investigating the coexpression and prognostic significance of
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the EGFR, HER-2 and IGF-TR in human cancers, and the association between receptor 
coexpression and response to the EGFR inhibitors are warranted.
1.10 Aims of this project
As described above, there has been no clear correlation between the expression of the 
EGFR and response to the EGFR inhibitors in pre-clinical and clinical studies. The aims 
of this study were therefore to investigate the expression of the EGFR, HER-2, and IGF- 
IR in a panel of human colorectal tumour cell lines, and investigate the association 
between receptor expression and response to the EGFR and/or IGF-IR inhibitors. The 
molecular mechanism by which the anti-EGFR mAh and EGFR TKI inhibit the growth 
of EGFR expressing tumour cells was investigated together with the therapeutic benefit 
of combining the two classes of EGFR inhibitors or using a combination of EGFR and 
IGF-IR inhibitors. In addition to studies in colorectal tumour cell lines, the expression 
pattern of the EGFR, pEGFR, EGFRvIII, HER-2, and IGF-IR was determined in the 
tumour sections fi'om a series of 87 Dukes’ C colorectal cancer patients. The aim was to 
determine whether there was any association between the expression of growth factor 
receptors and clinicopathological parameters, overall survival, and response to 
chemotherapy and radiotherapy.
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CHAPTER TWO 
Materials and Methods 
2.1 Tumour cell lines
A panel of human colorectal cancer cell lines were purchased from the American Type 
Culture Collection (ATCC; VA, USA) for use in this study. These are detailed in Table
2.1 along with the other tumour cell lines used in this study. The EGFR overexpressing 
cell line DiFi (4.8x10^ receptors/cell) was a kind gift from Dr. Zhen Fan (M.D. Anderson 
Cancer Centre, Texas, USA) to Dr. Modjtahedi. This cell line was established from a 
patient with FAP (Gross et al., 1991). The two new cell lines, Colo2 and Colo 13, were 
established in our laboratoiy from patients undergoing surgery for colorectal cancer at the 
Royal Surrey County Hospital (Guildford, UK). Colo2 was established from a Dukes’ A 
patient with a moderately differentiated tumour, following a short course (one week) of 
pre-operative radiotherapy. The Colo 13 cell line was established from a Dukes’ C patient 
with an invasive and moderately differentiated tumour.
Several non-colorectal cancer cell lines were also used in this study, these included 
SKBR3, MCF-7, and HN5 cells, which overexpress the HER-2, IGF-IR, and EGFR, 
respectively (Cowley et al, 1986; Lewis et al., 1993; Guvakova & Surmacz, 1997; 
Boente et al., 1998). Several transfected cell lines were also used in this study. These 
included R- cells, which are 3T3-like cells derived from mouse embryos with a targeted 
disruption of the IGF-IR gene (Burgaud & Baserga, 1996), and HC2 20 d2/c cells, which 
express approximately 2.1x10^ EGFRvIII molecules/cell
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Table 2.1 Summary of human colorectal and other cell lines used in this study.
CE A: Carcinoembryonic antigen.
Cell Line Characteristics
DiFi Adherent human colorectal tumour cell line, expressing 4.8x10^ EGFR 
molecules/cell. Isolated from a patient with FAP.
CCL-218 Adherent human colorectal tumour cell line. Alternative name WIDR 
(HT-29). Dukes’ stage not specified. CEA positive.
CCL-221 Adherent human colorectal tumour cell line isolated from a Dukes’ C 
tumour. Alternative name DLD-1. CEA positive.
CCL-225 Adherent human colorectal tumour cell line isolated from a Dukes’ C 
tumour. Alternative name HCT-15. CEA positive.
CCL-227 Adherent human colorectal tumour cell line isolated from a Dukes’ C 
tumour. Alternative name SW620. CEA positive.
CCL-228 Adherent human colorectal tumour cell line isolated from a Dukes’ B 
tumour. Alternative name SW480. CEA positive.
CCL-231 Adherent human colorectal tumour cell line isolated from a Dukes’ C 
tumour. Alternative name SW48 CEA positive.
CCL-235 Adherent human colorectal tumour cell line. Alternative name SW837 
Dukes’ stage not specified. CEA positive.
CCL-244 Adherent human colorectal tumour cell line. Alternative names HCT-8 or 
HRT-18. Dukes’ stage not specified. CEA positive.
HCT-116 Adherent human colorectal tumour cell line. Alternative name CCL-247. 
Dukes’ stage not specified. CEA positive.
Colo2 Newly established adherent human colorectal tumour cell line isolated 
from a Dukes’ A tumour.
C0 I0 I 3 Newly established adherent human colorectal tumour cell line isolated 
from a Dukes’ C tumour.
HN5 Adherent human head and neck tumour cell line expressing 1.4x10  ^EGFR 
molecules/cell.
SKBR3 Adherent human breast tumour cell line expressing 1.3x10  ^HER-2 
molecules/cell
MCF-7 Adherent human breast tumour cell line expressing 6x10"^  IGF-IR 
molecules/cell
HC2 20 d2/c Adherent transfected mouse fibroblast cell line expressing 2.1x10^ 
EGFRvIII molecules/cell
R- Adherent transfected mouse fibroblast cell line with a targeted disruption 
of the IGF-IR gene
(Wikstrand et al, 1995; Moscatello et al, 1996). The HC2 20 d2/c cell line is derived 
from the NIH 3T3 mouse embiyo fibroblast cell line, transfected with cDNA encoding 
the EGFRvIII, and was a kind gift from Dr David Moscatello and Dr Albert J Wong 
(Kimmel Cancer Institute, Philadelphia, USA) to Dr Helmout Modjtahedi.
2.2 Antibodies and inhibitors
A number of primary and secondaiy commercial antibodies were purchased for use in 
this study. These are detailed in Table 2.2 and Table 2.3. In addition, a number of 
monoclonal antibodies developed by Dr Modjtahedi were used in this study. Of these, 
the rat mAbs ICR 10 (IgG2a) and ICR16 (IgG2a) were raised against the external domain 
of the EGFR on the HN5 cell line (Modjtahedi et a l, 1993c; Modjtahedi et a l, 2003). 
The rat mAh ICR62 (IgG2b) and the mouse mAh HM43.16B were raised against the 
external domain of the EGFR on the breast carcinoma cell line MDA-MB468 and the 
HC2 20 d2/c cell line, respectively (Modjtahedi et a l, 1993d; Modjtahedi et a l, 2003; 
Modjtahedi, unpublished). Antibodies targeting the HER-2 included mAh ICR12 and 
HM50.67A. The rat mAh ICR12 (IgG2a) was raised against the external domain of the 
HER-2 on the human breast carcinoma cell line BT-474, and was a kind gift from the late 
Dr Christopher Dean (Institute of cancer Research, Sutton, UK) to Dr Helmout 
Modjtahedi (Styles et a l, 1990). The mouse mAh HM50.67A was raised against the 
external domain of the HER-2 on SKBR3 cells (Modjtahedi, unpublished).
Several small molecule tyrosine kinase inhibitors were also used in this study. The 
EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib were kind gifts to Dr 
Helmout Modjtahedi from AstraZeneca and OSI Pharmaceuticals, respectively.
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Table 2.2 Commercial primary antibodies used in this study. ELTSA: Enzyme- 
linked immunosorbant assay; FACS: Fluorescent activated cell-sorter analysis; IF: 
Immunofluorescence staining; IHC: Immunohistochemistry; mAb: Monoclonal antibody; 
pAb: Polyclonal antibody; WB: Western blotting.
Antibody Stated Specificity in 
humans
Experimental
Use
Product
Code/Company
Mouse anti- human 
EGFR mAh (IgGl; 
clone F4).
EGFR residues 985 to 
996 (internal domain).
WB (1/1000) #E3138; 
Sigma-Aldrich 
Company Ltd., 
Dorset, UK.
Mouse anti-human 
EGFR mAh (IgG2a; 
clone EGFR.113).
EGFR external domain. IHC (1/10); 
IF (1/10-/300)
#NCL-L-EGFR;
Novocastra; 
Laboratories Ltd., 
Newcastle; UK.
Rabbit anti-human 
EGFRpAb.
Total EGFR, residues 
surrounding tyrosine 
1068 (internal domain).
IHC (1/50) #2232;
New England 
Biolabs (UK) Ltd., 
Hitchin,UK.
Mouse anti-phosho- 
tyrosine mAb (IgGl; 
P-Tyr-100).
Peptides containing 
phosphoiylated 
tyrosine.
WB (1/2000) #9411;
New England 
Biolabs (UK) Ltd., 
Hitchin, UK
Rabbit anti-human 
pEGFR (pY1068) 
pAb.
Phosphorylated EGFR 
tyrosine residue 1068, 
slight cross­
reactivity with PDGRF.
IHC (1/25) 
WB (1/1000)
#2234;
New England 
Biolabs (UK) Ltd., 
Hitchin, UK
Rabbit anti-human 
pEGFR(pY1086) 
pAb.
Phosphoiylated EGFR 
tyrosine residue 1086.
WB (1/1000) #44-790; 
Biosource Europe 
S. A., Belgium
Rabbit anti-human 
pEGFR(pY1148) 
pAb.
Phosphoiylated EGFR 
tyrosine residue 1148.
WB (1/1000) #44-792G; 
Biosource Europe 
S.A., Belgium
Rabbit anti-human 
pEGFR(pY1173) 
pAb.
Phosphoiylated EGFR 
tyrosine residue 1173.
WB (1/1000) #44-794; 
Biosource Europe 
S.A., Belgium
Rabbit anti-human 
pEGFR(pY845) 
pAb.
Phosphorylated EGFR 
tyrosine residue 845.
WB (1/1000) #44-784G;
Biosource Europe 
S.A., Belgium
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Table 22 Commercial primary antibodies used in this study. Continued......
Mouse anti- human 
EGFRvIII mAh 
(IgGl; clone G100).
Deletion fusion 
junction of EGFRvIII
IHC(l/50); 
IF (1/4-1/9).
#18-7330;
Zymed 
Laboratories Inc., 
CA,USA.
Rabbit anti-human 
pan Akt/PKB pAb.
Aktl (carboxyl- 
terminus). Human 
Akt2 and Akt3 
expected.
WB (1/1000) #44-609G; 
Biosource Europe 
S.A., Belgium.
Rabbit anti-human 
p44/42 MAPK pAb.
Total MAPK, derived 
from the sequence of 
rat p42 MAPK.
WB (1/1000) #9102;
New England 
Biolabs (UK) Ltd., 
Hitchin, UK
Rabbit anti- human 
p Akt/PKB pAb.
Phosphoiylated Aktl, 
Akt2, and Akt3 residue 
serine 473.
WB (1/1000) #44-622G; 
Biosource 
International Inc., 
CA, USA.
Rabbit anti-human 
pMAPK pAb.
Phosphoiylated MAPK 
residues threonine 202 
and tyrosine 204.
WB(1/1000) #9101;
New England 
Biolabs (UK) Ltd., 
Hitchin, UK
Rabbit anti-p-actin 
pAb.
Endogenous levels of 
p-actin. May cross- 
react with y- actin.
WB (1/1000) #4967; 
Sigma-Aldrich 
Company Ltd., 
Dorset, UK.
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Table 23 Commercial secondary antibodies used in this study. ELISA: Enzyme- 
linked immunosorbant assay; FACS: Fluorescent activated cell-sorter analysis; IF: 
Immunofluorescence staining; IHC: Immunohistochemistiy.
Antibody Stated Specificity in 
humans
Experimental
Use
Product
Code/Company
Goat anti-mouse 
IgG, FITC 
conjugate.
Heavy and light 
chains of mouse 
IgGl,IgG2a,IgG2b, 
and IgG3. Light 
chains of mouse IgM 
and IgA.
FACS
(4ug/lxl0^cells/
ml);
IF (1/100)
#1034-02; Southern 
Biotechnology 
Associates Inc., AL, 
USA.
Mouse anti- rat 
IgG (IgGl/IgG2a; 
clone RT-39 and 
RL-6),HRP 
conjugate.
Kappa and Lambda 
light chains of rat IgG
ELISA 
(1/10 000)
#A-1687; 
Sigma-Aldrich 
Company Ltd., 
Dorset, UK.
Rabbit anti­
mouse IgG, HRP 
conjugate.
Mouse IgG (all 
subclasses). Some 
IgM.
ELISA
(1/500-1/1000)
#STAR13B; Serotec 
Ltd., Oxford, UK.
Rabbit anti­
mouse 
immunoglobulins 
(mainly IgG), 
biotin conjugate.
Mouse IgG (all 
subclasses) and 
mouse IgM.
IHC (1/200) #E0354;
DAKOLtd.,Ely,
UK.
Rabbit anti- rat 
IgG, FITC 
conjugate.
Rat IgG IF (1/400) #STAR17B; Serotec 
Ltd., Oxford, UK.
Rabbit anti- rat 
immunoglobulins 
(mainly IgG), 
biotin conjugate.
Rat immunoglobulins 
(all classes).
IHC (1/300) #E0467;
DAKOLtd.,Ely,
UK.
Swdne anti- rabbit 
immunoglobulins 
(mainly IgG), 
biotin conjugate.
Rabbit 
immunoglobulins 
(all classes).
IHC (1/200) #E0353; 
DAKO Ltd., Ely, 
UK.
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The IGF-IR TKI (NVP-AEW541) was a kind gift from Novartis to Dr Helmout 
Modjtahedi (Garcia-Echeverria et al, 2004). The MAPK (U0126) and PI-3K 
(LY294002) inhibitors were purchased from Sigma-Aldrich Company Ltd., (UK).
23 Cell culture 
23.1 Culture medium and solutions
All human colorectal cancer cell lines were cultured routinely in Dulbecco’s Modified 
Eagle’s Medium (DMEM; Sigma- Aldrich, UK), supplemented with 10% foetal calf 
serum (FCS; GIBCO Cell Culture Systems, Invitrogen Ltd., Paisley, UK) and Penicillin 
(50pg/ml), Streptomycin (50pg/ml), and Neomycin (lOOpg/ml) (GIBCO, UK). The FCS 
was heat inactivated at 56 “C for one hour prior to use. For HC2 20 d2/c cells, cell growth 
medium was supplemented with 350pg/ml geneticin (G418; GIBCO, UK), and for R- 
cells the cell growth medium was supplemented with 50pg/ml hygromycin B (GIBCO, 
UK).
23.2 Passaging of tumour cell lines
Tumour cells were cultured routinely in large (175cm^), medium (75cm^), or small 
(25cm^) tissue culture flasks (Greiner Bio-One Ltd., Gloucestershire, UK) at 37°C in a 
humidified atmosphere with 5% CO2. All of the tumour cell lines used in this study were 
adherent. Near confluent tumour cell monolayers were washed once with PBS containing 
0.04% ethylene diamine tetraacetic acid (di-sodium salt; Na2EDTA; PBS+), prior to 
incubation with 0.05% tiypsin (GIBCO, UK) at 37°C until the cells were dissociated. 
The tiypsin was inactivated by the addition of FCS, and the cell suspension was 
centrifuged at 1200rpm for 3 min (264 g) in an ALC® PK130 centrifuge (ALC®, VA,
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USA). The cell pellet was re-suspended in pre-warmed growth medium and cells were 
seeded in tissue culture flasks at the required density.
23.3 Long term storage of cells
Tumour cells were stored in liquid nitrogen for long term storage. Near-confluent tumour 
cells were dissociated using trypsin and centiifiiged at 1200 rpm for 3 minutes (264 g). 
Following removal of the supernatant fi'om the cell pellet, cells were re-suspended into 
FCS containing 7% dimethyl-sulphoxide (DMSO; Fisher Scientific UK; Loughborough, 
UK), and one millilitre aliquots were transferred to 1.5 ml ciyovials (Nalge (Europe) 
Limited, Hereford, UK). Following incubation at -80°C for 24 hours in a Ciyo 1°C 
freezing vessel (Nalge, UK) containing isopropanol, cells were transferred to liquid 
nitrogen. When required, cells were removed from liquid nitrogen, thawed rapidly at 
37°C, and transferred to 20ml of growth medium. Following centrifiigation, the cell 
pellet was re-suspended in fresh medium and cultured as described under section 2.3.2.
2.4 Enzyme-linked immunosorbant assay (ELISA)
ELISA was routinely performed to test the binding of primary antibodies to their target 
antigens (see section 2.2 for detail of antibodies). Human tumour cells were seeded into 
96-well culture plates in 200pi of DMEM/10% FCS and grown to near confluency at 
37°C. Tumour cells were washed three times in DMEM/2% FCS and incubated in 50pl 
of DMEM/2% FCS containing up to 25pg/ml of primary antibody for one hour on ice. 
Following three more washes, tumour cells were incubated with HRP-conjugated 
secondary antibody (Table 2.3) for one hour on ice. Cells were washed three more times 
prior to the addition of lOOpl TMB substrate for 15-20 minutes at room temperature. The 
TMB reaction was quenched with 50pl of 0.5M H2SO4, and the absorbance was read at
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450nM using a Labsystems MultiSkan RC plate reader (Thermo Electron Corporation, 
Cambridge, UK).
2.5 FACS analysis
2.5.1 FACS analysis of cell surface receptor expression
The cell surface expression of growth factor receptors was determined using FACS 
analysis. Approximately 1x10  ^tumour cells in one millilitre of DMEM/2% FCS were 
incubated with control medium or lOpg of mAh to the EGFR (HM43.16B), HER-2 
(HM50.67A), or IGF-IR (CN Biosciences, UK) for one hour by rotation at 4°C. Tumour 
cells were washed three times by centrifiigation for 5 minutes at 1200rpm (264 g) and re­
suspension in DMEM/2% FCS, prior to incubation with FITC-conjugated goat anti­
mouse IgG secondaiy antibody (Table 2.3). Following rotation for one hour at 4°C, 
tumour cells were washed a fiirther three times and the final cell pellet was re-suspended 
in 0.5ml of FACS Flow™ buffer (Becton Dickinson UK Ltd., Oxford, UK). A minimum 
of 10,000 events were recorded by excitation with an argon laser at 488nm, and analysed 
using the FL-1 detector (FITC detector; 525nm) of a Beckman Coulter Epics XL flow 
cytometer (Becton Dickinson, UK) and the CellQuest™ software.
2.5.2 FACS analysis of tumour cell cycle distribution
The effect of EGFR inhibitors on the cell cycle distribution of tumour cells was analysed 
by FACS analysis using a modified method of Nicoletti and colleagues (Nicoletti et al, 
1991). Approximately 1x10  ^ tumour cells were seeded in to 25cm  ^ culture flasks 
containing 15ml of DMEM/2% FCS and mAh ICR62 (156nM), gefitinib (300nM), 
erlotinib (300nM), NVP-AEW541 (300nM) or control medium. Following incubation for 
5 days at 37°C, the supernatant of the treated cells was harvested and pooled together
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with the adherent cells, which were dissociated using 0.05% trypsin as described in 
section 2.3.2. Tumour cells were washed three times by centrifugation at 1200rpm for 5 
minutes (264 g) and re-suspension in cold (4°C) PBS. The final cell pellet was re­
suspended in 200pl of cold PBS and fixed by the gradual addition of one millilitre of cold 
70% ethanol (in PBS) by vortex. Following incubation overnight at 4°C, tumour cells 
were harvested by centrifugation, washed once in PBS, and incubated with 500pi PBS 
containing 1 mg/ml ribonuclease and lOpg/ml propidium iodide (PI) for 30 minutes at 
37°C in the dark. Due to the low numbers of cells in samples treated with the EGFR 
inhibitors, 10, 000 events or up to 10,000 events captured within a 5 minute period were 
recorded by excitation with an argon laser at 488nm, and analysed using the FL-3 
detector (PI detector; 620nm) of a Beckman Coulter Epics XL flow cytometer (Becton 
Dickinson, UK).
2.6 In-vitro growth studies
The effect of EGFR, IGF-IR, MAPK, and PI-3K inhibitors on the growth of human 
tumour cell lines was investigated using a colorimetric assay, as described previously 
(Modjtahedi et al, 1993c; Modjtahedi & Dean, 1995). Approximately 5x10  ^tumour 
cells in 100pi DMEM containing 2% to 10% FCS were seeded into each well of a 96 
well plate. Following three hours incubation at 37 °C, lOOpl aliquots of anti-EGFR mAb, 
EGFR TKI, IGF-IR TKI, or inhibitors of the MAPK or PI-3K (single agent and 
combination) in DMEM/2% FCS were added to triplicate wells. The tumour cells were 
incubated for 6-12 days at 37°C until the cells in the wells containing control medium 
(i.e. no treatment) were confluent. Tumour cells were then fixed with 2.5% 
glutaraldehyde, washed in tap water, air dried, and stained with lOOpl of 0.05% 
methylene blue for 15 minutes. Following a further wash in tap water, 200pl of 0.33N
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HCl was added to each well and the absorbance at 620nm was read using a Labsystems 
MultiSkan RC plate reader (Thermo Electron Corporation, UK). In order to determine 
the initial absorbance of cells plated in each experiment, an extra plate containing 5x10  ^
cells in lOOpl DMEM/2% FCS (with no treatment) was fixed three hours post-seeding. 
Growth, as a percentage of the control cells, was determined fi'om the formula:
% Growth = B - A x 100 
C -A
Where A= A(620) before treatment, B= A(620) after treatment, and C= A(620) after 
incubation in medium alone.
In addition, the effect of lOpM or lOnM AR, BTC, EGF, EPI, HB-EGF, TGFa (R&D 
Systems, MN, USA), IGF-I, or IGF-II (Austral Biologicals, CA, USA) on the growth of 
tumour cells was determined as for the inhibitors above.
To investigate Miether growth inhibition by the EGFR inhibitors was reversible or 
permanent, DiFi cells were incubated with the EGFR inhibitors continuously for 5 days 
or 10 days. In addition, parallel plates were set up Wiich contained tumour cells treated 
with the inhibitors for 5 days and then incubated for a further 5 days in firesh medium 
lacking the inhibitors.
In addition, growth inhibition assays were performed using a modified method of Matar 
and colleagues (Matar et ah, 2004). For this purpose, approximately SxlO^cells were 
incubated in lOOpl DMEM containing 2% or 10% FCS for 24 hours at 37°C. Tumour 
cells were then treated with anti-EGFR mAh (up to 50nM) and/or EGFR TKI (up to
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lOjiM) for 72 hours at 37°C. The tumour cells were then fixed in glutaraldehyde and 
stained with methylene blue as described above.
2.7 Immunofluorescence staining of tumour cells
Immunofluorescence staining of cell monolayers was performed in order to investigate 
the location of the EGFR following treatment with the EGFR inhibitors and to determine 
the speciflcity of the anti-EGFR mAbs used for inununohistochemistiy. For this purpose, 
tumour cells in DMEM/10% FCS were grown to near confluency in fibronectin coated 
(1/40 in PBS; Sigma-Aldiich, UK) 16-well Lab-Tek® Chamber Slides™ (Nalge, UK). 
Following washes in DMEM/0.1% FCS, cells were incubated with anti- EGFR mAh (up 
to 200nM), EGFR TKI (up to 400nM), or control medium in DMEM/0.1% FCS for one 
hour or 24 hours at 37°C. To allow detection of intracellular EGFR, the tumour cells 
were then processed by a modified method of Moulder and colleagues (Moulder et a/., 
2001), and Lo and colleagues (Lo et a/., 2005). Briefly, tumour cells were washed three 
times in PBS, fixed for 15 minutes at room temperature in PBS containing 4% 
paraformaldehyde, washed a further three times in PBS, and permeabilised for 15 
minutes at room temperature in PBS containing 0.5% Triton X-100 detergent (Sigma- 
Aldrich, UK).
Following three washes in PBS, tumour cells were incubated in cold PBS (4°C)/0.5% 
BSA containing no treatment, mAb ICR62 (20pg/ml), or other anti-EGFR antibodies 
(Table 2.3) for one hour at 4°C. Tumour cells were washed three times in cold PBS, and 
incubated with FITC conjugated secondaiy antibody (Table 2.3) in cold PBS/0.5% BSA 
for 30 minutes at 4°C. Following three more washes in cold PBS, cells were incubated 
with 2pg/ml of Hoescht 33258 nuclear stain (Sigma-Aldrich, UK) for 5 minutes at room
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temperature. Tumour cells were washed three more times, mounted with H-1000 
mounting medium (Vector Laboratories Ltd., Peterborough, LiK), and examined for 
fluorescence under a Zeiss Axiovert 100 microscope (Carl Zeiss Ltd., Welwyn Garden 
City, UK), using the Leica Qwin software.
To investigate the cell surface expression of the EGFR on tumour cells growth inhibited 
by the EGFR inhibitors, tumour cells were fixed in ice-cold methanol for 5 minutes, 
washed twice in PBS, incubated in PBS for 30 minutes at 4°C, prior to the addition of 
mAh ICR62 (20pg/ml) for one hour at 4°C. The bound antibody was detected using 
FITC-conjugated secondaiy antibody as described above.
2.8 SDS-PAGE and Western blotting
The levels and phosphorylation status of growth factor receptors and their downstream 
signalling molecules were investigated by SDS-PAGE and Western blotting. Table 2.4 
details the products purchased fi'om Invitrogen (UK) for use SDS-PAGE and Western 
blotting. An alphabetical list of working solutions for this system is detailed below.
Lysis buffer (Ix): Consisted of 2.5ml NuPAGE® LDS sample buffer (4x; Invitrogen, 
UK), 1ml NuPAGE® sample reducing agent (lOx; Invitrogen, UK), and 6.5ml deionised 
water. The lysis buffer was supplemented with 100 pi of protein inhibitor cocktail 
(Sigma-Aldrich, UK), containing 104mM AEBSF, 80pM aprotinin, 2mM leupeptin, 
4mM bestatin, 1.5mM pepstatin A, and 1.4mM E-64.
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Table 2.4 Reagents purchased from Invitrogen (UK) for SDS-PAGE and 
Western blotting.
REAGENT DESCRIPTION
WestemBreeze® 
chemiluminescent 
western blot 
immunodetection Kit
Blocker/diluent A and B; secondaiy antibody solution; wash 
solution (16x); chemiluminescent substrate
Blocker/diluent A Buffered saline containing detergent.
Blocker/diluent B Concentrated Hammerstein casein solution
Secondary antibody 
solution
Alkaline phosphatase-conjugated, affinity purified, anti- rabbit 
or anti- mouse IgG.
Wash solution (16x) Buffered saline containing detergent
Chemiluminescent
substrate
CDP- Star® substrate for alkaline phosphatase.
Invitrolon'“  PVDF 
membranes
0.45 pm pore polyvinylidene difluoride (PVDF) membranes.
MultiMark® multi­
coloured standard
On NuPAGE® 4-12% Bis-Tris Gels/MOPS: Myosin 188kDa; 
Phosphorylase B 97kDa; Glutamic Dehydrogenase 52kDa;
Carbonic Anhydrase 33kDa; Myoglobin-Blue 21kDa; 
Myoglobin-Red 19kDa; Lysozyme 12kDa; Aprotinin N/A; 
Insulin N/A.
NuPAGE®
antioxidant
Constituents not specified
NuPAGE® gels 4-12% Bis-Tris 1.5mm, 15 well gels.
NuPAGE® LDS 
sample Buffer (4x)
106mM Tris HCl; 141mM Tris base; 2% LDS; 10% Glycerol; 
0.51mMEDTA; 0.22mM SERVA® Blue G250; 0.175mM 
Phenol Red; pH 8.5.
NuPAGE® MOPS 
SDS running 
buffer (20x)
50mM MOPS; 50mM Tris base; 0.1% SDS; ImM EDTA; pH
7.7.
NuPAGE® transfer 
buffer (20x)
25mM Bicine; 25mM Bis-Tris (fiiee base); ImM EDTA; pH 7.2.
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Running Buffer (Ix): Consisted of 50ml NuPAGE® MOPS SDS running buffer (20x; 
Invitrogen, UK) and 950ml deionised water. Enough for one XCell IF^ Surelock™ 
Mini- Cell tank.
Transfer Buffer (Ix): Consisted of 50ml NuPAGE® tansfer buffer (2Ox; Invitrogen, 
UK), 200ml methanol (100ml per gel), 1ml antioxidant, and 750ml of deionised water. 
Enough for one XCell II™ Surelock™ Mini- Cell tank.
Blocking solution: Consisted of 2ml blocker/diluent A (Invitrogen, UK), 3ml
blocker/diluent B (Invitrogen, UK), and 5 ml deionised water. Enough for one PVDF 
membrane.
Primary Antibody Diluent: Consisted of 2ml blocker/diluent A (Invitrogen, UK), 1ml 
of blocker/diluent B (Invitrogen, UK), and 7ml of deionised water. Enough for one 
PVDF membrane.
Antibody Wash (Ix): Consisted of 10ml antibody wash solution (16x; Invitrogen, UK) 
and 150ml deionised water. Enough for one PVDF membrane over two steps.
2.8.1 Preparation of whole cell lysates
The effect of anti- EGFR monoclonal antibodies, EGFR TKIs, and/or the IGF-IR TKI on 
the downstream signalling of human tumour cells was investigated using a modified 
method of Modjtahedi and colleagues (Modjtahedi et al, 1997). Tumour cells were 
grown to near confluency in 6-well tissue culture plates containing 5ml of growth 
medium (Greiner Bio-One, UK). The cell monolayers were washed once with 5ml of
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DMEM/0.1% FCS, and cells were incubated in 5ml DMEM/0.1% FCS containing no 
inhibitor (control medium), anti-EGFR mAb (400nM), EGFR TKI (400nM) and/or IGF- 
IR TKI (400nM) for one hour or 24 hours at 37°C. Following treatment with the 
inhibitors, the cells were incubated with up to 20nM of growth factor (AR, BTC, EGF, 
EP, EPI, HB-EGF, or TGFa) for 15 minutes at 37°C. Following one wash in 2ml of PBS, 
tumour cells were solubilised with 400pl of lysis buffer. The cell lysates were heated at 
72°C for 10 minutes in a 1.5ml eppendorf tube, the viscosity of the lysates were reduced 
by several passages through a 25x 5/8 gauge needle, and samples were used directly or 
were frozen at minus 20°C until required.
2.8.2 SDS-PAGE
SDS-PAGE was performed using the XCell IF^ Surelock™ Mini-Cell system 
(Invitrogen, UK). The prepared cell lysates were removed from minus 20°C, defrosted 
on ice, and 15 pi of whole cell lysate or 5pi of multi-coloured standard (Invitrogen, UK) 
was loaded in to separate wells of a 4-12% Bis-Tiis-gel (Invitrogen, UK). Gel 
electrophoresis was performed in Ix running buffer for 55 minutes at a constant voltage 
o f200 volts.
2.8.3 Western blotting
Following SDS-PAGE, proteins were transferred from the 4-12% Bis-Tris-gels 
(Invitrogen, UK) to PVDF membranes (Invitrogen, UK). This was performed in Ix 
transfer buffer, using the XCell II™ Mini- Cell Blot Module kit (Invitrogen, UK) and a 
constant voltage of 30 volts for two hours. Figure 2.1 illustrates the assembly of the 
sandwich for transfer. Effective transfer was indicated by the presence of all coloured
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Figure 2.1 The XCell H™ Mini-Cell Blot Module geFmembrane/filter paper 
assembly. One gel (A) and two gels (B) (Invitrogen, UK).
bands of the multi-coloured standard (Invitrogen, UK) on the PVDF membrane post­
transfer. Following Western transfer, membranes were washed briefly in deionised 
water and incubated with 10ml of blocking solution on a rotaiy shaker set at 1 
revolution/second for 30 minutes. Membranes were washed three times for 5 minutes 
with 20ml deionised water, prior to incubation with primary antibody made up in 10ml of 
antibody diluent. Following one hour incubation at room temperature, the membranes 
were washed three times for 5 minutes with antibody wash solution (Invitrogen, UK), and 
then incubated with 10ml of secondary antibody solution (Invitrogen, UK) for 30 minutes 
at room temperature. Following three more 5 minute washes in antibody wash solution, 
and three 2 minutes washes in 20ml deionised water, 2.5ml of chemiluminescent 
substrate (CDP star; Invitrogen, UK) was evenly added to each membrane. Following 5
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minutes incubation, the excess CDP star was blotted using filter paper, and membranes 
were wrapped in cling film in preparation for luminography.
For visualisation of transferred proteins, the membrane blot was exposed to Kodak 
BioMax XAR scientific imaging films (Sigma-Aldrich, UK) within a light-proof metal 
cassette containing a Kodak BioMax intensifying screen (Sigma-Aldrich, UK). Films 
were developed in CD 18 manual developer and then fixed in CF42 non-hardening fixer 
(both 1/5 in water; Photosol Ltd., Brentwood, UK).
2.8.4 Protein quantification
The Bio- Rad DC Protein Assay Kit (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK) 
was used to determine the protein concentration of cell lysates used in SDS-PAGE and 
Western blotting. The test is a colorimetric assay similar to the Lowiy assay.
Exponentially growing cells were dissociated using trypsin, washed twice in cold (4°C) 
PBS, and re-suspended in 120pi of lysis buffer containing 50mM TrisHCL, 150mM 
NaCl, l%NP-40,0.2% SDS, ImMPMSF, lOug/ml Aprotinin, lOug/ml Leupeptin, ImM 
NaV0 4 . Following incubation on ice for 10 minutes, the lysed cells were sonicated on 
ice for 10 seconds (1 cycle, amplitude 80%), and incubated on ice for a fiirther 20 
minutes. To remove nuclei and unbroken cells, the cell samples were centrifiiged at 
2400rpm (522 g) for 10 minutes at 4°C in an Eppendorf 5415R centrifuge (Eppendorf 
UK Ltd., Cambridge, UK). The protein concentration of the samples were determined by 
incubating 5pi of sample (or BSA standard) with 25pi of reagent A  [consisting of 20pl 
of reagent S (sodium dodecyl sulphate) and 1ml of reagent A (alkaline copper tartrate 
solution)] and 200pl reagent B (dilute Folin reagent) for 15 minutes at room temperature.
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The absorbance was read at 690nm on a Labsystems MultiSkan RC plate reader (Thermo 
Electron Corporation, UK), and protein concentrations were determined from a standard 
curve generated for Bovine Serum Albumin (0.2-1.5mg/ml) at 690nm.
2.9 Immunohistochemistry
2.9.1 Patient Information
Eighty seven patients with Dukes’ C colorectal cancer were included in this retrospective 
study. This group consisted of patients vriio underwent radical surgeiy at the Royal 
Surrey County Hospital (Guildford, UK) between January 1990 and December 1998, 
excluding those with no follow- up information, mis-diagnosis, and incomplete histology. 
Cases of peri- and post operative death (i.e. within 30 days after surgery) were excluded 
from this study, as were those with positive tumour resection margins on microscopy, and 
those with tumour blocks in a condition too poor for repeat immunohistochemical use.
Detailed clinicopathological information was available for each patient. This included 
tumour size, grade, presence of lymphovascular invasion, Dukes’ stage, the number of 
nodes involved in metastatic disease, metastasis to the apical node, and wfrether the 
patient had received radiotherapy or chemotherapy. None of the patients had received 
radiotherapy or chemotherapy before surgeiy. Follow up data was obtained by Dr 
Sharadah Essapen (Royal Surrey County Hospital, UK) by thorough review of patient 
notes, and in collaboration with the Thames Cancer Registry (London, UK), or the 
patient’s General Practitioner (Essapen et a l, 2004). Survival was measured from the 
date of patients’ operation until death, or the end of June 2002, whichever came first. For 
patients with recurrent disease, the date and site of relapse was obtained, as well as their 
last observation or date of death.
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2.9.2 Primary Antibodies
Detailed information on the antibodies used in this study can be found in section 2.2. The 
expression of the EGFR in colorectal tumour specimens was determined using three 
different anti-EGFR antibodies. The mAh ICR16 is directed to the external domain of 
the EGFR and has been used in previous studies investigating the expression pattern and 
prognostic significance of the EGFR in patients with breast, head and neck and gastric 
tumours (Gharesi- Fard et a l, 2000; Khademi et al, 2002; Modjtahedi et al, 2003). The 
mouse anti-human EGFR monoclonal antibody clone. 113 (EGFR. 113; Novocastra, UK) 
is also directed to the external domain of the EGFR, and the rabbit anti-human EGFR 
polyclonal antibody (New England Biolabs, UK) is directed to residues surrounding 
tyrosine 1068 of the internal domain of the EGFR.
The levels of phosphorylated EGFR (pEGFR) and EGFRvIII were assessed using the 
rabbit anti-human pEGFR (Tyrosine1068) antibody (New England Biolabs, UK) and the 
mouse anti-human EGFRvIII mAh (clone GlOO; Zymed, USA), respectively (Okamoto et 
al, 2003). The expression of HER-2 was determined using the rat monoclonal antibody 
ICR 12 (Styles et al, 1990; Gharesi- Fard et a l, 2000; Ghaderi et a l, 2002), and the 
expression of IGF-IR was determined using the mouse anti- IGF-IR mAh (Calbiochem, 
USA), which is directed to the external domain of the receptor.
2.9.3 Preparation of sections from tumour specimens and tumour cell pellets
Formalin-fixed paraffin-embedded tumour sections (3 pm) were cut from blocks used for 
histopathological diagnosis, and mounted on glass microscope slides. Sections were de­
waxed in two washes of xylene, and three washes of industrial methylated spirit for 5 
minutes each, and then rehydrated to water. The expression of receptor levels in the
biopsies from the 87 patients was determined using a standard avidin-biotin-peroxidase 
method. Before use in this study, sections from tumour blocks were initially stained with 
haematoxylin and eosin (H+E) to ensure that tumour sections were representative of the 
tumour, and a thorough standardisation procedure was performed to ensure 
reproducibility of staining with the receptor specific antibodies. The optimisation 
procedure included the use of a range of primary and secondaiy antibody concentrations, 
different antigen retrieval methods, and a range of incubation times with the primary 
antibody, on tissue sections as well as positive and negative control cell pellets.
The EGFR expressing human head and neck carcinoma cell line HN5, and tissues known 
to express high levels of EGFR were used as positive controls for EGFR staining. Tissues 
known to express high levels of HER-2 were used as a positive control for ICR 12 
staining, and HC2 20 d2/c cells, which are known to express the EGFRvIII, but not wild 
type EGFR, were used as a positive control for EGFRvIII staining (Wikstrand et al., 
1995; Moscatello et al, 1996). Because the EGFRvIII is associated with a constitutively 
active tyrosine kinase domain, the HC2 20 d2/c cell pellet was also used as a positive 
control for pEGFR expression. When a pEGFR positive case was identified, this was 
also used as a positive control to ensure consistent staining. For IGF-IR staining, the 
IGF-IR expressing cell line MCF-7 was used as a positive control, and the R- cell line 
was used as a negative control. The cell pellets were fixed, embedded, and cut, de-waxed 
and rehydrated in exactly the same way as the tumour sections above. Positive and 
negative controls were included on eveiy day of immunostaining, for each antibody. 
Negative controls consisted of tissue sections incubated with TBS in place of the primary 
antibody. Any anomalous results were repeated.
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2.9.4 Immunostaining with anti-EGFR mAb ICR16 and anti-HER-2 mAb ICR12
Like immunostaining with the rat anti-HER-2 mAh HM64.13 used in previous study 
(Essapen et ah, 2004) no antigen retrieval was necessary in the staining of tumour 
sections with mAh ICR 16 and ICR12. Following the preparation of tumour sections, the 
endogenous peroxidase activity of the tissues was blocked with 3% hydrogen peroxide 
for 5 minutes, followed by three washes in distilled water and a 5 minute wash in TBS. 
Non-specific binding was blocked using rabbit semm in a humidity chamber for 20 
minutes. After blotting off the excess semm, each section was incubated with 200pl of 
ICR 12 or ICR16 culture supernatant (diluted or % with TBS, respectively) overnight 
at 4°C. Each section was washed in TBS for 5 min and then incubated with biotinylated 
rabbit anti-rat secondary antibody (1/300 in TBS; DAKO, UK) for 30 minutes at room 
temperature. After washing with TBS, the tumour sections were incubated with 
avidin/biotin/horseradish peroxidase complex (DAKO, UK) for 30 minutes at room 
temperature. The bound antibody was visualised using liquid diaminobenzidine diluted 
1/50 in HRP substrate buffer (DAKO, UK), and sections were counterstained with 
Mayer’s Haematoxylin for 2 minutes and mounted in Xylene based mounting fluid.
2.9.5 Immunostaining with rabbit anti-EGFR and anti-pEGFR antibodies
Following deparafimisation and rehydration, tumour sections were washed in TBS for 5 
min followed by antigen retrieval in EDTA target retrieval solution (1/10; DAKO, UK) in 
a Goldstar 800W microwave at ftill power for one minute followed by 14 minutes at 
medium power. After allowing to cool for 20 minutes, sections were washed in three 
changes of distilled water, peroxidase blocked and washed as for ICR 12 and ICR 16 (see 
section 2.9.4). The sections were then bio tin blocked using a biotin blocking kit (Zymed, 
USA) and incubated with swine semm for 20 minutes. After blotting off the excess
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serum, the sections were incubated with 200pl of rabbit anti-human EGFR polyclonal 
antibody (diluted 1/50 in TBS) or rabbit anti- human pEGFR antibody (diluted 1/25 in 
TBS) overnight at 4°C. Following three washes in TBS, the tumour sections were 
incubated with biotinylated swine anti-rabbit secondaiy antibody (1/200 in TBS; DAKO, 
UK) for 30 minutes at room temperature. The visualisation, counterstaining and mounting 
were performed as described for the mAh ICR16 and ICR12 (section 2.9.4).
2.9.6 Immunostaining with mouse mAbs to the EGFR, EGFRvIII, and IGF-IR
Following deparafifinisation and rehydration, sections were washed in TBS for 5 minutes 
followed by antigen retrieval in citrate antigen unmasking solution, (1/100; Vector, UK.), 
in a pressure cooker at operating pressure for 1 min. Slides were immersed in tap water 
and washed in TBS for 5 minutes, prior to the blockade of endogenous peroxidase and 
biotin and incubation with rabbit serum for 20 minutes. After blotting off the excess 
semm, each section was incubated for one hour at room temperature with either the 
mouse anti- EGFR mAh EGFR.113 (1/10; Novocastra, UK), mouse anti-EGFRvHI mAh 
clone GlOO (1/50; Zymed, USA) or mouse anti- human IGF-IR mAb (1/50; Calbiochem, 
USA). The bound antibodies were detected by the addition of biotinylated rabbit anti­
mouse secondaiy antibody (DAKO, UK) for 30 minutes at room temperature (1/200 in 
TBS), and processed as for mAb ICR12 and ICR16 (please see section 2.9.4).
2.9.7 Scoring of immunostaining
The immunohistochemical staining with each of the antibodies was scored independently 
by myself and by Dr Margaret Green of the Royal Surrey County Hospital 
(Histopathology Department; Guildford, UK), with no prior knowledge of patient 
outcome or clinicopathological parameters. Sections were scored by the percentage and
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intensity of cells stained. Intensity was categorised as negative (0), weak (1+), 
intermediate (2+), and strong (3+). Membrane and cytoplasmic staining were both 
scored. Scoring was evaluated over the entire section, excluding any visually normal 
(untransformed) and adenomatous tissue. Immunostaining in greater than 10% of tumour 
cells was considered positive for growth factor receptor expression, and any disparity in 
scoring was resolved by simultaneous reassessment by both observers.
2.9.8 Statistical analysis
Statistical analyses were performed using the Statistical Package for the Social Sciences 
(SPSS) version 11.5.1 and 12.0 for Windows (SPSS UK Ltd, Woking, UK). The 
association between patient clinicopathological data and immunohistochemistry scores 
was assessed using the Chi-Squared test (Pearson Chi- Square). Univariate analysis of 
survival was performed using Kaplan-Meier survival plots, and evaluation of differences 
between groups was performed with the log rank test. For multivariate analysis, Cox 
proportional hazards regression analysis was used to determine the impact of patient 
clinicopathological parameters and receptor expression on overall survival. Using a 
stepwise forward selection method, the covariates considered for inclusion in the model 
were site and size of tumour, depth of tumour invasion (i.e. T stage), grade, 
lymphovascular invasion, node stage, (N1 or N2), and the presence of apical node 
métastasés. The effect of patient treatment with chemotherapy or radiotherapy was also 
included in the model. Significance levels for all statistical tests were set at P< 0.05.
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CHAPTER THREE
The expression of EGFR, HER-2 and IGF-IR in human colorectal tumour cells and 
the effect of EGFR and/or IGF-IR inhibitors on tumour cell proliferation.
3.1 Introduction
The aberrant expression of the EGFR has been reported in a wide range of epithelial 
tumours, including cancer of the breast, stomach, ovary, prostate, endometrium, brain, 
lung, colon and rectum (Foekens et ah, 1989; Bigner et a l, 1990; Niikura et al, 1996; 
Leav et al, 1998; Skimisdottir et al, 2001; Ghaderi et a l, 2002; McKay et a l, 2002b; 
Kanematsu et a l, 2003).
Since the early 1980s, a number of strategies have been developed for targeting the 
EGFR in human malignancies. These include ligand antagonists, tyrosine kinase 
inhibitors, antisense technology, antibodies to the receptor or its ligands, and EGFR 
vaccine approaches (Modjtahedi et al, 1998b; McCormick, 2001; Espinoza-Delgado, 
2002; Jansen & Zangemeister-Wittke, 2002; Wakeling, 2002). Of these, the most 
clinically advanced strategies are the anti-EGFR mAbs and the EGFR TKIs (Albanell & 
Gascon, 2005; Modjtahedi, 2005). In several pre-clinical studies, the anti-EGFR mAbs 
and EGFR TKIs have shown anti-tumour activity against a wide range of human EGFR 
expressing tumour cell lines including head and neck, breast, and colorectal cancer cells 
(Bos et al, 1997; Giaccone, 2005) and the anti-EGFR mAh cetuximab (Erbitux) and the 
EGFR TKIs gefitinib and erlotinib have now been approved for the treatment of patients 
with metastatic colorectal cancer and NSCLC (Albanell & Gascon, 2005; Modjtahedi, 
2005). However, there has been no clear association between the expression of EGFR
and response to the EGFR inhibitors in pre-clinical and clinical studies (Bos et al, 1997; 
Janmaat et a l, 2003; Campiglio et a l, 2004; Cunningham et a l, 2004; Saltz et al, 2004; 
Moroni et al, 2005). In addition, compared to conventional forms of therapy, treatment 
of patients with cetuximab, gefitinib, and erlotinib is currently expensive. For example, 
the cost for 2 weeks treatment with cetuximab is at least $2,400 (Schrag, 2004). 
Consequently, there is a need for fiirther studies to identify more specific predictive 
biomarkers which aid in the selection of patients who benefit from therapy with the 
EGFR inhibitors.
Several studies in the experimental setting have shown that continuous activation of the 
IGF-IR pathway may be one of the factors responsible for the development of tumour 
cells resistant to therapy with the anti-HER-2 mAh trastuzumab and EGFR inhibitors (Lu 
et al, 2001 ; Camirand et al, 2002; Chakravarti et a l, 2002). The aim of this chapter was 
therefore to examine the cell surface expression of the EGFR, HER-2, and IGF-IR in a 
panel of human colorectal tumour cell lines, and to determine the effect of anti-EGFR 
mAh, EGFR TKI and an IGF-IR TKI on the growth of such cell lines. In addition, the 
therapeutic advantage of combining anti-EGFR mAb with EGFR TKI as well as 
combining the EGFR inhibitors with an IGF-IR inhibitor was investigated together with 
the relationship between receptor expression and growth inhibition by the EGFR and/or 
IGF-IR inhibitors.
3.2 The cell surface expression of EGFR, HER-2, and IGF-IR in human 
colorectal tumour cell lines
The cell surface expression of the EGFR, HER-2 and IGF-IR in a panel of human Dukes’ 
stage A-C colorectal tumour cell lines was determined using FACS analysis. Briefiy,
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human colorectal tumour cells were incubated for one hour with antibodies to the external 
domain of the EGFR, HER-2, or IGF-IR respectively. Following one hour incubation 
with FITC conjugated antibody, the receptor levels were analysed using a Beckman 
Coulter Epics XL flow cytometer. The HN5 (1.4x10^ EGFR molecules/cell), SKBR3 
(1.3x10^ HER-2 molecules/cell), and MCF-7 (6x10"^  IGF-IR molecules/cell) cell lines 
were used as positive controls (Cowley et a l, 1986; Guvakova & Surmacz, 1997; Boente 
et al, 1998).
The cell surface expression of the EGFR, HER-2 and IGF-IR detected in the panel of 
human colorectal tumour cell lines and control cell lines is summarised in Table 3.1. Of 
the human colorectal cancer cell lines, DiFi was found to express the highest levels of the 
EGFR, with a mean fluorescence intensity (MFI) of 169.6. In contrast, the expression of 
EGFR was much lower in the remaining 11 colorectal cancer cell lines examined in this 
study (MFI 8.4 to 23), including the two newly established human colorectal cancer cell 
lines, Colo2 and Colol3. Interestingly, EGFR expression was found to be lower in the 
cell lines established from Dukes’ A (Colo2) and Dukes’ B (CCL228) tumours than the 
cell lines established from Dukes’ C tumours (Colo 13, CCL221,225,227,231).
The cell surface expression of HER-2 was also examined by FACS analysis. As the 
results in Table 3.1 show, the expression of HER-2 was also found to much lower in this 
panel of human colorectal cancer cell lines, ranging from a MFI of only 9.0 in HCT-116 
cells to 40.1 in the CCL-225 cell line, when compared to HER-2 expression in SKBR3 
cells (MFI 206.1). The expression of IGF-IR in the panel of cell lines was examined with 
a commercial anti-IGF-IR antibody. As the results in Table 3.1 show, the expression of 
IGF-IR in the DiFi (MFI 18.6), CCL221 (MFI 20.3), and CCL231 (MFI 19.8) cell lines
70
Table 3.1. Summary of cell surface expression of EGFR, HER2, and IGF-IR 
measured by FACS analysis in colorectal tumour cell lines. 1x10  ^human colorectal 
tumour cells were incubated for one hour with lOpg/ml of anti-EGFR mAb HM43.16B, 
anti-HER-2 mAb HM50.67A, a commercial anti-IGF-IR antibody, or control medium. 
Tumour cells were incubated with FITC conjugated antibody, and 10,000 events were 
recorded and analysed for receptor expression, as described under Materials and 
Methods. The data is presented as mean intensity of fluorescence ±SD.
Cell Line Mean Intensity of fluorescence ± SD
Control EGFR HER-2 IGF-IR
DiFi 3.6 ±0.34 169.6 ±0.34 19.6 ±0.96 18.6 ±0.35
Colo2 2.3 ±0.26 13.5 ±0.01 9.9 ±0.25 9.5 ±0.13
Colol3 4.5 ±0.41 23.0 ±0.02 9.6 ±0.37 9.0 ±0.07
HCT-116 2.3 ±0.19 9.0 ±0.2 9.0 ±0.5 10.4 ±0.09
CCL218 2.1 ±0.21 8.4 ±0.1 14.7 ±0.99 9.6 ±0.39
CCL221 3.7 ± 0.36 21.1 ±0.17 32.6 ± 1.3 20.3 ±0.55
CCL225 4.0 ±0.33 19.8 ±0.1 40.1 ±1.52 15.3 ±0.26
CCL227 2.9 ±0.31 19.2 ±0.08 15.5 ±0.84 11.9 ±0.71
CCL228 3.4 ±0.24 12.2±0.13 11.8 ±0.64 12.5 ±0.76
CCL231 3.5 ±0.36 20.4 ±0.63 21.8 ±0.09 19.8 ±0.1
CCL235 3.3 ±0.22 17.2 ±0.09 17.2 ±0.55 16.5 ±0.22
CCL244 4.0 ±0.28 13.2 ±0.013 20.1 ±0.12 13.8 ±0.18
HNS 4 ±0.28 186.1 ±11.4 12.3 ±0.12 27.8 ±1.1
SKBR3 2.5 ±0.09 11.2±0.17 206.1 ±5.6 12.9 ±0.04
MCF-7 4.1 ±0.13 20.9 ±0.04 17.8 ±0.34 20.6 ±0.78
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was close to TGF-TR levels in the control cell line MCF-7 (MFI 20.6). While the EGFR 
overexpressing control cell line HN5 expressed the highest levels of the IGF-IR (MFI 
27.8), the expression of IGF-IR was found to be lower in the other colorectal cells (MFI 
of 9.0- 20.3).
Therefore, from a panel of 12 human Dukes’ A to C colorectal cancer cell lines examined 
here, including two newly established colorectal cell lines, only DiFi cells express high 
levels of the EGFR and the expression levels of EGFR, HER-2 and IGF-IR are low to 
moderate in other colorectal cell lines. Histograms for EGFR, HER-2, and IGF-IR 
expression in selected human colorectal cell lines (i.e. DiFi, CCL235, CCL218, HCTl 16) 
and in the control cell lines HN5 (EGFR overexpressing) and SKBR3 (HER-2 
overexpressing) are illustrated in Figure 3.1.
33 The phosphoiylation status of the EGFR in human colorectal tumour cells
Sensitivity to the EGFR inhibitors may not simply depend on levels of EGFR expression 
(Arteaga, 2002; Ciardiello & Tortora, 2003). Therefore, following the determination of 
cell surface EGFR, HER-2 and IGF-IR expression, the phosphorylation status of the 
EGFR and the effect of exogenous EGFR ligands (EGF, HB-EGF) or IGF-IR ligands 
(IGF-I, IGF-II) on EGFR tyrosine-phosphoiylation was examined by Western blotting.
As shown in Figure 3.2a, of the panel of human colorectal tumour cell lines, the EGFR on 
DiFi cells was found to be constitutively active (i.e. tyrosine phosphorylated). The effect 
of exogenous growth factor on EGFR phosphorylation in selected human colorectal 
tumour cells is shown in Figure 3.2b.
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Figure 3.1. Cell surface expression of EGFR, HER2, and IGF-IR measured by 
FACS analysis in a panel of human colorectal and control cell lines. Human 
colorectal tumour cells (A-D), EGFR overexpressing HN5 cells (E) and HER-2 
overexpressing SKBR3 cells (F) were incubated for one hour with anti-EGFR mAb 
HM43.16B, anti-HER-2 mAb HM50.67A, a commercial anti-lGF-lR antibody, or control 
medium followed by incubation with FITC conjugated secondary antibodies. Data was 
analysed as described under Material and Method section 2.5.
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As the results show, EGFR tyrosine phosphorylation in DiFi cells was increased further 
following treatment with lOnM EGF and HB-EGF. In contrast, there was no IGF-I or 
IGF-II induced EGFR phosphorylation in DiFi cells. Interestingly, while there was also 
strong EGF and HB-EGF induced EGFR phosphorylation of EGFR overexpressing HN5 
cells, these cells did not contain a constitutively active EGFR (Figure 3.2b).
Of the remaining colorectal tumour cell lines, CCL 231 was most sensitive to treatment 
with exogenous EGF and demonstrated a strong increase in EGFR phosphorylation. 
However, HB-EGF was not as effective as EGF at increasing tyrosine-phosphorylation of 
the EGFR in CCL231 cells (Figure 3.2b). Prolonged exposure of PVDF membranes to 
scientific imaging film (i.e. >10 min) was required to detect EGFR phosphorylation in the 
remaining cell lines. However, there was only a moderate increase in the levels of EGF 
and HB-EGF induced EGFR phosphorylation in CCL218 (data not shown) and CCL235 
cells (Figure 3.2b), and minimal phosphorylation in the remaining cell lines (data not 
shown). While there was also modest IGF-I and IGF-II induced EGFR phosphorylation 
in HN5 and CCL235 cells, EGFR phosphorylation in response to the IGF-IR ligands was 
much lower in the remaining cell lines despite prolonged exposure of PVDF membranes 
to scientific imaging film (e.g. see CCL231 in Figure 3.2b). This is in accordance with 
the low levels of IGF-IR expression found in this panel of cell lines (Table 3.1).
Therefore, of the 12 human colorectal tumour cell lines examined in this study, DiFi 
expressed the highest levels of the EGFR, which were constitutively active. While the 
HN5 control cell line expressed more EGFR than DiFi cells, the EGFR on HN5 cells was 
not constitutively active. In addition, there was no clear correlation between the levels of
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Figure 3.2. EGFR tyrosine-phosphorylation status in human colorectal tumour 
cell lines and their response to the EGFR or IGF-IR ligands. Human tumour cells 
growing under normal conditions were lysed, quantified, and 50pg of transferred protein 
was probed for the EGFR phospho-tyrosine (170kDa), or (3-Actin loading control (A), as 
described under Materials and Methods section 2.8. Alternatively, colorectal tumour cell 
lines growing under normal growth conditions were incubated in DM EM containing 
0.1 % FCS for one hour prior to the addition of lOnM EGF, HB-EGF, IGF-I, IGF-II, or no 
growth factor (NS) for 15 minutes. Tumour cells were lysed and equal amounts of cell 
lysate were separated by SDS PAGE, transferred to PVDF membranes, and probed with 
an antibody to phospho-tyrosine (B).
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EGFR, HER-2, or IGF-IR expression and EGFR phosphoiylation in the other 11 
colorectal cancer cell lines.
3.4 The effect of EGFR or IGF-IR inhibitors on the proliferation of human 
colorectal tumour cells
Having determined the levels of EGFR, HER-2 and IGF-IR, and constitutively active 
EGFR (i.e. tyrosine-phosphoiylated) in the panel human colorectal tumour cell lines, the 
effect of the anti-EGFR mAh ICR62, the EGFR TKIs (gefitinib and erlotinib) and the 
IGF-IR TKI (NVP-AEW541) on the growth of these cells was investigated. Since there 
has been no clear correlation between EGFR expression and response to the EGFR 
inhibitors (Ciardiello & Tortora, 2003; Modjtahedi, 2005), the aim of this series of 
experiments was also to investigate the relationship between EGFR, HER-2 and IGF-IR 
expression and response to the EGFR and/or IGF-IR inhibitors.
3.4.1 Treatment with mAh ICR62, gefitinib or erlotinib as single-agent
The effects of EGFR inhibitors on the proliferation of human colorectal tumour cell lines 
were investigated using a colorimetric assay as described under Materials and Methods in 
section 2.6. For this purpose, tumour cells were incubated in 96-well plates in the 
presence of ICR62, gefitinib, erlotinib, or control medium at 37°C until the cells in wells 
containing control medium were confluent (6-12 days depending on the cell line).
Of the 12 human colorectal cancer cell lines investigated in this study, only the EGFR 
overexpressing cell line DiFi was highly sensitive to the EGFR inhibitors (Figure 3.3 & 
3.4). As the results in Figure 3.3a show, complete growth inhibition of DiFi cells by 
mAb ICR62 was achieved at a concentration of 3.2nM ( I C 50  = 0.52nM). In contrast, the
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same concentrations of the EGFR TKIs were not as effective as ICR62 at inhibiting the 
growth of DiFi cells. While the growth of DiFi cells was inhibited completely by 87.4nM 
gefitinib (IC50 = 27.5nM), erlotinib was less effective and at 200nM only inhibited the 
growth of DiFi cells by 35% (Figure 3.3a). This is in contrast to the growth of HN5 cells, 
which was inhibited by all three EGFR inhibitors (Figure 3.4). As the results presented 
in Figure 3.3 show, like DiFi cells, CCL244 cells were also more sensitive to treatment 
with mAh ICR62 than the EGFR TKIs, but none of the three EGFR inhibitors inhibited 
the growth of CCL244 cells in culture completely (Figure 3.3b). However, the remaining 
1 0  colorectal tumour cell lines investigated in this study were not as sensitive to growth 
inhibition by 200nM mAb ICR62, gefitinib, or erlotinib (Figure 3.4).
Because the majority of human colorectal tumour cell lines examined in this study were 
found to be insensitive to 200nM concentrations of the EGFR inhibitors, and because the 
growth of DiFi cells was not completely inhibited by 200nM erlotinib, further studies 
were conducted using a higher concentration of the EGFR TKIs (up to 500nM). As the 
results in Figure 3.4 show, in contrast to 200nM, there was complete growth inhibition of 
DiFi cells treated with 500nM erlotinib. Complete growth inhibition of DiFi cells by 
erlotinib was achieved at 250nM, with an IC50 of 133.6nM (data not shown). However, 
with the exception of DiFi, CCL235 and CCL244 cells, the majority of human colorectal 
tumour cell lines were still insensitive to 500nM concentrations of gefitinib and erlotinib, 
with only a slight increase in growth inhibition in several cell lines (Figure 3.4).
Interestingly, gefitinib has been reported to inhibit the growth of EGFR expressing cells 
with or without HER-2 expression and cells with low EGFR expression may be more
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Figure 3.3. The effect of mAh ICR62, gefitinib or erlotinib on the growth of DiFi 
and CCL244 cells. Tumour cells were grown in DMEM/2%FCS containing mAb 
ICR62, gefitinib, erlotinib, or control medium, until cells in wells containing control 
medium were confluent. Tumour cell proliferation was calculated as a percentage of 
control cell growth, as described under Materials and Methods in section 2.6. Each point 
represents the mean ± SD of triplicate values.
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Figure 3.4. The effect of mAb ICR62, gefitinib or erlotinib on the growth of 
human colorectal tumour cells. Tumour cells were grown in DMEM/2%FCS 
containing mAb ICR62 (A), gefitinib (B), erlotinib (C), or control medium, until cells in 
wells containing control medium were confluent. Tumour cell proliferation was 
calculated as a percentage of control cell growth, as described under Materials and 
Methods in section 2.6. Each point represents the mean ±SD of triplicate values at the 
highest concentrations of the EGFR inhibitors.
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sensitive to gefitinib if they express the HER-2 (Moasser et al., 2001; Moulder et al., 
2001; Anido et a l, 2003).
Indeed as shown in figure 3.4b, 500nM gefitinib inhibited the growth of HER-2 
overexpressing SKBR3 cells by 82%, vdiile mAb ICR62 (Figure 3.4a) and erlotinib 
(Figure 3.4c) did not inhibit the growth of SKBR3 cells in culture. The results presented 
here suggest that there are differences in the modes of action of the anti-EGFR mAb and 
the EGFR TKIs, and also between the EGFR TKIs gefitinib and erlotinib. However, of 
the 12 colorectal cancer cell lines investigated herein, DiFi cells, which overexpress the 
EGFR (Table 3.1) and contain a constitutively active EGFR (Figure 3.2), were the most 
sensitive human colorectal tumour cell line to treatment with all three EGFR inhibitors.
3.4.2 Treatment with mAh ICR62 in combination with gefitinib or erlotinib
The different modes of action of the anti-EGFR mAbs and EGFR TKIs provides the 
possibility of enhanced anti-tumour efficacy by simultaneously blocking the ligand 
binding domain and ATP binding domain of the EGFR. Consequently, having 
determined the effects of mAh ICR62, gefitinib, or erlotinib as single-agent in the panel 
of colorectal tumour cells, the growth inhibitory effects of mAb ICR62 in combination 
with the EGFR TKIs was investigated.
As the results presented in 3.5 show, mAh ICR62 in combination with gefitinib inhibited 
the growth of CCL227 cells by a further 10% when compared to treatment with the 
single-agent. Similarly, as the results presented in Figure 3.6 show, mAh ICR62 in 
combination with erlotinib inhibited the growth of Colo 13 cells by a firrther 11% when 
compared to treatment with the single-agent. However, the growth inhibition of the
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remaining tumour cells was increased by less than 10% with mAh ICR62 in combination 
with gefitinib or erlotinib, and this is within the standard deviations of the sample 
triplicates (Figure 3.5 & 3.6). Therefore, in this study, the combination of anti-EGFR 
mAb and EGFR TKI is not superior to treatment with the single-agent inhibitor, and as 
the results in Figure 3.7 show, this was found for cells with high and low EGFR 
expression (T able 3.1).
3.4.3 The effect of mAh ICR62 in combination with gefitinib or erlotinib using the 
method of Matar and colleagues
The effect of combining mAb ICR62 with gefitinib or erlotinib was also investigated 
using the same method and concentrations of inhibitors used by Matar and colleagues 
(2004), who recently found that combination of the anti-EGFR mAh cetuximab and 
gefitinib resulted in the synergistic growth inhibition of DiFi cells (Matar et a l, 2004). 
For this purpose, DiFi cells were incubated in DMEM/10% FCS for 24 hours at 37°C 
prior to treatment with mAh ICR62 (0.5, 5, and 50nM) and gefitinib or erlotinib (0.1, 1, 
and lOpM) for 72 hours at 37°C. However, as the results presented in Figure 3.8 show, 
there was still no substantial increase in growth inhibition with the combination of mAb 
ICR62 and gefitinib or erlotinib when compared to treatment with the single agent.
In addition, experiments were repeated using the concentrations of inhibitors used by 
Matar and colleagues (2004) in which DiFi cells were incubated with the inhibitors for a 
longer duration (i.e. for 12 days until cell in wells containing control medium were 
confluent, as in Figure 3.3).
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Figure 3.5. The effect of mAh ICR62 in combination with gefitinib on the growth 
of human colorectal tumour cells. Tumour cells were grown in DMEM/2%FCS 
containing mAb ICR62 (200nM) and/or gefitinib (200nM), or control medium, until cells 
in wells containing control medium were confluent. Tumour cell proliferation was 
calculated as a percentage of control cell growth, as described under Materials and 
Methods section 2.6. The growth inhibition of human colorectal tumour and positive 
control cells by the highest tested concentration of mAh ICR62 and/or gefitinib is shown. 
Each point represents the mean ±SD of triplicate values.
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Figure 3.6. The effect of mAh ICR62 in combination with erlotinib on the growth 
of human colorectal tumour cells. Tumour cells were grown in DMEM/2%FCS 
containing mAb ICR62 (200nM) and/or erlotinib (200nM), or control medium, until cells 
in wells containing control medium were confluent. Tumour cell proliferation was 
calculated as a percentage of control cell growth, as described under Materials and 
Methods section 2.6. The Growth inhibition of human colorectal tumour and positive 
control cells by the highest tested concentration of mAh ICR62 and/or erlotinib is shown. 
Each point represents the mean ±SD of triplicate values.
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Figure 3.7. The effect of mAh ICR62 in combination with gefitinib or erlotinib on 
the growth of human colorectal tumour cells with high (A) and low (B) EGFR 
expression. Tumour cells were grown in DMEM/2%FCS containing mAb ICR62, 
gefitinib, erlotinib, or control medium, until cells in wells containing control medium 
were confluent. Tumour cell proliferation was calculated as a percentage of control cell 
growth, as described under Materials and Methods section 2.6. Each point represents the 
mean ±SD of triplicate values.
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These experiments were performed in DMEM containing 2% and 10% FCS, as the 
concentration of serum used by Matar and colleagues (2004) was not indicated. 
However, as the results presented in Figure 3.9 show, while all three inhibitors were more 
effective at inhibiting the growth of DiFi cells growing in 2% FCS, there was still no 
synergistic growth inhibition of DiFi cells using mAb ICR62 in combination with either 
gefitinib or erlotinib. Furthermore, there was no synergistic inhibition of growth in DiFi 
cells treated with another anti-EGFR mAb, ICR16, in combination with gefitinib or 
erlotinib (data not shown).
3.4.4 The reversibility of growth arrest induced by the EGFR inhibitors
Having determined that the EGFR inhibitors inhibit the growth of DiFi cells in culture, it 
was next investigated whether the growth arrest was reversible or permanent and whether 
there were differences in the growth arrest induced by anti-EGFR mAb and EGFR TKI. 
For this purpose, DiFi cells were incubated for 5 days or 10 days with growth inhibitory 
concentrations of mAb ICR62, gefitinib, or erlotinib. In parallel, DiFi cells were 
incubated with the EGFR inhibitors for 5 days, followed by removal of the inhibitors and 
incubation for a firrther 5 days in fresh medium without inhibitors.
As the results presented in Figure 3.10 show, following treatment of DiFi cells for 5 days 
with mAb ICR62, gefitinib, and erlotinib, there was a reduction in the initial number of 
cells seeded on the first day of the experiment, indicating the induction of apoptosis by 
each of the EGFR inhibitors. Following removal of the EGFR inhibitors and incubation 
in fresh growth medium for 5 days, there was an increase in the number of DiFi cells 
treated with each of the inhibitors, suggesting that growth arrest by mAb ICR62, 
gefitinib, and erlotinib is reversible in the majority of DiFi cells (Figure 3.10).
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Figure 3.8. The effect of mAh ICR62 in combination with gefitinib or erlotinib on 
the growth of human colorectal tumour cells by the method of Matar and 
colleagues. DiFi cells were seeded in DMEM containing 10% FCS for 24 hours and 
incubated with ICR62 in combination with gefitinib (A) or erlotinib (B) at the same 
concentrations used by Matar and colleagues (2004) for 72 hours. Each point represents 
the mean ±SD of triplicate values.
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Figure 3.9. The effect of mAh ICR62 in combination with gefitinib or erlotinib on 
the growth of human colorectal tumour cells using the same concentrations as 
Matar and colleagues. DiFi cells grown in DMEM containing 2% FCS (A) or 10% FCS 
(B), were incubated with mAb ICR62, gefitinib, erlotinib, or control medium for 12 days, 
until the cells in wells containing medium were confluent. Each point represents the 
mean ±SD of triplicate values.
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Figure 3.10. The reversibility of growth arrest induced by the EGFR inhibitors.
DiFi cells were grown in DMEM/2%FCS containing mAb ICR62 (200nM), gefitinib 
(400nM), or erlotinib (400nM) continuously for 5 days or 10 days. In parallel, DiFi cells 
were incubated with the EGFR inhibitors for 5 days, followed by removal of the 
inhibitors and incubation for a further 5 days in fresh medium without inhibitors. 
Tumour cell proliferation was calculated as a percentage of control cell growth, as 
described under Materials and Methods in section 2.6. Each point represents the mean 
±SD of triplicate values.
Indeed, growth inhibition was maintained in cells cultured continuously with the EGFR 
inhibitors for 10 days. However, growth arrest induced by gefitinib may be less 
reversible than that induced by ICR62 or erlotinib. Following removal of the EGFR 
inhibitors, there was 17%, and 38% growth of DiFi cells treated with mAh ICR62 and 
erlotinib, respectively, but only 1% growth of DiFi cells treated with gefitinib (Figure
3.10). This could be due to the induction of more apoptosis in DiFi cells by gefitinib than 
by ICR62 or erlotinib.
3.4.5 The effect of combination of EGFR and IGF-IR inhibitors on the growth of 
human colorectal tumour cells
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A E W 5 4 1  i n h i b i t e d  t h e  g r o w t h  o f  C C L 2 1 8  c e l l s  b y  6 7 %  w i t h  a n  I C 50  o f  4 2 6 n M .  
H o w e v e r ,  t h e r e  a p p e a r s  t o  b e  n o  c l e a r  c o r r e l a t i o n  b e t w e e n  I G F - I R  e x p r e s s i o n  d e t e r m i n e d  
b y  F A C S  a n a l y s i s  ( T a b l e  3 . 1 )  a n d  r e s p o n s e  t o  N V P - A E W 5 4 1 ,  s i n c e  t h e  g r o w t h  o f  c e l l s  
w i t h  l o w  I G F - I R  e x p r e s s i o n  ( e . g .  C o l o  1 3 )  w a s  i n h i b i t e d  m o r e  t h a n  s o m e  c e l l s  w i t h  h i g h e r  
l e v e l s  o f  I G F - I R  e x p r e s s i o n  ( e . g .  C C L  2 2 1 ,  C C L 2 3 1 ;  T a b l e  3 . 1  &  F i g u r e  3 . 1 2 ) .
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Figure 3.11. The effect of NVP-AEW541 on the growth of tumour cells most 
sensitive to this inhibitor. Tumour cells were grown in DMEM/2%FCS containing the 
IGF-IR TKI (NVP-AEW541) or control medium, until cells in wells containing control 
medium were confluent. Tumour cell proliferation was calculated as a percentage of 
control cell growth, as described under Materials and Methods section 2.6. Each point 
represents the mean ±SD of triplicate values.
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Figure 3.12. The effect of NVP-AEW54I on the growth of human colorectal 
tumour ceils. Tumour cells were grown in DMEM/2%FCS containing NVP-AEW541 
or control medium, until cells in wells containing control medium were confluent. 
Tumour cell proliferation was calculated as a percentage of control cell growth, as 
described under Materials and Methods section 2.6. Growth inhibition of human 
colorectal tumour and positive control cells by the highest tested concentration of NVP- 
AEW541 are shown. Each point represents the mean ±SD of triplicate values.
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Next, the effect of NVP-AEW541 in combination with mAh TCR62, gefitinib and 
erlotinib was investigated, and the results are presented in Figures 3.13, 3.14, and 3.15 
respectively. There was increased growth inhibition in the majority of cells treated with 
a combination of NVP-AEW541 and the EGFR inhibitors when compared to treatment 
with the single agent (Figure 3.13 to 3.15). In particular, the increase in growth inhibition 
was above additive (by >10%) in a number of cell lines treated with NVP-AEW541 in 
combination with ICR62 (Colol3, CCL227, CCL244), gefitinib (Colol3, CCL221, 
CCL225, CCL227, CCL231, CCL244) or erlotinib (CCL225, CCL227, CCL244). As 
shown in Table 3.2, using the combination ratio of Yang and colleagues (2005), the 
combination of NVP-AEW541 with the EGFR inhibitors in each of theses cell lines was 
confirmed as synergistic.
Interestingly, of the colorectal tumour cell lines, while CCL218 cells were most sensitive 
to NVP-AEW541 (Figure 3.12), the combination of NVP-AEW541 with the EGFR 
inhibitors did not result in enhanced growth inhibition of this cell line when compared to 
treatment with single-agent NVP-AEW541. Indeed, while CCL218 cells were inhibited 
by 67% with NVP-AEW541 and 14% by gefitinib, their combination only inhibited 
CCL218 cells by 46% (Figure 3.14), and the combination ofNVP-AEW541 with each of 
the EGFR inhibitors was found to be antagonistic by the combination ratio (Table 3.2). 
Therefore, in some human colorectal tumour cell lines, combination of the EGFR and 
IGF-IR inhibitors may be superior over treatment with the single agent. However, there 
is no clear correlation between EGFR, HER-2, and IGF-IR expression and response to the 
combination of EGFR and IGF-IR inhibitors (Table 3.1; Figure 3.12-3.15).
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Figure 3.13, The eflFect of mAb ICR62 in combination with NVP-AEW541 on the 
growth of human colorectal tumour cells. Tumour cells were grown in 
DMEM/2%FCS containing mAb ICR62 (lOOnM) and/or NVP-AEW541 (500nM) or 
control medium, until cells in wells containing control medium were confluent. Tumour 
cell proliferation was calculated as a percentage of control cell growth, as described 
under Materials and Methods section 2.6. Growth inhibition of human colorectal tumour 
and positive control cells by the highest tested concentrations of the inhibitors are shown. 
Each point represents the mean ±SD of triplicate values.
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Figure 3.14. The effect of gefitinib in combination with NVP-AEW54I on the 
growth of human colorectal tumour cells. Tumour cells were grown in 
DMEM/2%FCS containing gefitinib (500nM) and/or NVP-AEW541 (SOOnM), or control 
medium, until cells in wells containing control medium were confluent. Tumour cell 
proliferation was calculated as a percentage of control cell growth, as described under 
Materials and Methods section 2.6. Growth inhibition of human colorectal tumour and 
positive control cells by the highest tested concentrations of the inhibitors are shown. 
Each point represents the mean ±SD of triplicate values.
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Figure 3.15. The effect of erlotinib in combination with NVP-AEW541 on the 
growth of human colorectal tumour cells. Tumour cells were grown in 
DMEM/2%FCS containing erlotinib (500nM) and/or NVP-AEW541 (500nM), or control 
medium, until cells in wells containing control medium were confluent. Tumour cell 
proliferation was calculated as a percentage of control cell growth, as described under 
Materials and Methods section 2.6. Growth inhibition of human colorectal tumour and 
positive control cells by the highest tested concentrations of the inhibitors are shown. 
Each point represents the mean ±SD of triplicate values.
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Table 3Jl. The effect of NVP-AEW541 in combination with mAb ICR62, 
gefitinib, or erlotinib on the growth of human colorectal tumour cells using the 
combination ratio. The combination ratio ±SD determined using the method of Yang 
and colleagues (2005) for the statistical analysis of growth inhibition by NVP-AEW541 
(500nM) in combination with mAh ICR62 (lOOnM), gefitinib (500nM), or erlotinib 
(500nM) versus single agent treatment. Using the combination ratio, a value of <0.9 is 
considered synergistic, 0.9-1 additivity, and >1 antagonistic. For the HN5 and DiFi cell 
lines, 100% growth inhibition was achieved by the anti-EGFR agents alone, and the 
combination ratio was not applicable (N/A) for these cell lines.
Cell Line Combination ratio ± SD
NVP-AEW541 + 
ICR62
NVP-AEW541 ± 
Gefitinib
NVP-AEW541 ± 
Erlotinib
DiFi N/A N/A . N/A
Colo2 0.91 ± 0.023 0.90 ± 0.03 0.93 ± 0.002
CololS 0.77 ±0.028 0.52 ± 0.007 0.82 ± 0.007
HCT-116 0.95 ±0.016 0.97 ±0.013 0.96 ± 0.042
CCL-218 2.22 ± 0.03 1.91 ±0.074 1.99 ±0.023
CCL-221 0.95 ± 0.005 0.70 ±0.02 1.03 ±0.01
CCL-225 0.90 ±0.021 0.89 ± 0.001 0.87 ± 0.008
CCL-227 0.85 ± 0.028 0.87 ±0.009 0.83 ± 0.007
CCL-228 0.98 ± 0.002 0.92 ±0.047 0.95 ± 0.003
CCL-231 1.10 ±0.035 0.79 ±0.012 0.9 ± 0.05
CCL-235 0.75 ± 0.042 0.20 ± 0.072 0.46 ± 0.021
CCL-244 0.68 ± 0.027 0.71 ±0.018 0.71 ± 0.029
HN5 N/A N/A N/A
SKBR3 1.14 ±0.034 1.28 ±0.07 1.16 ±0.007
MCF-7 1.1 ±0.017 0.89 ±0.101 1.07 ±0.049
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3.5 The effect of MAPK and PI-3K inhibitors on the growth of human colorectal 
tumour cells
In section 3.4 (Figure 3.4 & 3.12), the majority of human colorectal tumour cell lines 
used in this study were found to be insensitive to the EGFR and IGF-IR inhibitors. 
However, other members of the ErbB femily (e.g. HER-2, HER-3) and other 
heterologous receptors (e.g. VEGFR, PDGFR) can activate the MAPK and PI-3K 
pathways within tumour cells (Schlessinger, 2000; Moasser et a l, 2001 ; Normanno et al,
2003). Consequently, the effect of a PI-3K inhibitor (LY294002) and/or a MAPK 
inhibitor (U0126) on the growth of selected human tumour cell lines found to be sensitive 
or resistant to the EGFR inhibitors was investigated. For this purpose, tumour cells were 
incubated with the recommended concentration of LY294002 and/or U0126 or medium 
only control until the cells incubated with control medium were confluent.
As shown in Figure 3.16, the growth of tumour cells both sensitive (DiFi, HN5) and 
resistant (CCL225, CCL228) to the EGFR inhibitors was inhibited by LY294002 and 
U0126. At 50pM of the PI-3K inhibitor, the growth of DiFi, CCL225, and HN5 cells 
were inhibited completely and the growth of CCL228 cells was inhibited by 72% (Figure 
3.16). In addition, the growth of the CCL235 cell line, which was fairly sensitive to the 
EGFR inhibitors (Figure 3.4) was also inhibited completely by 50jxM of the PI-3K 
inhibitor (data not shown). At 20pM of the MAPK inhibitor, the growth of DiFi, 
CCL225, CCL228, and HN5 cells were inhibited by 81%, 39%, 33%, and 79%, 
respectively. In addition, there was 84% growth inhibition in the CCL235 cell line (data 
not shown).
Using a combination of the MAPK and PI-3K inhibitors, there was increased growth 
inhibition in each of the cell lines Wien compared to the single agent (Figure 3.16). 
However, while mAh ICR62, gefitinib, and erlotinib were found to completely inhibit the 
growth of DiFi cells with IC50 values o f0.52,27.5, 134nM (please see section 3.3.1), the 
growth of DiFi (as well as CCL225, CCL228, CCL235, and HN5) cells was unaffected 
by these concentrations of MAPK and/or PI3K inhibitors (Figure 3.16).
3.6 Discussion
The anti-EGFR mAbs and EGFR TKIs have shown good in-vitro and in-vivo activity in 
EGFR expressing cells or tumours from a range of human tissues (Bos et al, 1997; 
Sirotnak et al, 2000; Campiglio et a l, 2004; Matar et al, 2004). Consequently, a 
number of anti-EGFR mAbs and EGFR TKIs have progressed through clinical trials, and 
the anti-EGFR mAh cetuximab and the EGFR TKIs gefitinib and erlotinib have now been 
approved for the treatment of cancer patients (Albanell & Gascon, 2005; Modjtahedi, 
2005). However, there has been no clear association between the expression of EGFR 
and response to the EGFR inhibitors in pre-clinical and clinical studies (Ciardiello & 
Tortora, 2003; Campiglio et al, 2004; Saltz et al., 2004). Since treatment of patients 
with cetuximab, gefitinib, and erlotinib is currently expensive compared to conventional 
forms of therapy (Schrag, 2004), there is a need for further studies to identify more 
specific predictive biomarkers for response to therapy with the EGFR inhibitors.
In this chapter, the cell surface expression of the EGFR, HER-2, and IGF-IR was 
examined in a panel of 12 human colorectal cancer tumour cell lines. The aim was to 
investigate the relationship between growth factor receptor expression and response to the
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Figure 3.16, The effect of U0126 and/or LY294002 on the growth of human 
tumour cell lines. Tumour cells were grown in DMEM/2%FCS containing U0126 
and/or LY294002, or control medium, until cells in wells containing control medium 
were confluent. Tumour cell proliferation was calculated as a percentage of control cell 
growth, as described under Materials and Methods in section 2.6. Each point represents 
the mean ±SD of triplicate values.
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anti-EGFR mAbs, EGFR TKIs, an IGF-IR TKI as well as inhibitors to the MAPK and FI­
SK molecules.
While EGFR, HER-2, or IGF-IR expression has been reported for several of the cell lines 
used in this study, no study has examined the expression of all three growth factor 
receptors in this panel of 12 human colorectal tumour cell lines, which included the 
newly established Colo2 and CololS cell lines. Of the colorectal tumour cell lines 
studied here, DiFi was found to express the highest levels of the EGFR (Table S.l). 
Indeed, the DiFi cell line has previously been shown to express 4.1x10^ EGFR 
molecules/ cell (Gross et aA,1991; Olive et al., 199S; Untawale et a l, 199S). In contrast, 
EGFR expression was found to be much lower in the other 11 human colorectal tumour 
cell lines (Table S.l). This is in common with a recent study in which EGFR protein and 
gene copy number were found to be much higher in DiFi cells than in CCL221 (DLD-1), 
HCT-116, CCL218 (HT-29), CCL2S1 (SW48), CCL228 (SW480), and CCL227 
(SW620) cells (Moroni et al, 2005). In addition, in another study CCL218 and CCL228 
cells were demonstrated to only express 2.4x10"^  and 1.4x10  ^ EGFR molecules/cell, 
respectively (Culouscou et al, 1988; Ciardiello et al, 2001). Interestingly, in this study, 
EGFR expression was found to be higher in cell lines established from Dukes’ C tumours 
than Dukes’ A or ‘B tumours suggesting that EGFR expression may be higher in more 
advanced colorectal cancer.
While all of the cell lines investigated in this study were found to be HER-2 positive, 
none of the cell lines were found to express high levels of the HER-2 (Table 3.1). In 
common with a number of studies, HER-2 expression in these cell lines was much lower 
than that of SKBR3 cells, which express 1.3x10  ^ HER-2 molecules/cell (Table 3.1)
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(Boente et a l, 1998; Half et a l, 2004; Kuwada et al, 2004). In several studies using 
western blotting, the relative levels of HER-2 expression in CCL221, CCL218, CCL235, 
HCTl 16, and CCL228 cells was found to be similar to HER-2 expression detected using 
FACS analysis in the present study (please see Table 3.1) (Half et a l, 2004; Kuwada et 
al, 2004; Shimizu et al, 2005b).
In common with EGFR and HER-2 expression, while all 12 colorectal tumour cells were 
found to express the IGF-IR in this study, none of the cell lines express high levels of the 
IGF-IR (Table 3.1). The levels of IGF-IR expression in DiFi, CCL221 and CCL231 cells 
was found to be similar to the levels in MCF-7 cells, which express 6xlfr* IGF-IR 
molecules/cell (Guvakova & Surmacz, 1997). However, IGF-IR expression was lower in 
the remaining cell lines, and in common with a previous study, IGF-IR expression was 
found to decrease from CCL235 (SW837) to CCL228 (SW480) to CCL218 (HT-29) 
(Shimizu et al, 2005a; Table 3.1). The CCL225 (HCT-15) and CCL227 (SW620) cell 
lines have previously been shown to express only 8x10  ^ and 6x10  ^ IGF-IR 
molecules/cell, respectively (Warren et al, 1996).
Following the determination of the levels of cell surface EGFR, HER-2 and IGF-IR 
expression in the panel of human colorectal tumour cells lines, their sensitivity to the 
EGFR inhibitors was investigated. Of the 12 human colorectal cancer cell lines 
examined in this study, only the EGFR overexpressing cell line DiFi was sensitive to 
growth inhibition by mAb ICR62, gefitinib, and erlotinib with IC50 values of 0.52nM, 
27.5nM and 134nM, respectively (Figure 3.3). While there was some inhibition of 
CCL244 and CCL235 cells, the remaining cells were not sensitive to treatment with the 
EGFR inhibitors at concentrations that inhibited the growth of DiFi cells. Therefore,
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while EGFR overexpressing cells (DiFi, HN5) are sensitive to the EGFR inhibitors, 
human colorectal tumour cells with lower levels of EGFR expression are relatively 
resistant to the EGFR inhibitors (Table 3.1 & Figure 3.4). Indeed, it is suggested that 
sensitivity to the EGFR inhibitors may not simply depend on levels of EGFR expression, 
and may also rely on other factors such as production of autocrine ligand (e.g. EGF), the 
presence of EGFR mutations (e.g. EGFRvIH), and EGFR crosstalk with homologous and 
heterologous receptors (Arteaga, 2002; Ciardiello & Tortora, 2003). However, in this 
study there was also no clear correlation between the levels of EGFR phosphorylation 
(constitutive or ligand induced) and response to the EGFR inhibitors. For example, the 
growth of HN5 cells, which in contrast to DiFi, do not have a constitutively active EGFR, 
are also inhibited by the EGFR inhibitors (Figure 3.2).
While this is the first study to investigate the effects of mAh ICR62 on the growth of a 
panel of colorectal tumour cells lines, other studies have demonstrated EGFR inhibitors 
(e.g. mAbs 528 and cetuximab, gefitinib, erlotinib) to inhibit the growth of DiFi cells in 
culture (Wu et a l, 1995; Moyer et al, 1997; Goss & Groden, 2000; Albanell et a l, 2001 ; 
Liu et a l, 2001; Matar et a l, 2004; Moroni et a l, 2005). In addition, several of the low 
EGFR expressing colorectal tumour cells used in this study have been shown to be 
resistant to anti-EGFR mAb or EGFR TKI, or have IC50 values in the micromolar range 
(Prewett et al, 2002; Xu et a l, 2003; Koizumi et al, 2004; Kuwada et a l, 2004; Matar et 
al, 2004; Skvortsov et al, 2004; Moroni et a l, 2005; Yang et a l, 2005). For example, in 
the study by Koizumi and colleagues (2004) the growth of CCL 218 (WIDR), HCT-116, 
and CCL 228 (SW480) cells by gefitinib was inhibited with IC50 values of lOpM, 
177|xM, and 23pM, respectively (Koizumi et al, 2004). In common with the present 
study, the anti-EGFR mAh cetuximab has recently been shown to inhibit the growth of
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EGFR overexpressing DiFi cells at concentrations that do not inhibit the growth of low 
EGFR expressing CCL221, HCT-116, CCL218, CCL 231, CCL228, and CCL227 cells 
(Moroni et a l, 2005).
In this study, mAb ICR62 was more effective than gefitinib or erlotinib at inhibiting the 
growth of EGFR overexpressing DiFi cells, as well as the growth of the positive control 
HN5 cell line (Figure 3.3 & 3.4). Indeed, in a previous study, the anti-EGFR mAbs 
ICR63 and ICR80 inhibited the growth of HN5 cells with an IC50 of InM, whereas the 
EGFR TKI FDl53035 inhibited HN5 growth with an IC50 value of 40nM (Modjtahedi et 
al, 1998a). Interestingly, although gefitinib and erlotinib are both aniliquinizoline 
derivatives that reversibly compete with ATP for binding to the EGFR tyrosine kinase 
domain (Wakeling, 2002); erlotinib was not as effective as gefitinib at inhibiting the 
growth of DiFi cells (Figure 3.3). These results suggest that mAh ICR62, gefitinib, and 
erlotinib inhibit the growth of EGFR overexpressing cells by overlapping but not 
identical mechanisms, and this was investigated further in chapter four.
Since the anti-EGFR mAbs and EGFR TKIs target different domains of the EGFR, 
another aim of this study was to investigate the effect of co-targeting the EGFR with anti- 
EGFR antibody and EGFR TKI. In the majority of human colorectal tumour cell lines 
examined in this study, the combination of anti-EGFR mAb ICR62 with gefitinib or 
erlotinib was not superior to treatment with the single-agent (Figure 3.5 & 3.6). This was 
seen in cells with high and low EGFR expression (Figure 3.7). Interestingly, the results 
herein are in contrast to two recently published studies (Huang et a l, 2004; Matar et a l,
2004). In one study, the combination of cetuximab (up to 50nM) and gefitinib (up to 
lOpM) synergistically inhibited the growth of cells with moderate to high EGFR
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expression (A431, MDA-MB-468, DiFi, and DU-145), but not cells with low or 
undetectable EGFR expression (BT-474, SKBR3, T-47D, MDA-MB-453, and MDA- 
MB-435S) (Matar et a l, 2004).
Interestingly, using the same concentrations of inhibitors and time points as Matar and 
colleagues (2004), the combination of mAb ICR62 or mAb ICR16 with gefitinib or 
erlotinib was not found to be synergistic (Figure 3.8 & 3.9, data not shown for ICR 16). 
Consequently, the synergistic growth inhibition demonstrated by Matar and colleagues 
and Huang and colleagues (Matar et al, 2004) may be a specific property of the anti- 
EGFR mAh cetuximab that was used in their studies. Interestingly, in another recent 
study, the combination of gefitinib and cetuximab was found to be antagonistic at 
inhibiting the growth of CAL33 (Head and Neck) and CAL39 (Vulvar) cells (Fischel et 
al, 2005). However, the preliminary results of the first phase I trial investigating the 
effect of cetuximab in combination with gefitinib in patients with advanced colorectal 
cancer, NSCLC, and head-and neck cancer who express the EGFR have been reported at 
the recent AACR-NCI-EORTC conference in Philadelphia, USA (Tabemero et al,
2005). This study demonstrated superior reduction of EGFR, MAPK and Akt 
phosphorylation and cell proliferation in patients treated with the combination of 
cetuximab and gefitinib, and the results of future phase III trials should elucidate whether 
combination of these inhibitors is superior to the single-agent in cancer patients.
Several studies in the experimental setting have shown that continuous activation of the 
IGF-IR pathway may be one of the factors responsible for the development of tumour 
cells resistant to therapy with the anti-HER-2 mAh trastuzumab as well as the EGFR 
inhibitors (Camirand et a l, 2002; Chakravarti et a l, 2002; Wang et a l, 2002; Ahmad et
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al, 2004; Lu et al, 2004b). Tn addition, the majority of studies investigating the 
interaction between the EGFR and IGF-IR have used transfected cell lines rather than cell 
lines isolated from the tumours of colorectal cancer patients (Camirand et al, 2002; 
Chakravarti et al, 2002; Lu et a l, 2004b), and there has been no study investigating the 
effects of our anti-EGFR mAh ICR62, or any other EGFR inhibitor, in combination with 
an IGF-IR inhibitor on the growth of the panel of cell lines used in the present study.
Of the 12 human colorectal cancer cell lines investigated in this study, only CCL218 and 
CCL235 were sensitive to the IGF-IR TKI NVP-AEW541 (Figure 3.12). However, the 
growth of the most sensitive cell line, CCL218, was only inhibited by 67% by SOOnM 
NVP-AEW541, and no clear association was found between IGF-IR expression 
determined by FACS analysis (Table 3.1) and response to NVP-AEW541. Interestingly, 
while the growth of several colorectal tumour cell lines (Colo 13, CCL221, CCL225, 
CCL227, CCL231 and CCL244) was synergistically inhibited with the combination of 
EGFR and IGF-IR inhibitors, the combination was antagonistic in CCL218 cells (Figure 
3.13 to 3.15; Table 3.2). It is therefore possible that receptors other than the EGFR and 
IGF-IR may also be activating pro-survival pathways in CCL218 cells.
Indeed other members of the ErbB fomily (e.g. HER-2, HER-3) have been shown to 
activate the MAPK and PI3K pathways within tumour cells, and the continued activation 
of the PI-3K pathway has been associated with resistance to the EGFR inhibitors 
(Hanahan & Weinberg, 2000; Schlessinger, 2000; Moasser et al, 2001; Camirand et a l, 
2002; Chakravarti et al, 2002; Lu et a l, 2004b). Consequently, the effect of PI-3K 
(LY294002) and MAPK (U0126) inhibitors on the growth of colorectal tumour cell lines 
resistant (CCL225, CCL228) or sensitive to the EGFR inhibitors (DiFi, CCL235) was
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investigated, and such cell lines were found to be inhibited by the PI-3K and MAPK 
inhibitors. Following treatment with a combination of PI-3K and MAPK inhibitors, there 
was also an increase in growth inhibition compared to treatment with the single-agent 
(Figure 3.16). These results suggest that human colorectal tumour cell lines may be 
dependent upon receptors other than the EGFR and IGF-IR for activation of the 
MAPK/PI-3K pathways. This may explain vsfry there was no clear correlation between 
EGFR or IGF-IR expression and response to the EGFR and/or IGF-IR inhibitors (please 
see section 3.4).
In summary, of the 12 human colorectal tumour cell lines examined here, DiFi was found 
to express high levels of the EGFR, and EGFR expression was found to be higher in cells 
isolated from Dukes’C tumours than in cells isolated from Dukes’A or Dukes’B tumours. 
However, unlike EGFR expression by DiFi cells, expression of EGFR, HER-2, and IGF- 
IR was found to be much lower in the other 11 colorectal tumour cell lines. The anti- 
EGFR antibodies and EGFR TKIs were found to be highly effective for the growth 
inhibition of EGFR overexpressing cells, however, cells with lower levels of EGFR 
expression were relatively resistant to the EGFR inhibitors. While the combination of 
anti-EGFR mAb and EGFR TKI was not superior to treatment with the single-agent, the 
combination of the IGF-IR TKI with the EGFR inhibitors synergistically inhibited the 
growth of a number of colorectal tumour cell lines. Further detailed study of the 
mechanism of sensitivity to the anti-EGFR mAbs and EGFR TKIs in the DiFi colorectal 
cancer cell line, and the involvement of the IGF-IR in this process are addressed in 
chapter 4.
106
CHAPTER FOUR
The effect of EGFR inhibitors on the cellular location of EGFR and EGFRvHI, cell 
cycle distribution, and EGFR, EGFRvIH, MAPK and Akt phosphorylation
4.1 Introduction
In chapter three, the expression levels of EGFR, HER-2, and IGF-IR in a panel of 
colorectal cancer cell lines, and the sensitivity of these cell lines to the EGFR and/or IGF- 
IR inhibitors was investigated. The aim of this chapter was to investigate the molecular 
mechanism by which anti-EGFR mAbs and EGFR TKIs mediate their anti-tumour 
activity.
As described in the introduction, the EGFR is a 170kDa glycoprotein, consisting of an 
extracellular ligand binding domain, a transmembrane region, and an intracellular 
cytoplasmic domain. The cytoplasmic domain contains a number of regulatory sites, 
including five tyrosine autophosphoiylation sites (1173, 1148, 1086, 1068 and 992) and 
sites for c-Src phosphorylation (tyrosine 845) (Downward et al, 1984; Carpenter, 1987; 
Margolis eta l, 1989; Walton eta l, 1990; Sato eta l, 1997). The binding of ligand to the 
external domain of the EGFR ultimately leads to EGFR tyrosine autophosphorylation and 
activation of the Ras-Raf-MAPK pathway and PI3K-pathway which are responsible for 
cell growth, proliferation, survival, and motility (Wells, 1999; Yarden, 2001; Jorissen et 
al, 2003; Mendelsohn & Baselga, 2003),
Under normal physiological conditions, attenuation of ligand induced growth-promoting 
signals occurs principally via ligand mediated endocytosis (Wiley, 2003). Following
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ligand binding, the ligand receptor complex is rapidly internalised, and depending on the 
ligand and/or receptor, the complex is targeted for ly so some degradation or recycled back 
to the cell surface (Normanno et a l, 2003; Wiley, 2003). Some of the anti-EGFR mAbs, 
most notably mAb225, have been shown cross-link cell surface EGFR molecules to 
induce receptor internalisation and attenuate EGFR signalling (Sunada et a l, 1986; Fan et 
al, 1994; Friedman et al, 2005). However, while the anti-EGFR mAbs target the EGFR 
ligand binding domain, the EGFR TKIs target the intracellular domain of the EGFR and 
their effect on cellular EGFR distribution is less clear.
Both anti-EGFR mAbs and EGFR TKIs have been shown to decrease EGFR 
phosphorylation, and inhibit tumour cell growth via G1 arrest and up-regulation of the 
cell cycle inhibitor p27^ '^^ (Fan et al, 1994; Moyer et a l, 1997; Ciardiello et a l, 2000; 
Moasser et al, 2001 ; Li et al, 2003). In some studies, sensitivity to the anti-EGFR mAbs 
or EGFR TKIs in EGFR or HER-2 expressing tumour cells has been associated with a 
reduction of EGFR, MAPK, and/or Akt phosphorylation (Ciardiello et a l, 2000; Albanell 
et al, 2001 ; Anderson et a l, 2001 ; Moulder et al, 2001). However, the MAPK and PI- 
3K pathways may not be directly regulated by the EGFR and persistent activity of the 
MAPK and/or PI-3K pathways has been associated with resistance to cetuximab and 
gefitinib in human tumour cells (e.g. NSCLC, breast) (Janmaat et a l, 2003; Li et a l, 
2003). Indeed, activation of the PI-3K pathway by the IGF-IR has been associated with a 
reduction of the anti-proliferative and apoptotic effects of the EGFR and HER-2 
inhibitors (Wu eta l, 1995; Camirand eta l, 2002; Wang eta l, 2002).
There is therefore a need for fiirther investigation into the mechanism of sensitivity of 
tumour cells to the EGFR inhibitors. The aim of this chapter was to investigate the effect
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of the anti-EGFR mAbs and EGFR TKIs on the location of the EGFR and EGFRvIII, cell 
cycle distribution, their antagonising of EGFR ligand, and on the phosphorylation of the 
EGFR, EGFRvIII, MAPK and Akt.
4.2 The effect of the EGFR inhibitors on the cellular location of the EGFR
To further understand the mechanism by which DiFi cells are growth inhibited by the 
EGFR inhibitors, the effect of anti-EGFR mAbs and EGFR TKIs on the cellular 
distribution of EGFR within DiFi cells was investigated. For this purpose, near confluent 
DiFi cells were cultured for one hour or 24 hours with growth inhibitory concentrations 
of mAb ICR16, mAb ICR62, gefltinib, erlotinib, or control medium. The cellular location 
of the EGFR was detected using an FITC-conjugated secondary antibody, as described in 
Materials and Methods.
As the results in Figure 4.1a show, DiFi cells expressed high levels of membranous 
EGFR. Following one hour treatment of DiFi cells with the EGFR inhibitors, there were 
no major changes in the cellular location of the EGFR (data not shown). However, 
following 24 hour treatment with the EGFR inhibitors there were marked changes in the 
cellular location of the EGFR. As the results presented in Figure 4.1b and 4.1c show, 
there was a substantial loss of membranous EGFR expression in DiFi cells treated with 
the anti-EGFR mAbs ICR 16 and ICR62. In contrast, the EGFR TKIs were not as 
effective at reducing the levels of cell surfece EGFR expression (Figure 4.1d & 4.le). 
While there was some reduction in cell surface EGFR expression in DiFi cells treated 
with gefltinib (Figure 4. Id), there were no major changes in the location of EGFR in DiFi 
cells treated with growth inhibitory concentrations of erlotinib (Figure 4.1 e).
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Figure 4.1 Cellular location of EGFR in DiFi cells following treatment with anti- 
EGFR mAh or EGFR TKI. Near confluent DiFi cells were cultured for 24 hours in 
DMEM/0.1% FCS containing lOOnM of mAh ICR16, ICR62, 200nM of gefltinib and 
erlotinib, or control medium. DiFi cells were permeabilised with 0.5% Triton X-100, and 
the rat mAb ICR62 and FITC- conjugated anti-rat secondary antibody was used to detect 
the location of the EGFR within treated cells as described under Materials and Methods. 
DiFi cells treated with control medium (A), ICR16 (B), ICR62 (C), gefltinib (D), and 
erlotinib (E). Left panel: FFTC staining; Right panel: Hoescht 33258 nuclear staining. 
Magnification: xlOO.
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However, following the continued culture of DiFi cells with the EGFR inhibitors for 10 
days, cell surface expression of the EGFR could still be detected in cells growth inhibited 
by anti-EGFR mAb and EGFR TKI (Figure 4.2).
4 3  The effect of EGFR inhibitors on ceil cycle distribution
Several pre-clinical studies have shown that that the anti-EGFR mAh cetuximab may 
inhibit the growth of the DiFi cell line by inducing apoptosis and arrest in the G1 phase 
of the cell cycle (Wu et al, 1995; Fan et a l, 1997; Liu et a l, 2001). However, in chapter 
three, the EGFR inhibitors were found to differ in their ability to inhibit the growth of 
EGFR and HER-2 overexpressing tumour cells (Figure 3.4). Consequently, the effect of 
our anti-EGFR mAb ICR62, as well as the EGFR TKIs gefitinib and erlotinib on the cell 
cycle distribution of DiFi cells was investigated. For this purpose, DiFi cells were 
incubated for five days with growth inhibitoiy concentrations of the EGFR inhibitors or 
control medium, and PI staining of cellular DNA was analysed using a Beckman Coulter 
flow cytometer. In the growth inhibition assays presented in the previous sections, 
treatment of DiFi cells with mAh ICR62, gefitinib, and erlotinib resulted in a decrease in 
the initial number of cells seeded on the first day of the experiment, indicating that these 
inhibitors may be inducing apoptosis in DiFi cells (please see Figures 3.3 & 3.4). In 
accordance, as shown in Figure 4.3, treatment of DiFi cells with mAh ICR62, gefitinib 
and erlotinib was found to increase the proportion of cells in the SubGO/Gl phase of the 
cell cycle (apoptotic cells) fi’om 2.8% to 41%, 56.7%, and 22.4%, respectively. The 
induction of apoptosis by the anti-EGFR mAbs and EGFR TKIs was also accompanied 
with a reduction in the proportion of cells in the Gl, S, and G2/M phases of the cell cycle. 
This effect was greater for mAb ICR62 and gefitinib than for erlotinib (Figure 4.3).
I l l
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Figure 4.2. Cell surface expression of EGFR in DiFi ceils growth inhibited by 
anti-EGFR mAh or EGFR TKI. Sub-confluent DiFi cells were cultured continuously 
in DMEM/2% FCS containing lOOnM of mAb ICR62, 200nM of gefitinib or erlotinib, or 
control medium, and incubated for 10 days until the control cells were confluent. The rat 
mAh ICR62 and FITC-conjugated anti-rat secondary antibody was used to detect the 
location of the EGFR within treated cells as described under Materials and Methods. 
DiFi cells treated with control medium (A), ICR62 (B), gefltinib (C), and erlotinib (D). 
Left panel: FITC staining; Right panel: Hoescht 33258 nuclear staining. Magnification: 
xlOO.
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Figure 4.3 The eflfect of EGFR inhibitors on the cell cycle distribution of EGFR 
overexpressing DiFi cells. Tumour cells were incubated for 5 days in DMEM/2% FCS 
containing mAb ICR62 (156nM), gefitinib (SOOnM), erlotinib (SOOnM), or control 
medium. Cells were incubated with 1 Opg/ml propidium iodide, and analysed for DNA 
content using FACS analysis, as described under Materials and Methods section 2.5. The 
DNA Histograms for DiFi cells treated with control medium, ICR62, gefitinib, or 
erlotinib (A); and the percentage ± SD of treated DiFi cells (B) in the subGO/Gl (Ap; 
apoptotic cells), G l, S, and G2/M phases of the cell cycle.
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For example, five day treatment of DiFi cells with mAb ICR62 and gefitinib decreased 
the proportion of cells in Gl fi*om 60%, to 45.2% and 30.5%, respectively. However, in 
DiFi cells treated with erlotinib, there were still 50.9% of cells in the G1 phase of the cell 
cycle. In chapter three (Figure 3.12), DiFi cells were found to be relatively insensitive to 
the IGF-IR inhibitor NVP-AEW541. Accordingly, DiFi cells treated with NVP-AEW541 
had a very similar cell cycle distribution to DiFi cells treated with control medium (data 
not shown).
In addition to DiFi cells, the effect of the EGFR inhibitors on the cell cycle distribution of 
EGFR overexpressing HN5 cells was investigated. While mAb ICR62, gefitinib, and 
erlotinib also decreased the proportion of cells in the S and G2/M phases of the cell cycle, 
there was less apoptosis (subGO/Gl cells) in HN5 cells than in DiFi cells treated with the 
EGFR inhibitors (data not shown). Interestingly, in contrast to DiFi cells, mAh ICR62, 
gefitinib, and erlotinib were all found to increase the proportion of HN5 cells in the Gl 
phase of the cell cycle (data not shown).
In addition, in the earlier section HN5 cells were found to be growth inhibited by NVP- 
AEW541 please see Figure 3.11). In HN5 cells treated with NVP-AEW541, there was 
also an increase of HN5 cells in G l, and a decrease of HN5 cells in the S and G2/M 
phases of the cell cycle, although this effect was not as great as that caused by the EGFR 
inhibitors (data not shown).
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4.4 The effect of EGFR and IGF-IR ligands on the anti-EGFR mAh and EGFR TKI 
induced growth inhibition of DiFi cells
The growth of EGFR overexpressing cells can be stimulated by picomolar 
concentrations, but inhibited by nanomolar concentrations of EGFR ligand (Modjtahedi 
et al, 1993c; Wu et a l, 1995; Liu et al, 2000). Since the anti-EGFR mAbs and EGFR 
TKIs target distinct domains of the EGFR, the effects of EGFR and IGF-IR ligand on the 
proliferation of DiFi cells grown in the presence or absence of anti-EGFR mAb or EGFR 
TKI was investigated.
As shown in figure 4.4a, the growth of DiFi cells was completely inhibited by lOnM 
EGF, TGFa, BTC, EPI and HB-EGF, and also by 36% with lOnM AR. The mAb ICR62 
was able to compete with the EGFR ligands for EGFR binding and consequently reversed 
the growth inhibition induced by each of the ligands. For example, while there was 
complete growth inhibition of DiFi cells by lOnM EPI, there was only 6% growth 
inhibition of DiFi cells co-incubated with mAh ICR62 (Figure 4.4a). Interestingly, 
although the target of the EGFR TKIs is intracellular, the growth inhibition of DiFi cells 
induced by the EGFR ligands was also reversed by gefitinib and erlotinib. However, as 
shown in Figure 4.4a, the EGFR TKIs were not as effective as mAb ICR62 at reversing 
the growth factor-induced growth inhibition of DiFi cells.
The IGF-IR ligand IGF-I has been shown to delay, but not prevent, anti-EGFR mAb-225 
induced apoptosis of DiFi cells in-vitro (Wu eta l, 1995; Liu eta l, 2001). Consequently, 
the effect of IGF-IR ligands on the growth of DiFi cells was also investigated. As the 
results presented in Figure 4.4a show, treatment with lOnM IGF-I and IGF-II had no
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effect on the proliferation of DiFi cells, and these ligands were unable to prevent mAb 
ICR62, gefitinib, and erlotinib-induced growth inhibition of DiFi cells (Figure 4.4a).
Each of the EGF-like ligands increased the levels of EGFR phosphorylation in DiFi cells, 
demonstrating that they are binding to and activating the EGFR within DiFi cells (Figure 
4.4b). However, in accordance with the lower percentage of growth inhibition of DiFi 
cells by amphiregulin, amphiregulin was not as effective at increasing EGFR 
phosphorylation in DiFi cells compared to the other EGF-like ligands. In contrast to the 
EGFR ligands, IGF-I and IGF-II did not induce EGFR phosphorylation in DiFi cells 
(Figure 4.4b).
4.5 The effect of inhibitors of the EGFR and/or IGF-IR on the phosphorylation 
status of the EGFR, MAPK and Akt
In several studies, the anti-EGFR mAbs and EGFR TKIs have been shown to reduce the 
levels of total EGFR tyrosine phosphorylation or the phosphorylation of selected EGFR 
autophosphorylation sites in human tumour cells (Moyer et a l, 1997; Anderson et a l, 
2001; Prewett et al, 2002; Koizumi et al, 2004). However, there has been no 
comprehensive study investigating the effect of EGFR inhibitors on the phosphorylation 
status of multiple EGFR phosphorylation sites. Consequently, the effect of EGFR 
inhibitors on the phosphorylation status of five distinct EGFR tyrosine phosphorylation 
sites (pEGFR 1173, 1148, 1086, 1068, 845), which included the three major EGFR 
autophosphorylation sites, were investigated in this study. In addition, while several 
studies have examined the effect of the monoclonal antibody cetuximab (or mAb225) on 
EGFR induced signal transduction (Wu et al, 1995; Liu et al, 2000; Albanell et a l, 
2001 ; Liu et a l , 2001 ), this is the first study to investigate the effect of the mAb ICR62,
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Figure 4.4 The effects of EGFR and IGF-IR ligand on EGFR phosphorylation 
and the growth inhibition of DiFi cells by the EGFR inhibitors. D i F i  c e l l s  w e r e  
i n c u b a t e d  a t  3 7 ° C  w i t h  D M E M / 2 %  F C S  c o n t a i n i n g  l O n M  E G F ,  T G F a ,  A R ,  B T C ,  E P I ,  
H B - E G F ,  I G F - I ,  I G F - I I ,  c o n t r o l  m e d i u m  ( N S )  a n d / o r  m A h  I C R 6 2  ( l O O n M ) ,  g e f i t i n i b  
( 4 0 0 n M ) ,  e r l o t i n i b  ( 4 0 0 n M ) ,  o r  c o n t r o l  m e d i u m .  D i F i  c e l l s  w e r e  i n c u b a t e d  f o r  1 2  d a y s  
u n t i l  c e l l s  i n  t h e  w e l l s  c o n t a i n i n g  c o n t r o l  m e d i u m  w e r e  c o n f l u e n t  ( A ) .  E a c h  p o i n t  
r e p r e s e n t s  t h e  m e a n  ± S D  o f  t r i p l i c a t e  v a l u e s .  T o  i n v e s t i g a t e  E G F R  a c t i v a t i o n  b y  t h e  
E G F R  l i g a n d s ,  e q u a l  n u m b e r s  o f  D i F i  c e l l s  w e r e  i n c u b a t e d  i n  D M E M / 0 . 1 %  F C S  f o r  o n e  
h o u r  a t  3 7 ° C  p r i o r  t o  t h e  a d d i t i o n  o f  E G F  ( 1 0  a n d  2 0 n M ) , o r  T G F a ,  A R ,  B T C ,  E P I ,  H B -  
E G F ,  I G F - I  o r  I G F - I I  ( a l l  2 0 n M )  f o r  1 5  m i n u t e s  ( B ) .  T h e  t r e a t e d  c e l l s  w e r e  l y s e d  a n d  
e q u a l  a m o u n t s  o f  c e l l  l y s a t e  w e r e  s e p a r a t e d  b y  S D S - P A G E ,  t r a n s f e r r e d  t o  P V D F  
m e m b r a n e s ,  a n d  p r o b e d  w i t h  a n t i b o d i e s  t o  t h e  E G F R  o r  p h o s p h o - t y r o s i n e .
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as single-agent or in combination with the EGFR TKIs, on downstream signalling 
molecules in DiFi cells.
4.5.1 The phosphoiylation status of the EGFR following treatment with the EGFR 
inhibitors
To investigate the effect of anti-EGFR mAh or EGFR TKI on the basal levels of EGFR 
phosphorylation and signal transduction, DiFi cells were grown to near confluence in 
DMEM containing 10% FCS, then treated in DMEM/0.1% FCS containing 400nM of 
mAh ICR62 and/ or 400nM gefltinib or erlotinib for 24 hours at 37°C. The treated cells 
were lysed and equal amounts of cell lysate were separated by SDS-PAGE, transferred to 
PVDF membranes, and probed with antibodies specific for the molecule of interest.
As shown in Figure 4.5, the EGFR on DiFi cells was constitutively active at each of the 
five tyrosine phosphorylation sites investigated (1173, 1148, 1086, 1068, and 845). The 
levels of total EGFR protein and phosphorylation of all five EGFR tyrosine residues were 
decreased following 24 hour treatment of DiFi cells with ICR62 and gefitinib. 
Interestingly, as shown in Figure 4.5, at 400nM, mAh ICR62 was not as effective as 
gefltinib at reducing total EGFR protein and constitutive EGFR phosphorylation. 
However, in contrast to both mAh ICR62 and gefltinib, there was only moderate 
reduction of total EGFR protein and EGFR phosphorylation following 24 hour treatment 
of DiFi cells with erlotinib (Figure 4.5).
As the results in Figure 4.5 show, the treatment of DiFi cells with lOnM EGF for 15 
minutes did not affect the levels of total EGFR protein. However, total EGFR tyrosine 
phosphorylation at 170kDa and phosphorylation at each of the five EGFR
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Figure 4.5. The phosphorylation status of EGFR, MAPK and Akt in DiFi cells 
treated with anti-EGFR mAh and EGFR TKIs for 24 hours. DiFi cells were grown 
to near confluence in DMEM containing 10% FCS, then treated in DMEM/0.1% FCS 
containing mAb ICR62 (400nM), and/or gefitinib (400nM) or erlotinib (400nM) for 24 
hours at 37°C. Cells were then incubated with no growth factor or lOnM EGF for 15 
minutes at 37®C. The treated cells were lysed and equal amounts of cell lysate were 
separated by SDS-PAGE, transferred to PVDF membranes, and probed with antibodies 
specific for the molecule of interest. The results are representative of at least two 
independent experiments
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phosphorylation sites was increased by EGF (Figure 4.5). The mAh ICR62, gefitinib, 
and erlotinib were able to reduce EGF-induced EGFR phosphorylation at each of the five 
EGFR phosphorylation sites. Indeed, the treatment of DiFi cells with EGF did not 
reverse the reduction of EGFR protein or phosphorylation achieved with each of the three 
EGFR inhibitors (Figure 4.5). When DiFi cells were treated with mAh ICR62 in 
combination with gefitinib or erlotinib, the levels of EGFR protein and EGF-induced 
phosphorylation were similar to the levels in DiFi cells treated with the single agent 
(Figure 4.5).
4.5.2 The phosphorylation status of MAPK and Akt following treatment with the 
EGFR inhibitors
As the results presented in Figure 4.5 show, both MAPK and Akt were constitutively 
phosphorylated in DiFi cells. However, there were only low levels of Akt 
phosphorylation and this was reduced completely by the three EGFR inhibitors (Figure
4.5). While ICR62, gefitinib and erlotinib all reduced MAPK phosphorylation, in 
common with the reduction of EGFR phosphorylation by these inhibitors, the decrease in 
MAPK phosphorylation by erlotinib was only moderate (Figure 4.5).
The treatment of DiFi cells with lOnM EGF for 15 minutes resulted in an increase in the 
levels of MAPK and Akt phosphorylation (Figure 4.5). EGF completely reversed the 
reduction of MAPK phosphorylation by mAb ICR62, gefitinib, and erlotinib in DiFi cells 
(Figure 4.5). Both gefitinib and erlotinib were able to reduce, but not completely inhibit, 
EGF-induced Akt phosphorylation in DiFi cells (Figure 4.5). However, interestingly, 
there was an increase in EGF-induced Akt phosphorylation in DiFi cells treated with 
mAh ICR62, and this was greater than in DrFi cells treated with EGF alone (Figure 4.5).
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It was also interesting that the treatment of DiFi cells with the EGFR inhibitors, notably 
gefitinib, reduced the levels of total Akt protein (Figure 4.5).
While single-agent mAh ICR62, gefitinib, or erlotinib did not prevent EGF-induced 
MAPK activation, EGF-induced MAPK phosphorylation was completely inhibited using 
a combination of mAb ICR62 and gefitinib (Figure 4.5). However, the combination of 
mAb ICR62 with erlotinib did not prevent EGF-induced MAPK phosphorylation and was 
not superior over the single-agent (Figure 4.5). In addition, while single-agent gefitinib 
and erlotinib reduced the basal levels of pAkt, EGF-induced pAkt was not reduced 
fiirther by combination with mAh ICR62 (Figure 4.5).
4.5.3 The phosphorylation status of the EGFR, MAPK and Akt in DiFi cells 
following short-term treatment with the EGFR inhibitors
Since studies in the literature investigating the mechanisms of action of the EGFR 
inhibitors have used different treatment durations, and the duration of treatment (i.e. one 
hour versus 24 hour) was shown to affect the cellular location of the EGFR in this study 
(section 4.2), the phosphorylation status of EGFR, MAPK, and Akt in DiFi cells were 
also investigated one hour post-treatment with the EGFR inhibitors (Figure 4.6).
Following the treatment of DiFi cells with the EGFR inhibitors for one hour, there was 
still a reduction in the constitutive levels of EGFR phosphorylation. However, EGFR 
phosphorylation was not reduced to the same levels as that achieved following treatment 
with the inhibitors for 24 hours. Like the immunofluorescence staining of DiFi cells 
discussed in section 4.2, there was also no reduction in total EGFR protein following one 
hour treatment of DiFi cells with the EGFR inhibitors (Figure 4.6). Interestingly, while
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Figure 4.6. The phosphorylation status of EGFR, MAPK and Akt in DiFi cells 
treated with anti-EGFR mAh and EGFR TKIs for one hour. D i F i  c e l l s  w e r e  g r o w n  
t o  n e a r  c o n f l u e n c e  i n  D M E M  c o n t a i n i n g  1 0 %  F C S ,  t h e n  t r e a t e d  i n  D M E M  c o n t a i n i n g  
0 . 1 %  F C S  w i t h  m A h  I C R 6 2  ( 4 0 0 n M ) ,  a n d / o r  g e f i t i n i b  ( 4 0 0 n M )  o r  e r l o t i n i b  ( 4 0 0 n M )  f o r  
o n e  h o u r  a t  3 7 ° C .  C e l l s  w e r e  t h e n  i n c u b a t e d  w i t h  n o  g r o w t h  f a c t o r  o r  l O n M  E G F  f o r  1 5  
m i n u t e s .  T h e  t r e a t e d  c e l l s  w e r e  l y s e d  a n d  e q u a l  a m o u n t s  o f  c e l l  l y s a t e  w e r e  s e p a r a t e d  b y  
S D S - P A G E ,  t r a n s f e r r e d  t o  P V D F  m e m b r a n e s ,  a n d  p r o b e d  w i t h  a n t i b o d i e s  s p e c i f i c  f o r  t h e  
m o l e c u l e  o f  i n t e r e s t .  T h e  r e s u l t s  a r e  r e p r e s e n t a t i v e  o f  a t  l e a s t  t w o  i n d e p e n d e n t  
e x p e r i m e n t s
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erlotinib was not as effective as mAb TCR62 and gefitinib at inhibiting constitutive EGFR 
and MAPK phosphorylation in DiFi cells treated with the inhibitors for 24 hours (Figure
4.5), there was greater inhibition of EGFR and MAPK phosphorylation following 
treatment of DiFi cells with erlotinib for one hour (Figure 4.6). Indeed, like gefitinib, 
erlotinib was more effective than ICR62 at reducing EGFR and MAPK phosphorylation 
in DiFi cells treated with the inhibitors for one hour (Figure 4.6). In addition, following 
the treatment of DiFi cells for one hour with mAh ICR62 in combination with erlotinib, 
EGF-induced MAPK phosphorylation was inhibited similar to that achieved with ICR62 
in combination with gefitinib (Figure 4.6).
4.5.4 The phosphorylation status of the EGFR, MAPK, and Akt following 
treatment of DiFi cells with the EGFR inhibitors and/or the IGF-IR inhibitor
As shown in Figure 3.12, the IGF-IR TKI NVP-AEW541 did not inhibit the growth of 
DiFi cells in culture. In addition, IGF-I and IGF-II did not reverse the growth inhibition 
of DiFi cells by the EGFR inhibitors (Figure 4.4a). However, the IGF-IR has been shown 
to transactivate the EGFR in tumour cells and has been associated with resistance to the 
EGFR inhibitors in several experimental studies (Camirand et al^ 2002; Chakravarti et 
ah, 2002). Consequently, the effect of an IGF-IR inhibitor (NVP-AEW541) or IGF-IR 
ligand (IGF-I) on the phosphorylation status of the EGFR, MAPK, and Akt in DiFi cells 
was investigated in this study. For this purpose, DiFi cells were grown to near 
confluence then treated with 400nM NVP-AEW541 for 24 hours prior to no treatment, or 
treatment with lOnM IGF-I for 15 minutes. As the results presented in Figure 4.7 show, 
unlike the EGFR inhibitors, the treatment of DiFi cells with NVP-AEW541 for 24 hours 
did not reduce the levels of total EGFR protein, or the constitutive levels of EGFR and 
MAPK phosphorylation.
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Figure 4.7. The phosphorylation status of EGFR, MAPK and Akt in DiFi cells 
treated with EGFR inhibitors and/or 1WP-AEW541. DiFi cells were grown to near 
confluence in DMEM containing 10% FCS, then treated in DMEM/ 0.1% FCS 
containing mAh ICR62, gefitinib, or erlotinib (400nM), and/or NVP-AEW541 (400nM) 
for 24 hours at 37°C. The cells were then incubated with no growth factor or lOnM IGF-I 
for 15 minutes. The treated cells were lysed and equal amounts of cell lysate were 
separated by SDS-PAGE, transferred to PVDF membranes, and probed with antibodies 
specific for the molecule of interest. The results are representative of at least two 
independent experiments.
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Following the treatment of DiFi cells with lOnM TGF-T for 15 minutes, in contrast to 
EGF, there was no increase in the constitutive levels of EGFR phosphoiylation (Figure 
4.7). Similarly, IGF-I did not reverse the reduction in EGFR phosphoiylation in DiFi 
cells treated with mAh ICR62 and gefitinib (Figure 4.7). Unlike EGF, the reduction of 
constitutive MAPK phosphorylation by the EGFR inhibitors was not reversed by lOnM 
IGF-I (Figure 4.7). As shown in Figure 4.7, IGF-I induced strong phosphoiylation of Akt 
in DiFi cells. The IGF-I induced Akt phosphoiylation was reduced by NVP-AEW541, 
however, there was no substantial reduction in IGF-I induced Akt phosphoiylation by the 
EGFR inhibitors (Figure 4.7). Interestingly, while mAh ICR62 did not inhibit IGF-I 
induced Akt phosphoiylation (Figure 4.7), and actually increased EGF-induced Akt 
phosphorylation (Figure 4.5), the combination of mAb ICR62 and NVP-AEW541 
decreased IGF-I induced Akt phosphoiylation to levels below that of NVP-AEW541 as 
single-agent (Figure 4.7). However, the treatment of DiFi cells with mAh ICR62 in 
combination with gefitinib or erlotinib did not reduce the levels of IGF-I induced Akt 
phosphoiylation below that achieved following treatment with the single-agent (data not 
shown).
4.6 The cellular location and signal transduction of the EGFRvHI following 
treatment with the EGFR inhibitors
The expression of the wild-type EGFR in human malignancies may be accompanied by 
the expression of the EGFRvIII (please see chapter 5; Bigner et a l, 1990; Humphrey et 
al, 1991; Moscatello et al, 1995). The anti-EGFR mAh ICR62 has been shown 
previously to bind to the EGFRvIII and induce strong antibody- dependent cell- mediated 
cytotoxicity (ADCC) against EGFRvIII expressing HC2 20 d2/c cells in culture and in- 
vivo (Modjtahedi et al., 2003). However, no study has compared the effect of mAh
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TCR62 and the EGFR TKIs on the cellular location of the EGFRvIII or the 
phosphoiylation of the EGFRvIII, MAPK, and Akt in EGFRvHI expressing tumour cells. 
Consequently, like the wild-type EGFR in DiFi cells, the effect of the anti-EGFR mAbs 
and EGFR TKIs on the location and signal transduction of the EGFRvHI within HC2 20 
d2 /c cells was investigated.
4.6.1 The effect of EGFR inhibitors on the cellular location of the EGFRvIII
To investigate the effect of the EGFR inhibitors on the cellular distribution of the 
EGFRvHI, near confluent HC2 20 d2/c cells were cultured for one hour with anti-EGFR 
mAbs ICR16 and ICR62 or the EGFR TKIs gefitinib or erlotinib. The location of the 
EGFRvHI within permeabilised HC2 20 d2/c cells was determined using mAb ICR62 and 
FITC-conjugated secondary antibody as described under Materials and Methods. As the 
results presented in Figure 4.8 show, the cellular distribution of the EGFRvHI following 
the treatment of HC2 20 d2/c cells with mAh ICR62, mAh ICR16, gefitinib or erlotinib, 
was found to be similar to the location of the EGFRvHI in untreated HC2 20 d2/c cells.
The cell surfoce expression of the EGFRvIH within HC2 20 d2/c cells following 
prolonged treatment with the EGFR inhibitors was also investigated in this study (Figure 
4.9). However, as the results presented in Figure 4.9 show, the cell surface levels of 
EGFRvHI expression were also found to be similar in untreated HC2 20 d2/c cells and in 
cells cultured continuously with mAh ICR16, mAh ICR62, gefitinib or erlotinib for 6  
days.
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Figure 4.8 Cellular location of EGFRvIII in HC2 20 d2/c cells following 
treatment with the EGFR inhibitors. Near confluent HC2 20 d2/c cells were cultured 
for one hour in DMEM/0.1% FCS containing mAb ICR16 (200nM), ICR62 (200nM), 
gefitinib (400nM), erlotinib (400nM), or control medium. Cells were permeabilised with 
0.5% Triton X-100, and the rat mAb ICR62 and FITC- conjugated anti-rat secondary 
antibody was used to detect the location of the EGFRvIII as described under Materials 
and Methods. HC2 20 d2/c cells treated with control medium (A), ICR16 (B), ICR62 
(C), gefltinib (D), and erlotinib (E). Left panel: FITC staining; Right panel: Hoescht 
33258 nuclear staining. Magnification: xl 00.
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Figure 4.9 Cell surface expression of the EGFRvHI in HC2 20 d2/c cells 
following 6 day treatment with the EGFR inhibitors. Sub-confluent HC2 20 d2/c cells 
were cultured continuously in DMEM/2% FCS containing mAb ICR16 (200nM), ICR62 
(200nM), gefltinib (400nM), erlotinib (400nM), or control medium, and incubated for 6  
days until the control cells were confluent. The rat mAb ICR62 and FITC- conjugated 
anti-rat secondary antibody were used to detect the location of the EGFRvIII as described 
under Materials and Methods. HC2 20 d2/c cells treated with control medium (A), 
ICR16 (B) ICR62 (C), gefltinib (D), and erlotinib (E). Left panel: FITC staining; Right 
panel: Hoescht 33258 nuclear staining. Magnification: xlOO.
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4.6.2 The phosphorylation status of the EGFRvIII, MAPK and Akt in HC2 20 d2/c 
cells following treatment with the EGFR inhibitors
The EGFRvIII is reported to be ligand independent and constitutively active (Bigner et 
ah, 1990; Humphrey et ah, 1991; Moscatello et al, 1995). Therefore, the effect of the 
EGFR inhibitors on levels of the EGFRvIII, tyrosine phosphorylated EGFRvIII, MAPK 
and Akt phosphoiylation in HC2 20 d2/c cells was investigated in this study. In addition, 
the levels of EGFRvIII phosphorylation at tyrosine 1173, 1148, 1086, 1068 and 845 was 
investigated as no study has investigated the effect of the EGFR inhibitors on multiple 
EGFRvIII phosphoiylation sites.
As the results presented in Figure 4.10 show, the EGFRvIII within HC2 20 d2/c cells was 
found to be constitutively active with high levels of tyrosine phosphoiylation at 140kDa, 
and at each of five tyrosine phosphoiylation sites. Interestingly, despite constitutive 
EGFRvIII phosphoiylation, there was no MAPK phosphoiylation in HC2 20 d2/c cells. 
In contrast, Akt was constitutively phosphorylated in HC2 20 d2/c cells (Figure 4.10). 
As the results in Figure 4.10 show, the EGFR ligands (EGF, HB-EGF) had no effect on 
the levels or phosphoiylation status of the EGFRvHI, MAPK or Akt. In contrast, while 
the IGF-IR ligands IGF-I and IGF-II did not affect EGFRvIH or MAPK phosphoiylation, 
both ligands increased the levels of Akt phosphoiylation (Figure 4.10).
As the results presented in Figure 4.11 show, at 400nM, both gefitinib and erlotinib 
reduced the constitutive levels of phosphorylation of the five investigated EGFRvIH 
tyrosine residues in HC2 20 d2/c cells (Figure 4.11). However, mAh ICR62 and NVP- 
AEW541 were not as effective at reducing the levels of EGFRvHI phosphorylation. In 
common with their effects on EGFRvHI phosphoiylation in HC2 20 d2/c cells, while
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Figure 4.10 The phosphorylation status of the EGFRvIII, MAPK and Akt in HC2 
20 d2/c cells treated with EGFR or IGF-IR ligand. HC2 20 d2/c cells were grown to 
near confluence in DMEM containing 10% FCS, and incubated in DMEM containing 
0.1% FCS or one hour at 37°C prior to the addition of lOnM EGF, HB-EGF, lGF-1, IGF- 
II, or no growth factor for 15 minutes. The treated cells were lysed and equal amounts of 
cell lysate were separated by SDS-PAGE, transferred to PVDF membranes, and probed 
with antibodies specific for the molecule of interest.
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Figure 4.11. The phosphorylation status of the EGFRvIII, MAPK and Akt in HC2 
20 d2/c cells treated with auti-EGFR mAh, EGFR TKI, or IGF-IR TKI. HC2 20
d2/c cells were grown to near confluence in DMEM containing 10% FCS, then treated 
with DMEM/0.1% FCS containing 400nM of mAh ICR62, gefltinib, erlotinib, or NVP- 
AEW541 for one hour at 37°C. The treated cells were lysed and equal amounts of cell 
lysate were separated by SDS-PAGE, transferred to PVDF membranes, and probed with 
antibodies specific for the molecule of interest.
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constitutive levels of pAkt were completely reduced by both gefltinib and erlotinib, mAb 
ICR62 and NVP-AEW541 were not as effective at reducing the levels of Akt 
phosphorylation (Figure 4.11).
4.7 Discussion
As described in the introduction, in pre-clinical studies, the anti-EGFR mAbs and EGFR 
TKIs have shown good in-vitro and in-vivo activity in EGFR expressing cells or tumours 
fi*om a range of human tissues (Ciardiello & Tortora, 2003; Albanell & Gascon, 2005). 
The anti-EGFR mAh cetuximab and the EGFR TKIs gefltinib and erlotinib have now 
been approved for the treatment of patients with colorectal cancer and NSCLC, 
respectively. However, there has been no clear association between the expression of 
EGFR and response to the EGFR inhibitors in pre-clinical and clinical studies (Bos et a/., 
1997; Sirotnak et al, 2000; Campiglio et a l, 2004; Saltz et a l, 2004), and further 
investigation on the underlying mechanism of sensitivity to the anti-EGFR antibodies and 
EGFR TKIs are therefore warranted.
The aim of this chapter was therefore to investigate the effect of the anti-EGFR mAbs 
and EGFR TKIs on the cellular location of the EGFR and EGFRvIII, cell cycle 
distribution, their interactions with EGFR ligand, and their effect on the phosphorylation 
of the EGFR, EGFRvIII, MAPK and Akt. The role of EGFR crosstalk with the IGF-IR 
in mediating sensitivity to the EGFR inhibitors was also investigated. For this purpose, 
studies were performed on the DiFi cell line, as of a panel of 12 colorectal cell lines, DiFi 
cells were found to be the most sensitive to the EGFR inhibitors and they were found to 
be EGFR and IGF-IR positive (Figure 3.4 & Table 3.1).
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Some of the monoclonal antibodies (e.g. mAb C225) can cross-link cell surface EGFR 
molecules to induce receptor internalisation to attenuate EGFR signalling (Rowinsky, 
2004; Fan et al, 1994; Friedman et a l, 2005). Similarly, in this study, mAbs ICR16 and 
ICR62 were found to reduce membranous expression of the EGFR in DiFi cells (Figure 
4.1). Interestingly, while the EGFR TKIs do not target the extracellular domain of the 
EGFR, there was also a reduction in the expression of membranous EGFR in DiFi cells 
treated with gefltinib for 24 hours (Figure 4.1). However, there was no major 
downregulation of membranous EGFR expression in DiFi cells treated with erlotinib for 
24 hours (Figure 4.1).
The mechanism of EGFR downregulation by gefltinib is unclear. However, there was a 
decrease in EGFR phosphorylation following the treatment of DiFi cells for 24 hours 
with mAh ICR62 and gefltinib, but not erlotinib (Figure 4.5). It is therefore possible that 
attenuation of EGFR phosphorylation by the EGFR TKIs, as well as the formation of 
cross-linked EGFR lattices by anti-EGFR mAb, may lead to EGFR downregulation. 
Several pre-clinical studies have shown that that the anti-EGFR mAh cetuximab may 
inhibit the growth of the DiFi cell line by inducing apoptosis and arrest in the G1 phase 
of the cell cycle (Wu et al, 1995; Fan et al, 1997; Liu et al, 2000; Liu et a l, 2001). In 
this study, mAh ICR62, gefltinib, and erlotinib were found to induce growth arrest in the 
G1 phase of the cell cycle (Figure 4.3). While there was much more apoptosis in DiFi 
cells treated with ICR62 and gefltinib than in cells treated with erlotinib, apoptosis was 
greatest in DiFi cells treated with gefltinib. This was despite gefltinib having a higher 
IC50 value than ICR62 for DiFi cells (Figure 3.3). Gefltinib has previously been shown 
to induce the formation of inactive EGFR/HER-2 and EGFR/HER-3 heterodimers and 
prevent the association of the p85 subunit of PI-3K with the HER-3 (Anido et a l, 2003;
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Hirata et al, 2005). It is therefore possible that there was higher apoptosis in DiFi cells 
treated with gefltinib as gefltinib may inhibit signalling through the anti-apoptotic PI- 
3K/Akt pathway. Indeed, as shown in Figure 4.6, mAh ICR62 was found not to be as 
effective as gefltinib at inhibiting Akt phosphorylation in DiFi cells.
However, in contrast to previous studies in DiFi cells treated with cetuximab or erlotinib 
(Wu et al, 1995; Fan et a l, 1997; Moyer et al, 1997; Liu et al, 2001), the decrease of 
cells in the S and G2/M phases and G1 arrest by mAb ICR62, gefltinib, or erlotinib was 
not accompanied with an accumulation of cells in the G1 phase. This was despite an 
increase in the proportion of HN5 cells in the G1 phase of the cell cycle by all three 
EGFR inhibitors, as demonstrated previously in HN5 cells treated with mAb ICR 16 and 
ICR62 (Modjtahedi et al, 1994). In this study, treatment with ICR62, gefltinib, and 
erlotinib induced more apoptosis in DiFi cells than HN5 cells. Since the tumour cells 
were treated with the EGFR inhibitors for 5 days before analysing their DNA content, it 
is possible that some DiFi cells arrested in G1 undergo apoptosis following prolonged 
EGFR inhibition. Indeed, in response to mitogenic signals, cells move fl-om GO and 
through Gl, but undergo apoptosis, re-enter GO, or undergo terminal differentiation in the 
absence of a mitogenic signal (Modjtahedi et al, 1994; Israels & Israels, 2001). In 
addition, in the studies in Wiich cetuximab has been shown to induce Gl arrest in DiFi 
cells, DiFi cells have only been treated with the anti-EGFR mAh for 24 hours, while 
longer (i.e. 5 day) treatment was not investigated (Wu et a l, 1995; Liu et al, 2001).
The Ras-Raf-MAPK and PI3-K/Akt pathways are two major signal transduction cascades 
associated with EGFR activation. Activation of these pathways, ultimately results in 
increased cell proliferation and cell survival (Hackel et al, 1999; Yarden, 2001). In some
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studies sensitivity to the anti-EGFR mAbs or EGFR TKIs in EGFR or HER-2 expressing 
tumour cells has been associated with a reduction of EGFR, MAPK, or Akt 
phosphorylation (Ciardiello et al, 2000; Albanell et a l, 2001; Anderson et al, 2001; 
Moulder et a l, 2001 ; Anido et a l, 2003; Janmaat et a l, 2003; Ono et a l, 2004; Hirata et 
al, 2005). In this study, 24 hours post-treatment, mAh ICR62 and gefltinib attenuated 
the constitutive levels of EGFR, MAPK, and Akt phosphoiylation in DiFi cells. In 
common with these results, attenuation of MAPK activation in DiFi cells, as well as 
EGFR overexpressing A431 cells, has been associated with the growth inhibition of these 
cells by gefltinib and cetuximab (Albanell et al, 2001 ; Liu et al, 2001). However, there 
were differences in the ability of the EGFR inhibitors to attenuate EGFR, MAPK and Akt 
phosphorylation in this study. In particular, while the levels of EGFR and MAPK 
phosphorylation were reduced more in DiFi cells treated with ICR62 and gefltinib for 24 
hours, erlotinib was more effective at decreasing EGFR and MAPK phosphorylation 
following the treatment of DiFi cells for one hour (Figure 4.5 & 4.6).
In the study by Huang and colleagues (2004), the combination of cetuximab and gefltinib 
or erlotinib enhanced growth inhibition of several NSCLC and head and neck cell lines 
over that achieved with the single agent. This was accompanied with the synergistic 
inhibition of MAPK and Akt activation (Huang et a l, 2004). However, in this study, 
there was no synergistic inhibition of DiFi cell growth following treatment with mAh 
ICR62 in combination with the EGFR TKIs despite the inhibition of MAPK and Akt in 
DiFi cells by these inhibitors (Figure 3.8 & 4.5 & 4.6). As discussed in chapter three, the 
synergistic inhibition of tumour cells with a combination of anti-EGFR mAb and EGFR 
TKI in the above study may therefore be a speciflc property of the anti-EGFR mAh 
cetuximab (Huang et a l, 2004).
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In several tumour cell lines, the TGF-IR has been shown to be necessary for prolonged 
EGF-induced MAPK activation, and to up-regulate components of the EGFR-TGFa 
autocrine loop (Coppola et al, 1994; Swantek & Baserga, 1999; Wang et a l, 2002). In 
addition, signalling via the IGF-IR has been associated with resistance to the EGFR and 
HER-2 inhibitors in several experimental studies (Wu et a l, 1995; Jones et a l, 2004; Lu 
et al, 2004a; Lu et a l, 2004b; Camirand et a l, 2005). In this study, the treatment of DiFi 
cells with IGF-I and IGF-II did not affect the growth of DiFi cells in culture and did not 
prevent growth inhibition of DiFi cells by the EGFR inhibitors (Figure 4.4). In addition, 
IGF-I and the IGF-IR inhibitor had no major effect on EGFR or MAPK phosphorylation 
in DiFi cells (Figure 4.7), suggesting that EGFR mediated MAPK signalling may be 
independent of IGF-IR function. In common with these results, maximum IGF-I 
induced-MAPK phosphorylation in DiFi cells was shown previously to occur between 
two and eight hours and the slow kinetics of MAPK activation by IGF-I suggest that the 
IGF-IR is not the primary mediator of the MAPK pathway within DiFi cells (Liu et a l, 
2001).
While the EGFR TKIs have been shown to inhibit IGF-I signalling via the MAPK 
pathway, they may not be as effective at inhibiting the activation of the IGF-IR associated 
molecule IRS-1 which can continue to activate the pro-survival PI-3K/Akt pathway 
(Roudabush et al, 2000; Lu et a l, 2004b). In common with a previous study (Liu et al, 
2001), in this study both IGF-I and EGF were found to induce Akt phosphorylation in 
DiFi cells (Figure 4.5 & 4.7). However, IGF-I induced Akt phosphorylation was only 
substantially reduced by the IGF-IR TKI (Figure 4.7). The results of this study therefore 
suggest that the combination of EGFR and IGF-IR inhibitors may have the potential for 
enhanced inhibition of downstream signalling molecules in tumour cells. Indeed, while
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no direct interaction was found between the EGFR and TGF-TR in DiFi cells (Figure 4.7), 
the EGFR in HN5 and CCL235 cells was found to be activated by the IGF-IR ligand 
IGF-I (Figure 3.2a). Consequently, further studies investigating the effect of EGFR 
inhibitors in combination with the IGF-IR inhibitors on the phosphorylation of the EGFR, 
MAPK, and Akt in such cells are warranted.
The expression of the wild-type EGFR in human malignancies may be accompanied by 
the expression of the EGFRvIH (please see chapter 5; Moscatello et al, 1995). In 
common with previous studies, the EGFRvIH in the present study was found to be 
EGFR-ligand independent, constitutively active, and to preferentially activate the PI- 
3K/Akt pathway in HC2 20 d2/c cells (Figure 4.10 & 4.11; Montgomery et a l, 1995; 
Moscatello et al, 1998; Pedersen et a l, 2001). While mAh ICR62 and gefltinib were 
found to reduce cell surface expression of the wild-type EGFR in DiFi cells, the EGFR 
inhibitors were not able to downregulate the cell surface expression of the EGFRvIH in 
HC2 20 d2/c cells (Figure 4.8 & 4.9). Interestingly, unlike mAh ICR62 both gefltinib 
and erlotinib were found to reduce the constitutive levels of EGFRvHI and Akt 
phosphorylation in HC2 20 d2/c cells (Figure 4.11), highlightling further mechanistic 
differences between the anti-EGFR mAbs and the EGFR TKIs.
Because the EGFRvHI has been associated with a number of tumorigenic processes, 
including cell transformation, increased motility and invasion, and resistance to 
radiotherapy (Haley et al, 1989; Lai et a l, 2002; Lammering et a l, 2003), the EGFR 
inhibitors may therefore have potential in the treatment of patients who express the 
EGFRvHI. Indeed, the mAh ICR62 has been shown to inhibit the growth of EGFRvHI 
expressing cells in-vivo via the induction of antibody dependent cellular cytotoxicity
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(ADCC; Modjtahedi et a l, 2003). Since the target of the anti-EGFR mAbs is 
extracellular, the inability of mAb ICR62 to induce EGFRvIH internalisation may make 
this antibody ideal for prolonged treatment of EGFRvHI expressing tumours and 
consequent tumour destruction via ADCC. However, although the EGFR TKIs were 
found to attenuate PI-3K/Akt signalling in HC2 20 d2/c cells, such cells were found to be 
resistant to growth inhibition by 200nM gefltinib and erlotinib in-vitro (data not shown). 
Indeed, in a recent study, cells expressing the EGFRvHI were found to resistant to 
concentrations of gefltinib Wiich suppressed EGFR phosphorylation, EGFR mediated 
proliferation and EGFR mediated anchorage-independent growth (Pedersen et a l, 2005).
In summary, the results of this chapter investigating the effect of EGFR inhibitors on the 
cellular location of the EGFR and EGFRvHI, cell cycle distribution, their interactions 
with EGFR and IGF-IR ligand, and their effect on the phosphorylation of the EGFR, 
EGFRvHI, MAPK and Akt, have shown the anti-EGFR mAbs and EGFR TKIs to have 
overlapping but not identical modes of action. Future clinical trials should unravel the 
flail potential of anti-EGFR mAbs and/or tyrosine kinase inhibitors to the EGFR and IGF- 
IR for targeting tumours that express the EGFR and/or EGFRvHI.
138
CHAPTER FIVE
The expression pattern and prognostic significance of the EGFR, phosphorylated 
EGFR, and EGFRvIII in colorectal cancer patients
5.1 Introduction
As discussed in the first chapter, colorectal cancer is the third most common malignancy 
in the world (Walker & Quirke, 2002; Jemal et al, 2005). While early stage disease can 
be cured by surgery alone, the majority of colorectal cancer patients are diagnosed with 
locally advanced or metastatic disease and have a poor response to conventional forms of 
therapy (Jemal et a l, 2005). It is, therefore, of prime importance to identify molecular 
markers of biological and prognostic significance and predictive value in patients with 
colorectal cancer.
Since the early 1980s, aberrant expression of the EGF receptor (EGFR) has been reported 
in a wide range of epithelial tumours, including cancers of the breast, brain, prostate, 
stomach, and colon (Foekens et al, 1989; Bigner et al, 1990; Leav et al, 1998; 
Goldstein & Armin, 2001; Ghaderi et al, 2002). However, the expression of EGFR has 
been determined using a variety of techniques, including, ligand (^^ I^-EGF) binding 
assays (Moorghen et a l, 1990; Koenders et a l, 1992), in- situ hybridisation (Komuta et 
al, 1995), PCR (Ge et a l, 2002), ELISA (Messa et a l, 1998) and immunohistochemistiy 
(Goldstein & Armin, 2001; McKay et al, 2002b; Spano et a l, 2005). While 
immunohistochemistry is the ideal method for determining the level of EGFR protein and 
its subcellular localisation, the reported fi^quency of EGFR expression in colorectal
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cancer determined by this technique ranges from 8 to 100% (Steele et a l, 1990a; Ooi et 
a/., 2004).
In addition, overexpression of the EGFR in human cancers may be accompanied by the 
expression of mutated forms of the receptor (Bigner et a l, 1990; Pedersen et al, 2001; 
Paez et a l, 2004). Of these, EGFRvIII is the most common mutated form of the EGFR, 
which is ligand-independent, constitutively active and highly transforming. While 
EGFRvIII expression has been reported on both the cell surface and in the cytoplasm of 
several human malignancies including cancer of the brain, breast, ovary, lung and 
prostate (Bigner et al, 1990; Moscatello et a l, 1995; Olapade-Olaopa er al, 2000; 
Pedersen et al, 2001; Paez et al, 2004), there has been no comprehensive study on the 
coexpression and prognostic significance of the EGFR, EGFRvIII and phosphorylated 
EGFR (pEGFR) in colorectal cancer.
In this chapter, EGFR expression was examined immunohistochemically in 87 tumour 
specimens from Dukes’ C colorectal cancer patients. Due to the wide range of EGFR 
expression reported for colorectal cancer, the expression of EGFR was determined using 
two commercially available anti-EGFR antibodies directed against the external or 
internal domain of EGFR, and the anti-EGFR mAh ICR 16. In addition, the relative 
expression of EGFRvIII and pEGFR in EGFR positive colorectal cancer patients and 
their association with clinicopathological parameters, overall survival and response to 
chemotherapy and radiotherapy were also investigated.
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5.2 Patient clinicopathological characteristics
Eighty-seven patients with Dukes’C colorectal cancer who underwent radical surgery at 
the Royal Surrey County Hospital between January 1990 and December 1998 were 
included in this retrospective study. Patient clinicopathological characteristics are 
detailed in Table 5.1. All 87 patients used in this study were diagnosed with node 
positive (Dukes’ C, N1/N2) colorectal cancer, and were a sub-group of 105 Dukes’ C 
patients used in a recent study reporting the expression pattern and prognostic 
significance of HER-2 in colorectal cancer (Essapen et a l, 2004). The median patient 
follow-up time of the study population was 4.1 years. There were 47 male, and 40 female 
patients, with a median age of 70 years (range 40-87 years). Fifty patients had a cancer 
of the colon, six of which were classified as recto-sigmoid cancers, and 37 patients had a 
cancer of the rectum. Twenty-six patients received post-operative radiotherapy, and of 
these, 20 had a cancer of the rectum and 6 had a recto-sigmoid cancer. Forty-nine patients 
received post-operative chemotherapy, which was predominantly 5-fluorouracil based. 
None of the patients had received radiotherapy or chemotherapy before surgery.
The mean overall survival time of the study population was 4.5 ± 0.3 years (median 
survival 4.1 years). Univariate analysis of survival was performed using Kaplan- Meier 
survival curves and the log rank test was used to statistically evaluate differences between 
groups of patients (Table 5.1). On univariate analysis, there was a poorer survival in 
patients with T stage 4 disease (P = 0.001), those with métastasés which had spread to the 
apical node (P = 0.007), and those over 70 years old (P = 0.014). However, no significant 
association was found between survival and the remaining clinicopathological 
characteristics (Table 5.1). The Cox model is used for multivariate analysis of patient 
survival and takes into affect the presence of confounders, other than the characteristic of
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Table 5.1. Clinicopathological characteristics and overall survival of Dukes’ C 
colorectal cancer patients. Overall survival relative to the indicated parameters 
determined using Kaplan-Meier survival curves and the log-rank test. Significance 
values were set at P<0.05, and any value above this was considered non-significant.
Clinicopathological Number of patients Overall survival in Significance
Characteristic (%) years (mean ± SE) (P- value)
Sex
Male 47 (54.0) 5.07 ±0.59
Female 40 (46.0) 6.16 ± 0.57 NS
Age in years
<70 47 (54.0) 6.65 ± 0.61
>70 40 (46.0) 4.51 ±0.51 0.014
Tumour site
Right colon 26 (29.9) 5.60 ±0.72
Left colon 24 (27.6) 5.88 ±0.82
Rectum 37 (42.5) 5.22 ±0.59 NS
Size
<5cm 56 (64.4) 5.58 ±0.51
>5 cm 31 (35.6) 5.74 ±0.74 NS
Grade
1 3 (3.4) 4.74 ±2.68
2 48 (55.2) 6.32 ±0.59
3 32 (36.8) 4.47 ±0.54
Mucinous 4 (4.6) 5.47 ±1.09 NS
LVI
Absent 65 (74.7) 5.70 ±0.44
Present 22 (25.3) 5.14 ±0.94 NS
T-stage
T2 10(11.5) 6.15 ±1.19
T3 56 (64.4) 6.42 ±0.53
T4 21 (24.1) 3.30 ±0.63 0.0012
Apical Node
Negative 45 (51.7) 5.91 ±0.54
Positive 11(12.6) 3.00 ±0.67
Unknown 31 (35.6) 6.04 ±0.75 0.0068
Positive nodes
1-3 57 (65.5) 5.88 ±0.49
>4 30 (34.5) 4.92 ±0.72 NS
*NS: Not Significant; LVI: Lymphovascular Invasion
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interest, which may influence patient survival. Using multivariate analysis, T stage (P= 
0.002), metastasis to the apical node (P= 0.026), and age category (P= 0.021), remained 
significant prognostic indicators of patient survival.
53 The specificity of antibodies for use in the immunohistochemical detection of 
EGFR, EGFRvin and pEGFR
The specificity of antibodies for their respective receptor was confirmed by the 
immunohistochemical staining of the HN5 cell line, which expresses 1.4x10  ^ EGFR 
molecules/cell (Cowley et a l, 1986), and HC2 20 d2/c cells vdiich express approximately 
2.1x10^ EGFRvIII molecules/cell (Wikstrand et al, 1995; Moscatello et a l, 1996). The 
expression of the EGFR was determined using antibodies directed against the external 
(ICR 16 and EGFR.113) or the internal domain (rabbit pAb) of the receptor. Of these, 
mAh ICR16 has been used in previous studies to demonstrate the expression pattern of 
the EGFR in tumour sections fi-om a wide range of human epithelial tumours including 
breast, and head and neck cancer (Gharesi- Fard et a l, 2000; Khademi et al, 2002). In 
addition, mAh ICR16 has also been shown to cross-react with the EGFRvIII (Modjtahedi 
et al., 2003).
As results presented in Figure 5.1 show, the commercial antibodies to the external 
domain (EGFR.113) and intemal domain (rabbit pAb) of the EGFR demonstrated strong, 
predominantly membranous staining of the HN5 cell pellet. Interestingly, both of these 
antibodies also demonstrated strong, predominantly membranous staining of the 
EGFRvIII expressing cell line HC2 20 d2/c (Figure 5.1).
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Figure 5.1. Immunohistochemical staining of HN5 (EGFR overexpressing) and 
HC2 20 d2/c (EGFRvIII overexpressing) cell pellets with anti-EGFR antibodies.
Three pm sections of formalin fixed paraffin embedded HN5 (A, C) or HC2 20 d2/c (B, 
D) cell pellets were immunohistochemically stained with anti-EGFR antibodies as 
described under Materials and Methods. Immunostaining with rabbit pAb (A, B) or 
EGFR 113 (C, D). Magnification: x200.
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Immunostaining of HN5 and HC2 20 d2/c cell pellets with the anti-EGFRvIII and 
pEGFR specific antibodies is shown in Figure 5.2. In contrast to the anti-EGFR 
antibodies, the mAh G100 was specific for the EGFRvIH. This antibody only 
demonstrated strong immunostaining of the HC2 20 d2/c cell line, Wiich overexpress the 
EGFRvHI (Figure 5.2b) and did not stain the cell membrane of the HN5 cells, which 
overexpress the wild type EGFR (Figure 5.2a). The rabbit anti-pEGFR (Tyrl068) 
polyclonal antibody demonstrated strong cell membrane staining of HC2 20 d2/c cells, 
which overexpress EGFRvIH and contain a constitutively active (i.e. phosphoiylated) 
tyrosine kinase domain (Figure 5.2d), but immunostaining with the pEGFR antibody was 
much weaker in HN5 cells (Figure 5.2c). The constitutive activation of the EGFRvHI at 
tyrosine residue 1068 in HC2 20 d2/c cells was shown previously in Figure 4.10. In 
contrast, as was shown in Figure 3.2, the EGFR on HN5 cells were not constitutively 
active.
To demonstrate the cross reactivity of anti-EGFR mAbs ICR16 and EGFR.113 with both 
the wild type EGFR and EGFRvIH, immunofluorescence staining of HC2 20 d2/c cells 
and DiFi cells was also conducted (Figure 5.3). Briefly, tumour cells were grown to near 
confluence and fixed in paraformaldehyde prior to permeabilisation with Triton X-100. 
Following incubation with primary antibodies (i.e. mAbs ICR 16, EGFR.113, or ICR 10), 
the bound antibodies were detected using FITC-conjugated secondary antibody. The mAh 
ICR 10 has been shown previously to be specific for the wild-type EGFR (Modjtahedi et 
al, 2003). As shown in Figure 5.3, immunofluorescence staining of both DiFi and HC2 
20 d2/c cells were obtained with mAbs ICR16 (Figure 5.3a & 5.3b) and similar results 
were obtained with EGFR.113 (Figure 5.3c & 5.3d).
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Figure 5.2. Immunohistochemical staining of HN5 and HC2 20 d2/c cell pellets 
with anti-EGFRvni and anti-pEGFR antibodies. Three pm sections of formalin fixed 
paraffin embedded HN5 (A, C) or HC2 20 d2/c (B, D) cell pellets were 
immunohistochemically stained with anti-EGFRvIII mAb GlOO (A, B) or anti- pEGFR 
(tyrosine 1068) antibodies (C, D), as described under Materials and Methods. 
Magnification: x200.
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Figure 5.3. Immunofluorescence staining of DiFi and HC2 20 d2/c cells by anti- 
EGFR and anti-EGFRvIII antibodies. DiFi (A, C, E) or HC2 20 d2/c cells (B, D, F) 
were grown to near confluency, fixed in 4% paraformaldehyde, and permeabilised in 
0.5% Triton X-100. Immunofluorescence staining was conducted using mAbs ICR16 (A, 
B), EGFR.113 (C, D) or ICRIO (E, F) as described under Materials and Methods. Left 
panel; FITC staining; Right panel: Hoescht 33258 nuclear staining.
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In contrast, mAb ICRIO demonstrated immunofluorescence staining of DiFi cells (Figure 
5.3e) but not HC2 20d2/c cells (Figure 5.3Q. These results therefore suggest that mAbs 
ICR 16 and EGFR.113, that recognise an epitope on the external domain of the EGFR, 
bind to both wild type EGFR and the EGFRvIII (Figure 5.3).
5.4 The expression of EGFR in patients with Dukes’ C colorectal cancer
The expression of the EGFR was determined in tumour specimens from 87 colorectal 
cancer patients, using the three anti-EGFR antibodies. For this purpose, tumour sections 
were incubated with the primary antibodies, the bound antibodies were detected using the 
corresponding biotinylated secondary antibody and immunostaining was visualised using 
a standard avidin/biotin/horseradish peroxidase system. In order to be able to compare 
the results of this study with those in the literature, EGFR immunostaining was scored by 
both the percentage of cells stained and the intensity (0 negative, to 3 strong) of staining. 
In common with the majority of published studies, EGFR immunostaining was 
considered positive if more than 10% of the tumour cells were stained by the antibody.
As the results in Table 5.2 show, although the majority of tumours (i.e. 76%) were found 
to be EGFR positive with the three anti-EGFR antibodies, the levels of EGFR expression 
varied with respect to both the percentage of EGFR positive cells and intensity of 
immunostaining (Table 5.2). Using the rabbit pAb to the intemal domain of the EGFR, 
87 cases (100%) were found to be EGFR positive. In contrast, 72 cases (83%) and 66 
cases (76%) were found to be EGFR positive using mAb ICR62 and mAb EGFR.113 
which are directed to the external domain of the EGFR (Table 5.2). In contrast to the 
predominantly membranous expression of the EGFR in the HN5 and HC2 20 d2/c cell 
pellets (Figure 5.1), the predominant pattern of EGFR immunostaining with all three anti-
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Table 52. Immunohistochemical examination of EGFR expression in Dukes’ C 
colorectal cancer patients. The levels of EGFR expression were determined using anti- 
EGFR polyclonal antibody (pAb) to the intemal domain of the receptor, or mAbs ICR 16 
and EGFR.113 that are directed to the extemal domain of the EGFR. The levels of EGFR 
are presented according to the percentage of EGFR positive cells (A) and the intensity of 
immunostaining (B).
A)
Percentage of positive 
tumour cells
Number of cases with receptor expression (any intensity)
EGFR (pAb) mAh ICR16 EGFR.113
0-10 (Negative) 0 15 21
>10 87 72 66
>50 84 55 49
B)
Antibody % of positive 
tumour cells
Number of cases with indicated immunostaining
0 1+ 2+ 3+
EGFR pAb 0-10 (Negative) 74 44 35 55
>10 13 43 52 32
>50 3 22 24 24
ICR16 0-10 (Negative) 36 26 52 78
>10 51 61 35 9
>50 27 30 12 4
EGFR.113 0-10 (Negative) 26 28 54 67
>10 61 59 33 20
>50 31 14 7 5
0: negative; 1+: weak; 2+: moderate; 3+: strong immunostaining
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EGFR antibodies was found to be cytoplasmic in patient biopsies (Figure 5.4). Using the 
rabbit pAb, no clear membranous expression of the EGFR could be detected in any of the 
biopsies, and membranous EGFR expression was only detected in 3 (3%) and 7 (8%) of 
the cases using mAbs ICR62 and mAb EGFR.113 (e.g. Figure 5.5a). Only one case was 
found to express membranous EGFR in more than 10% of tumour cells with both mAh 
ICR16 and mAh EGFR.113.
When EGFR immunostaining was scored on the basis of the intensity of staining, there 
were more cases of 3+ intensity with the rabbit anti-EGFR polyclonal antibody, which is 
directed against the intemal domain of the EGFR, than for mAh ICR16 or EGFR.113 
(Table 5.2b). For example, 32 cases (37%), 9 cases (10%) and 20 cases (23%) were 
found to have EGFR immunostaining intensity of 3+ in more than 10% of tumour cells, 
using rabbit EGFR pAb, mAb ICR 16 and EGFR.113, respectively (Table 5.2b). 
Interestingly, compared to the rabbit pAb, a similar number of cases were found to 
express the immunostaining intensity of 1+ and 2+ in more than 10% of tumour cells 
with mAh ICR16 and EGFR.113, vriiich are both directed to the extemal domain of the 
EGFR (Table 5.2b). The results of tumour sections immunostained at different intensities 
(1+, 2+, 3+) using mAh 113 are presented in Figure 5.5.
5.5 The expression of EGFRvHI in patients with Dukes’ C colorectal cancer
The expression of the EGFRvIII was determined in the same series of tumour sections 
using the EGFRvIII specific monoclonal antibody GlOO. This is the first study to report 
the relative expression of EGFRvIII in EGFR positive tumours fi’om human colorectal 
cancer patients. The immunohistochemical staining was scored by the percentage of
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Figure 5.4. Immunohistochemical staining of EGFR in Dukes’ C colorectal 
cancer patients. Formalin fixed paraffin embedded tumour sections were 
immunohistochemically stained with anti-EGFR antibodies as described under Materials 
and Methods. 3+ immunostaining with EGFR.113 (A), 3+ immunostaining with rabbit 
pAb (B), and 3+ immunostaining with mAh ICR16 (C). Magnification: x200.
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Figure 5.5. Immunohistochemical staining of Dukes’ C colorectal cancer biopsies 
with EGFR.113. F o r m a l i n  f i x e d  p a r a f f i n  e m b e d d e d  t u m o u r  s e c t i o n s  w e r e  
i m m u n o h i s t o c h e m i c a l l y  s t a i n e d  w i t h  m A b  E G F R . 1 1 3  a s  d e s c r i b e d  u n d e r  M a t e r i a l s  a n d  
M e t h o d s .  3 +  i m m u n o s t a i n i n g  ( A ) ,  t h e  n e g a t i v e  c o n t r o l  o f  t h e  s a m e  t u m o u r  s e c t i o n  ( B ) ,  
2 +  i m m u n o s t a i n i n g  ( C ) ,  a n d  1 +  i m m u n o s t a i n i n g  (D). M a g n i f i c a t i o n :  x 2 0 0 .
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positive tumour cells and intensity of immunostaining. Immunostaining in greater than 
10% of tumour cells was considered positive.
Using mAb GlOO, 30 of the EGFR positive cases were found to be EGFR positive (Table 
5.3). Unlike EGFR immunostaining, none of the EGFRvIH positive cases displayed 
immunostaining of 3+ intensity and only 14 patients expressed the EGFRvHI in more 
than 50% of tumour cells (Table 5.3). In contrast to the predominant membrane staining 
demonstrated in the HC2 20 d2/c cell pellet (Figure 5.2), the expression of EGFRvHI in 
all of the patient biopsies was found to be exclusively cytoplasmic (Figure 5.6).
5.6 The expression of pEGFR in patients with Dukes’ C colorectal cancer
Tumour specimens from 87 Dukes’ C colorectal cancer patients were also examined for 
the expression of phosphorylated EGFR using the rabbit anti-pEGFR (tyrosine 1068) 
antibody. Tyrosine 1068 is one of three major autophosphoiylation sites of the EGFR, 
and is associated with the activation of the MAPK and PI-3K pathways which ultimately 
lead to the activation of proliferative and pro-survival pathways within tumour cells 
(Downward et al, 1984; Margolis et a l, 1989; Walton et al, 1990). Using the anti- 
pEGFR (Tyrl068) polyclonal antibody, only 7 cases out of 87 (8%) were found to 
express pEGFR. However, pEGFR immunostaining was never present in more than 10% 
of tumour cells. Immunohistochemical staining of tumour specimens with the anti- 
pEGFR antibody are presented in Figure 5.7. While there was weak and diffuse 
cytoplasmic staining in several tumour sections, the immunostaining for pEGFR was 
predominantly membranous, similar to the membrane immunostaining demonstrated in 
the HC2 20 d2/c cell pellet (Figure 5.2).
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Table 53. Immunohistochemical examination of EGFRvIII expression in Dukes’ 
C colorectal cancer patients. The levels of EGFRvIII expression in colorectal tumour 
specimens were determined using the anti-EGFRvIII mAh GlOO. The levels of 
EGFRvHI expression are presented according to the percentage of EGFRvIH positive 
cells and the intensity of immunostaining.
Percentage of 
positive tumour cells
Number of cases with EGFRvHI expression (any intensity)
0-10 (Negative) 57
>10 30
>50 14
Percentage of Number of cases with indicated immunostaining
positive tumour cells
0 1+ 2+ 3+
0-10 (Negative) 3 58 80 0
>10 84 29 7 0
>50 68 9 2 0
0: negative; 1+: weak; 2+: moderate; 3+: strong immunostaining
154
' -tv^y •.^ <'»»T^ « f .Ar ^  ^  _ ... JTW r ^  - , . ^ T  : \
Figure 5.6. Immunohistochemical staining of EGFRvin in Dukes  ^ C colorectal 
cancer patients. Formalin fixed paraffin embedded tumour sections were 
immunohistochemically stained with anti-EGFRvin mAh GlOO as described under 
Materials and Methods. EGFRvin immunostaining of 2+ intensity (A, B), and 14- 
intensity (C). Magnification: x200.
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Figure 5.7. Immunohistochemical staining of phosphorylated EGFR in Dukes’ C 
colorectal cancer patients. Formalin fixed paraffin embedded tumour sections were 
immunohistochemically stained with anti-pEGFR (tyrosine 1068) pAb as described under 
Materials and Methods. Predominantly membranous pEGFR immunostaining (A, B) or 
predominantly cytoplasmic pEGFR immunostaining (C). Magnification: x200.
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5.7 The association between EGFR, EGFRvIII and pEGFR expression and 
clinicopathological parameters
Following the determination of EGFR, EGFRvIII, and pEGFR expression in the 87 
patients with Dukes’ C colorectal cancer, the chi-squared test was used to investigate any 
association between the expression of these markers and clinicopathological parameters 
(Table 5.4). As shown in Table 5.4, no significant association was found between 
clinicopathological parameters and the expression of EGFR, determined with mAb 
ICR16, or EGFR.113. Because EGFR expression was detected in all 87 patients using 
the rabbit pAb, no statistical analysis with this antibody was possible. However, the 
expression of the EGFRvin was significantly associated with T stage (P =0.001), with 
expression of the EGFRvIII decreasing fi'om tumour stage T2 to T4 (Table 5.4). There 
was, however, no significant association between the expression of EGFRvIII or pEGFR 
and the other clinicopathological parameters in this group of patients (Table 5.4).
5.8 The association between EGFR, EGFRvIII and pEGFR expression and 
overall survival
In colorectal cancer, the expression of the EGFR has been associated with a poor 
prognosis in some studies, while other studies have found no such association or have not 
investigated the impact of EGFR expression on patient survival (Steele et al^ 1990b; 
Mayer et a l, 1993; Goldstein & Armin, 2001; Nicholson et a/., 2001; McKay et ah, 
2002b; Khorana et ah, 2003; Mawdsley et ah, 2004; Spano et ah, 2005). In addition, 
there has been no comprehensive study on the relative expression and prognostic 
significance of EGFRvIII in EGFR positive colorectal cancer patients. The majority of 
anti-EGFR antibodies used for the immunohistochemical examination of tumour 
specimens in studies reported in the literature do not differentiate between the expression
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Table 5.4. The association between clinicopathological parameters and EGFR or 
EGFRvIII expression determined using the chi-squared test. Significance values 
were set at P<0.05, and any value above this was considered non-significant
Clinicopathological
characteristic
Number of patients with receptor expression 
(P-value for association with patient characteristic)
EGFR(ICR16) EGFR (113) EGFRvin
Sex
Male 36 36 17
Female 36 NS 30 NS 13 NS
Age in years
<70 41 37 18
>70 31 NS 29 NS 12 NS
Tumour site
Right colon 20 16 7
Left colon 21 19 6
Rectum 31 NS 31 NS 17 NS
Size
<5 cm 45 42 19
>5 cm 27 NS 24 NS 11 NS
Grade
1 3 2 1
2 39 38 19
3 27 24 8
Mucinous 3 NS 2 NS 2 NS
LVI
Absent 54 49 26
Present 18 NS 17 NS 4 NS
T-stage
T2 9 9 8
T3 48 43 20
T4 15 NS 14 NS 2 0.001
Apical Node
Negative 38 35 13
Positive 10 8 3
Unknown 24 NS 23 NS 14 NS
Positive nodes
1-3 47 44 16
>4 25 NS 22 NS 21 NS
NS: Not significant (P>0.05); LVI : Lymphovascular Invasion
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of EGFR and EGFRvTTT. Furthermore, recent studies in non-small cell lung cancer 
patients suggest that the determination of EGFR phosphorylation status, rather than 
EGFR overexpression, may be a better indicator of cancer prognosis (Kanematsu et al., 
2003). In this study, the effect of EGFR, EGFRvIII, and pEGFR expression on patient 
prognosis was thus explored.
For univariate analysis of survival, Kaplan- Meier survival curves and the log rank test 
was used to evaluate the impact of receptor expression on patient outcome. As shown in 
Figure 5.8a and 5.8b, no significant association was found between overall survival and 
EGFR expression using mAb ICR16 (5.87 ± 0.47 versus 4.34 ± 0.86 years), or EGFR.l 13 
(5.94 ± 0.48 versus 4.33 ± 0.69 years). Because EGFR expression was detected in all 87 
patients using the rabbit pAb, no survival analysis with this antibody was possible. As 
the Kaplan-Meier survival curve in Figure 5.8c shows, in common with patients 
expressing the EGFR, there was a trend for improved overall survival in patients 
expressing the EGFRvIII (6.46 ± 0.7 versus 5.15 ± 0.52 years), but this was not 
statistically significant (P= 0.162; Figure 5.8c). Because pEGFR expression was never 
detected in more than 10% of tumour cells, pEGFR immunostaining in greater than 1% of 
tumour cells was considered positive for survival analysis. However, there was no 
significant association between pEGFR expression and overall survival (4.45 ± 1.28 
versus 5.69 ± 0.45 years; P= 0.45; data not shown).
In addition to determining the impact of EGFR or EGFRvin expression in patients with 
immunostaining in more than 10% of tumour cells, the impact of different EGFR and 
EGFRvIII immunostaining intensities on patient survival was investigated. However, no
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Figure 5.8. The impact of EGFR and EGFRvIII expression on overall survival in 
Dukes’ C colorectal cancer patients. Kaplan- Meier survival curves for patients 
with EGFR expression using mAbs EGFR113 (A) and ICR16 (B) or patients with 
EGFRvin expression using mAh GlOO (C). A log rank test value of ?<0.05 was 
considered statistically significant.
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strong association was found between the intensity (1+, 2+, or 3+) of EGFR or EGFRvIII 
immunostaining and overall survival in this study (data not shown).
5.9 The association between EGFR, EGFRvIII and pEGFR expression and 
overall survival in patients receiving radiotherapy or chemotherapy
The expression of the EGFR has been associated with a poor response to radiotherapy in 
locally advanced rectal cancer patients (Giralt et a l, 2002), and radiation can induce the 
release of TGFa to activate the EGFR and MAPK pathway leading to increased cellular 
proliferation and protection from radiation induced cell death (Dent et al, 1999). 
Consequently, Kaplan-Meier survival curves and the log rank test were used to evaluate 
the association between the expression of EGFR or EGFRvIII and overall survival in 
patients receiving radiotherapy.
Interestingly, as the results in Figure 5.9a & 5.9b show, there was an improved survival 
in patients receiving radiotherapy if their tumours were expressing the EGFR, and this 
was significant using both mAh ICR16 (6.1 ± 0.78 versus 2.42 ± 0.62 years; P= 0.0041) 
and EGFR.113 (5.95 ± 0.75 versus 2.25 ± 0.49 years; P= 0.014). In addition, there was 
also an improved survival in patients receiving radiotherapy if their tumours were 
expressing the EGFRvIII (8.03 ±1.11 versus 3.85 ± 0.65 years; P = 0.005; Figure 5.9c). 
On multivariate analysis, T-stage was the greatest indicator of overall survival in patients 
receiving radiotherapy, and EGFR expression determined by mAb ICR16 (P= 0.192) and 
EGFR.l 13 (P= 0.05), was not a significant predictor of survival in patients receiving 
radiotherapy. Following the removal of T-stage from the list of covariâtes, EGFR 
expression by mAb ICR16 (P= 0.001) and EGFR.113 (P= 0.023) remained significant
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Figure 5.9. The impact of EGFR and EGFRvIII expression on overall survival in 
Dukes’ C patients receiving radiotherapy. Kaplan- Meier survival curves for patients 
receiving radiotherapy who were found to express the EGFR, determined by mAh 
EGFRl 13 (A) or mAb ICR16 (B), or the EGFRvIE (C). A log rank test value of ?<0.05 
was considered statistically significant.
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indicators of improved survival. In contrast to EGFR expression, EGFRvTTT expression 
remained a significant predictor of overall survival in patients receiving radiotherapy, 
irrespective of T-stage (P= 0.001).
A number of pre-clinical studies have also shown that tumours with EGFR expression 
may be more resistant to chemotherapy, and the cytogenic action of some 
chemotherapeutic agents may be enhanced by simultaneous EGFR inhibition (Ciardiello 
et al, 2000; Sirotnak et al, 2000; Prewett et al, 2002). Consequently, Kaplan-Meier 
survival curves and the log rank test was also used to evaluate the association between the 
expression of EGFR or EGFRvIII and overall survival in patients receiving 
chemotherapy. However, in contrast to patients receiving radiotherapy, there were no 
significant associations between the expression of EGFR or EGFRvIII and overall 
survival in patients receiving chemotherapy (Figure 5.10).
5.10 The impact of different cut-off values on the association between receptor 
expression and overall survival
In this study, a patient was scored as growth factor receptor positive if the section fi'om 
their tumour biopsy demonstrated immunostaining in greater than 10% of tumour cells. 
This was principally because the majority of studies in the literature use a 10% “cut-off’ 
value. However, although the 10% cut-off value is the most fi’equently used in the 
literature, this is by no means standardised, and a variety of cut-off values have 
resultantly been used in the literature. Consequently, in this study the expression of the 
EGFR and EGFRvIII was also analysed using patients with growth factor expression in 
>1% (i.e. any level of expression), >25%, >50%, and >75% of tumour cells.
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Figure 5.10. The impact of EGFR and EGFRvIII expression on overall survival in 
Dukes C patients receiving chemotherapy. Kaplan- Meier survival curves for patients 
receiving chemotherapy who were found to express the EGFR, determined by mAh 
EGFR.113 (A) or mAh ICR16 (B), or the EGFRvin (C) log rank test value of P<0.05 
was considered statistically significant.
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However, there were no significant associations between the percentage of expression of 
EGFR, using mAh ICR16, EGFR.113, or rabbit pAb, or the expression of EGFRvIII and 
overall survival using cut-off values of 1%, 25%, 50%, and 75% (data not shown).
5.11 Discussion
This is the first study to examine the expression pattern of the EGFR in colorectal cancer 
patients using three anti-EGFR antibodies directed to different domains of the receptor. 
This is also the first study to report the relative expression of EGFRvIII and pEGFR in 
EGFR-positive colorectal cancer.
While immunohistochemistiy is the ideal method for determining the level of EGFR 
protein and its subcellular localisation, in this study the choice of antibody was found to 
influence the percentage and intensity of EGFR positive cases detected by this technique 
(Table 5.2). Using antibodies to the external or internal domain of EGFR, 76% 
(EGFR.113), 83% (mAh ICR16), and 100% (rabbit pAb) of Dukes’ C colorectal tumour 
specimens were found to be EGFR positive. In another study using mAh EGFR 113, 
EGFR expression was reported in 72.7% of 249 Dukes’ stage A-D patients (McKay et 
al, 2002b). While the authors did not specify what percentage of Dukes’ C patients were 
expressing the EGFR in greater than 10% of tumour cells, 52.2% of Dukes’ C patients 
were found to express the EGFR in greater than 50% of tumour cells (McKay et aL, 
2002b). Likewise, in this study, 56.3% of patients were found to express the EGFR in 
greater than 50% of tumour cells using EGFR. 113 (Table 5.2). However, in some studies, 
the expression of EGFR has been reported in much lower percentage of colorectal cases. 
For example, in another study, EGFR expression was reported in 8% of 244 stage I-IV 
(Dukes’A-D) colorectal carcinomas using an antibody to the external domain of the
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EGFR. The low percentage of colorectal cancer cases reported could be due to the 
differences in the EGFR scoring, as they did not consider EGFR immunostaining 
intensity of 1+ (which was classified as definite cytoplasmic and/or discontinuous 
membrane staining) as EGFR positive (Ooi et a l, 2004).
Unlike mAbs ICR16 and EGFR.l 13, the rabbit polyclonal antibody used in this study is 
directed to an epitope on the internal domain of the EGFR. The rabbit pAb should 
therefore bind to various forms of EGFR expressed on tumour cells, including EGFR 
mutations with deletions in the extracellular domain of the receptor, and the rabbit pAb 
should also bind tumours that proteolytically shed the extracellular domain (BCD) of the 
EGFR (Modjtahedi et al, 2003; Jacot et a l, 2004). Therefore, this may have contributed 
to the higher percentage of EGFR positive colorectal cancer cases detected with the rabbit 
pAb in this study. However, in common with most studies, the results presented in this 
chapter suggest that EGFR expression is common in patients with Dukes’ C colorectal 
tumours as 76% of the cases were positive with three different anti-EGFR antibodies 
(Goldstein & Armin, 2001; Vlahovie & Crawford, 2003; Perez-Soler, 2004).
While some studies have found the predominant pattern of EGFR immunostaining to be 
cytoplasmic (Hayashi et al, 1994; Fric et al, 2000), other studies have reported the 
expression of both membranous and cytoplasmic EGFR (Nakae et a l, 1993; Goldstein & 
Armin, 2001; Lee et al, 2002; Spano et al, 2005) or scored only the membranous 
expression of EGFR (Khorana et al, 2003). One particular reason for the latter is that 
membranous EGFR forms an ideal target for monoclonal antibody based therapy (Nakae 
et al, 1993; Lee et a l, 2002; Khorana et a l, 2003). In this study, the predominant 
expression of EGFR in patients with Dukes’ C colorectal tumours was found to be
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cytoplasmic. Interestingly, in the study by McKay and colleagues (2002), 167/181 
(92.3%) of EGFR positive patients were found to express membranous only or 
membranous and cytoplasmic EGFR using the mAh EGFR.113. While a similar 
percentage of cases were found to express the EGFR in the study by McKay and 
colleagues (72.9%) and in this study (76%; see above) using EGFR.113, the expression 
of membranous EGFR was found in only 7/66 (11%) of EGFR positive cases in this 
study. These differences may be due to the use of Dukes’ C patients in this study and the 
inclusion of Dukes’ A-D patients in the study by McKay and colleagues (McKay et ah, 
2002b).
The EGFRvIII has been implicated in a number of processes including cell 
transformation, increased motility and invasion, and resistance to radiotherapy (Haley et 
al, 1989; Lai et al, 2002; Lammering et al, 2003). The majority of anti-EGFR 
antibodies that are commonly used in immunohistochemistiy (e.g. mAh EGFR.113, 2- 
18C9, or antibodies against internal domain of the EGFR) can also interact with the 
EGFRvIII. Consequently, it has been difficult to elucidate the prognostic significance of 
wild type EGFR and EGFRvIII expression in EGFR positive patients. Indeed, mAh 
ICR 16 has previously been demonstrated to detect the EGFRvIII as well as the wild-type 
EGFR (Modjtahedi et al, 2003). The results presented in Figures 5.1 and 5.3 also 
confirm that the anti-EGFR mAbs ICR16, EGFR.l 13, and rabbit anti-EGFR pAb used in 
this study cross-react with EGFRvin. Therefore, the relative expression of EGFRvIII in 
EGFR positive cases was examined using an EGFRvIII specific antibody.
While 76% of cases were EGFR positive with all three anti-EGFR antibodies, 34% of 
cases were EGFRvIII positive. In another study using mAbGlOO, 39% of tumour
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specimens from 76 NSCLC patients were found to express the EGFRvIII (membrane and 
cytoplasmic), and the constitutive activity of the EGFRvIII was implicated in the 
pathogenesis of NSCLC (Okamoto et a l, 2003). In another study, using the EGFRvIII 
specific antibody Ab-18, EGFRvIII was detected in 57.8% of breast cancer patients, and 
in contrast to the wild-type EGFR, EGFRvIII expression was found to be predominantly 
cytoplasmic (Ge et a l, 2002). Similarly, expression of the EGFRvin has also been 
reported in patients with prostate cancer, and although there was some membranous 
expression, EGFRvIII expression was found to be mainly cytoplasmic (Olapade-Olaopa 
et al, 2000). In common to these and several studies in other epithelial tumours, the 
expression of EGFRvin in patients with Dukes’C colorectal tumours was found to be 
predominantly cytoplasmic (Ekstrand et al, 1995; Moscatello et al, 1995; Olapade- 
Olaopa et al, 2000; Ge et a l, 2002). The cytoplasmic EGFRvin expression in such 
patients may make them unsuitable for treatment with anti-EGFRvni antibodies.
While 34% of colorectal cancer patients were found to express the constitutively active 
EGFRvni, phosphorylation of the EGFR at tyrosine 1068 was only present in 8% of 
specimens and was never present in more than 10% of tumour cells. Therefore, unlike 
EGFR and EGFRvin expression, the expression of the pEGFR was not common in 
patients with Dukes’C colorectal cancer. The low levels of pEGFR (Tyrl068) detected in 
this study could be due to several factors, including inactivation of the receptor following 
tumour removal and storage (Ciardiello & Tortora, 2003; Atkins et a l, 2004). However, 
using the HC2 20 d2/c cell pellet, there were no changes in the phosphorylation status of 
tyrosine 1068 up to 2 years post formalin fixation and paraffin embedding (data not 
shown). Alternatively, as Tyrosine 1068 is one of the five autophosphorylation sites 
(pEGFR 1173, 1148, 1086, 1068, and 992) on the EGFR (Figure 4.5), it may be possible
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that the phosphorylation of sites other than pEGFR 1068 may be more frequent in 
colorectal cancer patients (Kanematsu et a l, 2003; Okamoto et at, 2003). Further 
investigations on the clinical significance of other EGFR phosphorylation sites in 
colorectal cancers are therefore warranted.
The expression of the EGFR in patients with colorectal cancer has been associated with a 
poor prognosis in some studies, while there has been no such association in other studies 
(Magnusson et a l, 1989; Mayer et a l, 1993; Hayashi et a l, 1994; Goldstein & Armin, 
2001; McKay et al, 2002b; Khorana et al, 2003; Kopp et a l, 2003; Spano et a l, 2005). 
Choice of antibody, fixative, storage time of tumour sections, scoring system, patient 
population (e.g. Dukes’ stage) and sample size may be some of the factors contributing to 
the conflicting data on the expression of EGFR in human cancers including colorectal 
cancer (Ciardiello & Tortora, 2003; Atkins et al, 2004). In this study, using three 
different anti-EGFR antibodies, no significant association was found between EGFR 
expression, which was predominantly cytoplasmic, and clinicopathological parameters or 
overall survival (Table 5.4 & Figure 5.8). In a study involving 82 stage I-IV (Dukes’ A-
D) colorectal cancer patients, 98% were found to express predominantly cytoplasmic 
EGFR, but this was associated with a poor prognosis (Mayer et a l, 1993). In contrast, 
more recently, mainly cytoplasmic EGFR expression has been associated with improved 
disease free survival in 60 patients with locally advanced rectal carcinoma (Mawdsley et 
al, 2004). In addition, in other studies, no significant association has been found 
between EGFR expression and overall survival in colorectal cancer patients with 
predominantly membranous (Lee et al, 2002; Khorana et a l, 2003), or membranous and 
cytoplasmic EGFR expression (Goldstein & Armin, 2001; McKay et a l, 2002b; Spano et 
al, 2005). The results presented here show that expression of the EGFR and EGFRvIII in
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patients with Dukes’ C colorectal cancer is predominantly cytoplasmic and is not 
associated with overall survival. In addition, no significant association has been found 
between overall survival and EGFR or EGFRvIII expression using cut-off values of 1%, 
25%, 50%, and 75%.
In another study, phosphoiylation of the EGFR, but not EGFR overexpression was shown 
to be associated with poor prognosis in NSCLC patients (Kanematsu et a l, 2003). This 
in turn may have also contributed to the lack of association between EGFR expression 
and survival in this study. However, no association was found between pEGFR and 
patient survival or clinicopathological parameters in this study.
Finally, in some studies, EGFR expression has been associated with a poor response to 
radiotherapy (Giralt et a l, 2002; Lammering et al, 2003; Harari & Huang, 2004). In one 
study EGFR expression was found to be present in 29 of 45 (64%) locally advanced 
rectal cancer patients, and this in turn was an indicator of poor response to radiotherapy 
(i.e. 34% response in EGFR+ patients vs. 62% in EGFR- patients) (Giralt et a l, 2002). 
In another study, radiation was found to increase the tyrosine phosphorylation of EGFR 
and EGFRvIII, and EGFRvIII expression was found to confer a stronger cytoprotective 
response to radiation than wild type EGFR (Lammering et al, 2003). Interestingly, in 
this study the expression of EGFR and EGFRvIII was found to be associated with 
improved survival in Dukes’ C colorectal patients receiving radiotherapy (Figure 5.9). It 
is likely that this is, at least in part, due to the localisation of EGFR and EGFRvIII 
immunostaining in the present study, which was predominantly cytoplasmic.
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Cytoplasmic EGFR and EGFRvTTT should not transmit the action of the EGF-like ligands 
(e.g. TGFa), and can not heterodimerise with other ErbB molecules, which are required 
for the activation of the MAPK or PI-3K pathway and subsequent protection from 
radiation therapy (Dent et a l, 1999; Harari & Huang, 2004). Indeed, mainly cytoplasmic 
expression of EGFR has recently been associated with improved disease free survival in 
60 patients with locally advanced rectal carcinoma treated with chemoradiation 
(Mawdsley et a l, 2004). Consequently, the cytoplasmic location of EGFR and EGFRvIII 
and the low level of pEGFR may have contributed to an improved overall survival in this 
group of patients receiving radiotherapy (Herbst, 2004; Mawdsley et a l, 2004). 
However, in contrast to patients receiving radiotherapy, there was no significant 
association between EGFR or EGFRvin expression and overall survival in patients 
receiving chemotherapy in this study (Figure 5.10).
In conclusion, using three different anti-EGFR antibodies, the expression of the EGFR 
was found to be common in patients with Dukes’ C colorectal cancer, with coexpression 
of the EGFR and EGFRvIE in 34% of the cases. While no significant association was 
found between EGFR, EGFRvIE or pEGFR (tyrosine 1068) expression and overall 
survival in this study, cytoplasmic expression of the EGFR and EGFRvEI is associated 
with improved survival in patients receiving radiotherapy. Consequently, further studies 
investigating the phosphorylation status of other EGFR phosphorylation sites and the 
location of the EGFR immunostaining, as well as the relative expression of EGFRvEI in 
EGFR positive tumours are warranted. Such studies should unravel their potential as 
therapeutic targets, prognostic factors and predictive factors for response to therapy with 
EGFR inhibitors and/or conventional forms of therapy.
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CHAPTER SIX
Coexpression pattern and prognostic significance of the IGF-IR, EGFR and HER-2
in colorectal cancer patients
6.1 Introduction
The insulin-like growth factor-I receptor (IGF-IR) is another important growth factor 
receptor with tyrosine kinase activity. As discussed in the introduction, the results of 
several studies in the experimental system suggest that the IGF-IR system has mitogenic 
and anti-apoptotic properties and may therefore play an important role in the 
pathophysiology of human cancers (Baserga et al, 2003). Deregulation of signalling via 
the IGF-IR and/or its ligands (IGF-I, IGF-II) has been associated with the establishment 
and maintenance of the transformed phenotype, angiogenesis, invasion, métastasés, 
resistance to apoptosis, and resistance to conventional and receptor specific forms of 
therapy (Rubini et a l, 1997; Perer et a l, 2000; Reinmuth et al, 2002a; Sekharam et al, 
2003; Goetsch et a l, 2005; Min et a l, 2005)
Further studies in the experimental system have demonstrated that the IGF-IR can 
transactivate other growth factor receptor families (e.g. EGFR) to enhance the malignant 
behaviour of tumour cells, and continuous activation of the IGF-IR pathway has been 
implicated as one of the factors responsible for the development of tumour cells resistant 
to therapy with the anti-HER-2 mAh trastuzumab and the EGFR inhibitors (Lu et a l, 
2001; Camirand et a l, 2002; Chakravarti et al, 2002). These studies therefore provide a 
rationale for investigating the coexpression of the IGF-IR, EGFR and HER-2 in human
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malignancies, and their association with clinicopathological parameters, patient survival 
and response to therapy.
In chapter five, it was shown that the expression of the EGFR is common in Dukes’C 
colorectal cancer but it did not have any prognostic significance in the cohort of patients 
used in this study. However, there has been no comprehensive study on the coexpression 
and prognostic significance of the IGF-IR, EGFR, and HER-2 in patients with colorectal 
cancer or any other human malignancy. Therefore, the aim of this chapter was to 
investigate the coexpression of IGF-IR, EGFR and HER-2 in the same series of Dukes’ C 
colorectal cancer patients, and determine whether there was any association between 
receptor expression and patient clinicopathological parameters, overall survival, and 
response to radiotherapy and predominantly 5- fluorouracil based chemotherapy.
6.2 Specificity of antibodies for the immunohistochemical detection of IGF-IR 
and HER-2 in colorectal tumours
The expression of IGF-IR in tumour specimens was determined using a mouse 
monoclonal antibody (mAb) directed against the alpha-subunit (extracellular domain) of 
the human IGF-IR (Calbiochem). The specificity of the anti-IGF-IR antibody for the 
IGF-IR was confirmed by immunostaining of IGF-IR positive and negative tumour cell 
pellets. As the results in Figure 6.1 show, the anti-IGF-IR antibody stained the membrane 
of the MCF-7 cell line, which expresses 6x10"^  IGF-IR molecules/cell (Guvakova & 
Surmacz, 1997) with strong intensity, but did not stain the cell pellet of non-IGF-IR 
expressing R-minus cells (Burgaud & Baserga, 1996).
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Figure 6.1. Immunohistochemical staining of IGF-IR positive and negative cell 
pellets with anti-IGF-IR antibody. Three pm sections of formalin fixed paraffin 
embedded MCF-7 (A) and R- (B) cell pellets were immunohistochemically stained with 
the anti-IGF-IR mAh, as described under Materials and Methods. Magnification: x200.
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The expression of HER-2 was determined using the rat mAh ICR 12, which has been used 
in previous studies to detect HER-2 expression in patients with gastric and breast cancer 
(Styles et al, 1990; Gharesi- Fard et al, 2000; Ghaderi et al, 2002). The specificity of 
mAh ICR 12 was confirmed using tissues which were previously demonstrated by Dr 
Essapen, using the HER-2 specific antibody HM64.13, to express varying levels of the 
HER-2 [(Essapen et a l, 2004); data not shown].
63 The expression of IGF-IR in patients with Dukes’ C colorectal cancer
The expression of the IGF-IR was determined in the tumour specimens fi'om the same 
series of 87 colorectal cancer patients using immunohistochemistiy. Immunostaining was 
scored by the percentage of positive tumour cells and the intensity of immunostaining. 
The expression of IGF-IR in greater than 10% of tumour cells was considered positive.
As the results in Table 6.1 show, the expression of IGF-IR was detected in the tumour 
sections fi'om 81 (93%) of the 87 Dukes’ C colorectal cancer patients. The pattern of 
IGF-IR immunostaining was both membranous and cytoplasmic. Where membrane IGF- 
IR was present, the intensity of staining was of predominantly strong (3+) intensity. In 
contrast, the intensity of cytoplasmic IGF-IR immunostaining was more diverse, and 
consequently, an overall IGF-IR immunostaining intensity score was allocated (0, 
negative to 3+, strong) for the entire tumour section (Table 6.1 & Figure 6.3).
As shown in Table 6.1, membranous IGF-IR was present in 52 of 87 (60%) Dukes’ C 
colorectal cancer patients. This was considerably higher than the expression of 
membranous EGFR detected by the rabbit pAb, mAb ICR16, and EGFR.113 (please see
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Table 6.1. Immunohistochemical examination of IGF-IR expression in Dukes’ C 
colorectal cancer patients. The levels of IGF-IR protein were determined using the 
mouse anti-human-IGF-IR mAh. The levels of IGF-IR are presented according to the 
percentage of IGF-IR positive cells and the overall intensity of immunostaining.
Percentage of positive 
tumour cells
Number of patients with IGF-IR expression 
[Total expression (membrane only expression)]
Negative 6 (35)
>10 81 (52)
>50 62 (12)
Overall intensity of Number of patients with indicated
Immunostaining Intensity of immunostaining
0 4
1+ 41
2+ 35
3+ 7
0: negative; 1+: weak; 2+: moderate; 3+: strong immunostaining
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chapter five), in which 0 (0%), 3 (3%) and 7 (8%) of 87 patients demonstrated 
membranous EGFR expression, respectively. The intensity of cytoplasmic IGF-IR 
expression within the colorectal tumour sections was moderate to low. Only 7 of 87 
cases (8%) demonstrated cytoplasmic IGF-IR immunostaining of 3+ intensity, while 35 
(40%) and 41 of the cases (47%) demonstrated IGF-IR immunostaining intensity of 2+ 
and 1+, respectively (Table 6.1). The results of typical immunostaining with the anti- 
IGF-IR antibody are presented in Figures 6.2 and 6.3.
6.4 The expression of HER-2 in patients with Dukes’ C colorectal cancer
The expression of HER-2 was examined in the tumour specimens fi'om the same series of 
87 Dukes’ C colorectal cancer patients using the anti-HER-2 mAh ICR12. 
Immunostaining was scored by the percentage of positive tumour cells and the intensity 
of immunostaining, and the expression of HER-2 in greater than 10% of tumour cells was 
considered positive.
The expression of the HER-2 was detected in the tumour sections firom 77 (89%) of 87 
Dukes’ C colorectal cancer patients (Table 6.2). Unlike the IGF-IR, the expression of 
HER-2 was predominantly cytoplasmic (Tables 6.1 & 6.2, Figure 6.4). In addition, the 
intensity of HER-2 immunostaining was found to be higher than EGFR (Table 5.2) or 
IGF-IR (Table 6.1) immunostaining. Of the 87 cases examined, 27 (31%), 43 (49%), and 
62 cases (71%) had HER-2 immunostaining intensity of 3+, 2+, and 1+, respectively 
(Table 6.2). In common with the IGF-IR, HER-2 and EGFR immunostaining intensity 
were also re-scored to give an overall intensity of immunostaining for each tumour 
section. These results are presented in Table 6.3. When scored by the overall intensity of 
immunostaining, with exception to the anti-EGFR pAb, there were also more cases
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demonstrating 3+ intensity immunostaining for HER-2 (22/87 cases) than for the IGF-TR 
(7/87 cases) or EGFR (e.g. 11/87 cases with mAh EGFR.113; Table 6.3). The results of 
typical immunostaining with the anti-HER-2 mAh ICR12 are illustrated in Figure 6.4.
6.5 The association between IGF-IR and HER 2 expression and 
clinicopathological characteristics
The clinicopathological characteristics of the 87 Dukes’ C colorectal cancer patients used 
in this study and the impact of these parameters on patient survival was presented in 
chapter five (Table 5.1). Following the determination of IGF-IR and HER-2 expression 
in the 87 patients with Dukes’ C colorectal cancer, the chi-squared test was used to 
investigate any association between the expression of these receptors and 
clinicopathological parameters (Table 6.4). As shown in Table 6.4, no associations were 
found between total IGF-IR expression (membranous and cytoplasmic) and 
clinicopathological parameters. However, significant associations were found between 
membranous IGF-IR expression and tumour size, with more expression in tumours less 
than or equal to 5cm (P = 0.001), and patient age, with more expression in patients older 
than 70 years (P = 0.025) (Table 6.4). Like total IGF-IR expression, there were no 
significant associations between HER-2 expression and clinicopathological parameters 
(Table 6.4).
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Figure 6.2 Immunohistochemical staining IGF-IR in Dukes’ C colorectal cancer 
patients. Formalin fixed paraffin embedded tumour sections were stained with the anti- 
IGF-IR mAb, as described under Materials and Methods. Tumour specimens 
demonstrating predominantly membranous (A), membrane and cytoplasmic (B), and 
predominantly cytoplasmic (C) IGF-IR immunostaining. Magnification: x200.
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Figure 6.3 The intensity of IGF-IR immunostaining in Dukes’ C colorectal 
tumour specimens. Formalin fixed paraffin embedded tumour sections were 
immunohistochemically stained with the anti-IGF-IR mAh, as described under Materials 
and Methods. IGF-IR immunostaining intensity of 3+ (A), 2+ (B) or 1+ (C). 
Magnification: x200.
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Table 6.2. Immunohîstoehemical examination of HER-2 expression in Dukes’ C 
colorectal cancer patients. The levels of HER-2 expression in colorectal tumour 
specimens were determined using the anti-HER-2 mAh ICR12. The levels of HER-2 
expression are presented according to the percentage of HER-2 positive cells and the 
intensity of immunostaining.
Percentage positive Number of cases with HER-2 expression
tumour cells [Total expression (membrane only expression)]
Negative 10 (82)
>10 77(5)
>50 66(0)
Positive tumour cells Number of patients with indicated immunostaining
(%)
0 1+ 2+ 3+
Negative 47 25 44 60
>10 40 62 43 27
>50 18 22 7 13
0: negative; 1+: weak staining; 2+: moderate staining; 3+: strong immunostaining
Table 63 Overall intensity of IGF-IR, HER-2 and EGER immunostaining in 
Dukes’ C colorectal cancer patients. The intensity of IGF-IR, HER-2 and EGFR 
immunostaining are presented according to the overall intensity of immunostaining of 
tumour sections, as described in section 6.4. Data is shown according to the number of 
cases demonstrating an overall intensity of 0-3+ immunostaining.
Overall Intensity of Immunostaining
Receptor: 0 1+ 2+ 3+
IGF-IR 4 41 35 7
HER-2 6 43 16 22
EGFR:
pAb 0 26 33 28
ICR16 11 51 17 8
EGFR (113) 16 41 19 11
0: negative; 1+: weak; 2+: moderate; 3+: strong immunostaining
181
f t - , m##m• S ’f ' % . ,
% m m 2
Figure 6.4. Immunohistochemical staining of HER-2 in Dukes’ C colorectal 
cancer patients. Formalin fixed paraffin embedded tumour sections were stained with 
anti-HER-2 mAh ICR12, as described under Materials and Methods. Tumour specimens 
demonstrating cytoplasmic HER-2 immunostaining of 3+ intensity (A) and membranous 
and cytoplasmic HER-2 immunostaining of 3+ intensity (B). Magnification: x200.
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Table 6.4 The association between clinicopathologîcal parameters and IGF-IR 
and HER-2 expression determined using the chi-squared test. Significance values 
were set at P<0.05, and any value above this was considered non-significant.
Clinicopathological
characteristic
Number of patients with receptor expression 
(P-value ft)r association with patient characteristic)
Total IGF-IR Membrane IGF-IR HER-2
Sex
Male 43 26 40
Female 38 NS 26 NS 37 NS
Age in years
<70 43 23 42
>70 38 NS 29 0.025 35 NS
Tumour site
Right colon 23 18 23
Left colon 24 13 20
Rectum 24 NS 21 NS 34 NS
Size
<5 cm 53 41 50
>5 cm 28 NS 11 0.001 27 NS
Grade
1 3 2 2
2 46 27 42
3 29 22 30
Mucinous 3 NS 1 NS 3 NS
LVI
Absent 60 37 56
Present 21 NS 15 NS 21 NS
T-stage
T2 9 4 9
T3 54 35 49
T4 18 NS 13 NS 19 NS
Apical Node
Negative 43 31 40
Positive 11 7 11
Unknown 27 NS 14 NS 26 NS
Positive nodes
1-3 51 34 49
4+ 30 NS 18 NS 28 NS
NS: Not significant (P>0.05); LV : Lymphovascular Invasion
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6.6 The association between IGF-IR and HER-2 expression and overall survival
For univariate analysis of overall survival, Kaplan-Meier survival curves and the log rank 
test was used to evaluate the effect of receptor expression on patient outcome. As shown 
in Figure 6.5, no significant association was found between overall survival and the 
expression of total IGF-IR (5.61 ± 0.44 versus 4.17 ± 0.92 years; Figure 6.5a), 
membranous IGF-IR (5.35 ± 0.52 versus 6.24 ± 0.72 years; Figure 6.5b), or HER-2 (5.60 
± 0.46 versus 5.74 ± 0.98 years; Figure 6.5 c). In contrast to the expression of the EGFR 
and EGFRvIII, there was no trend for improved survival in patients expressing the IGF- 
IR or HER-2 (Figure 6.5).
6.7 The association between IGF-IR and HER-2 expression and overall survival 
in patients receiving radiotherapy or chemotherapy
As shown in chapter five, the expression of EGFR or EGFRvIII, which was 
predominantly cytoplasmic, was associated with significantly improved overall survival 
in patients receiving radiotherapy. Consequently, the effect of IGF-IR and HER-2 
expression on overall survival in patients receiving radiotherapy and chemotherapy 
(predominantly 5-fiuorouracil based) was investigated in this chapter. As the results in 
Figure 6.6 show, there was no significant association between overall survival in patients 
receiving radiotherapy and total IGF-IR expression (5.57 ± 0.73 versus 3.46 ± 2.85 years; 
Figure 6.6a), membranous IGF-IR expression (4.94 ± 0.81 versus 5.93 ±1.18 years; 
Figure 6.6b) or HER-2 expression (5.69 ± 0.77 versus 3.14 ± 0.63 years; Figure 6.6c).
Like the expression of EGFR and EGFRvIII (Figure 5.10), there were also no significant 
associations between the expression of IGF-IR or HER-2 and overall survival in patients 
receiving chemotherapy (data not shown).
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Figure 6.5 The impact of IGF-IR and HER-2 expression on overall survival in 
Dukes C colorectal cancer patients. Kaplan-Meier survival curves for patients with 
total IGF-IR expression (A), membranous IGF-IR (mIGF-IR) expression (B), and HER-2 
expression (C). A log rank test value of P<0.05 was considered statistically significant.
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Figure 6.6. The impact of IGF-IR and HER-2 expression on overall survival in 
Dukes C patients receiving radiotherapy. Kaplan-Meier survival curves for patients 
receiving radiotherapy with total IGF-IR expression (A), membranous IGF-IR (mIGF-IR) 
expression (B), and HER-2 expression (C). A log rank test value of P<0.05 was 
considered statistically significant.
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6.8 The coexpression of IGF-IR, EGFR and HER-2 in Dnkes’C colorectal cancer 
patients and the association with clinicopathological parameters and overall 
survival
Following the determination of the expression pattern and prognostic significance of the 
EGFR in chapter five, and the IGF-IR and HER-2 in this chapter, the significance of IGF- 
IR, EGFR, and HER-2 coexpression in colorectal cancer was investigated. There has 
been no study investigating the coexpression and prognostic significance of the IGF-IR, 
EGFR, and HER-2 in patients with colorectal cancer or any other human malignancy. 
Since 100% of cases were found to express the EGFR using the rabbit pAb to the internal 
domain of the EGFR, coexpression analysis of the IGF-IR, EGFR, and HER-2 was 
performed using the data obtained with the anti-EGFR mAbs ICR 16 and EGFR. 113.
In this study, 65 of 87 (75%) Dukes’ C colorectal cancer patients were found to coexpress 
the IGF-IR, EGFR (mAh ICR16) and HER-2. Using EGFR. 113, 54 of 87 (62%) cases 
were found to coexpress the IGF-IR, EGFR, and HER-2. Using membranous IGF-IR 
expression, the coexpression of IGF-IR, EGFR, and HER-2 was present in 49% (using 
mAh ICR16) and 39% (using EGFR. 113) of the cases examined. Overall, these results 
suggest that coexpression of the IGF-IR, EGFR, and HER-2 is common in Dukes’ C 
colorectal cancer since at least 62% of patients coexpress these receptors.
Following the determination of IGF-IR, EGFR, and HER-2 coexpression in the 87 
patients with Dukes’ C colorectal cancer, the chi-squared test was used to investigate any 
association between receptor coexpression and clinicopathological parameters. Kaplan- 
Meier survival curves and the log rank test was used to evaluate the effect of receptor 
coexpression on patient outcome. No significant association was found between the
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coexpression of IGF-IR (total or membranous), EGFR, and HER-2 and 
clinicopathological parameters (Tables 6.5 & 6.6) or overall survival (Figure 6.7). 
However, as shown in Table 6.4, membranous IGF-IR expression was found to be 
significantly associated with decreased tumour size (P= 0.001) and this was still 
significant Wien coexpressed with the EGFR and HER-2 (P=0.005; Table 6.6). In 
addition, no significant association was found between the coexpression of IGF-IR and 
HER-2, IGF-IR and EGFR, or EGFR and HER-2 and overall survival (data not shown).
6.9 The association between IGF-IR, EGFR, and HER-2 coexpression and 
overall survival in patients receiving radiotherapy or chemotherapy
It was shown in the previous chapter that the expression of predominantly cytoplasmic 
EGFR and EGFRvIII is associated with improved overall survival in Dukes’ C colorectal 
patients receiving radiotherapy (Figure 5.9). However, no significant association was 
found between the expression of IGF-IR or HER-2 and overall survival in patients 
receiving radiotherapy (Figure 6.6). Consequently, the effect of IGF-IR, HER-2 and 
EGFR coexpression on the overall survival in patients receiving radiotherapy was 
investigated.
As shown in Figure 6.8a, there was significantly improved survival in patients receiving 
radiotherapy if they were coexpressing the IGF-IR, EGFR (using mAh ICR16) and HER- 
2 (P= 0.008). However, when the significance of two receptors was investigated, the 
coexpression of EGFR and HER-2 (P=0.0007; Figure 6.8c) was found to be more 
significant than EGFR alone (P= 0.004; Figure 5.9b) or the coexpression of EGFR and 
IGF-IR (P= 0.028; Figure 6.8b) in its association with improved survival. A similar trend
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Table 6.5. The association between clinicopathological parameters and the 
coexpression of total IGF-IR, HER-2, and EGFR determined using the chi-squared 
test. Coexpression analysis was performed with the anti-EGFR mAbs ICR16 and 
EGFR.113. Significance values were set at P<0.05, and any value above this was 
considered non-significant.
Clinicopathological
characteristic
Number of patients with receptor expression 
(P-value for association with patient characteristic)
IGF-IR/EGFR(ICR16)/HER-2 IGF-IR/EGFR(.l 13)/HER-2
Sex
Male 31 27
Female 34 NS 27 NS
Age in years
<70 37 29
>70 28 NS 25 NS
Tumour site
Right colon 17 13
Left colon 20 10
Rectum 28 NS 31 NS
Size
<5cm 41 35
>5cm 24 NS 19 NS
Grade
1 2 1
2 37 31
3 24 20
Mucinous 2 NS 2 NS
LVI
Absent 48 39
Present 17 NS 15 NS
T-stage
T2 8 8
T3 44 36
T4 13 NS 10 NS
Apical Node
Negative 35 28
Positive 10 8
Unknown 20 NS 18 NS
Positive nodes
1-3 40 34
4+ 25 NS 20 NS
NS: Not significant (P>0.05); LVI : Lymphovascular Invasion
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Table 6.6 The association between clinicopathological parameters and the 
coexpression of membranous IGF-IR, HER-2, and EGFR determined using the chi- 
squared test. Coexpression analysis was performed with the anti-EGFR mAbs ICR16 
and EGFR.113. Significance values were set at P<0.05, and any value above this was 
considered non-significant.
Clinicopathological
characteristic
Number of patients with receptor expression 
(P-value for association with patient characteristic)
IGF-IRÆGFR(ICR16)/HER-2 IGF-IR/EGFR(.l 13)/HER-2
Sex
Male 19 16
Female 24 NS 18 NS
Age in years
<70 22 15
>70 21 NS 19 NS
Tumour site
Right colon 14 11
Left colon 9 5
Rectum 20 NS 18 NS
Size
<5 cm 34 28
>5 cm 9 0.005 6 0.005
Grade
1 1 1
2 23 17
3 18 15
Mucinous 1 NS 1 NS
LVI
Absent 32 25
Present 11 NS 9 NS
T-stage
T2 4 4
T3 30 23
T4 9 NS 7 NS
Apical Node
Negative 27 20
Positive 6 4
Unknown 10 NS 10 NS
Positive nodes
1-3 28 24
4+ 15 NS 10 NS
NS: Not significant (P>0.05); LVI : Lymphovascular Invasion
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Figure 6.7. The impact of IGF-IR, EGFR, and HER-2 coexpression on overall 
survival in Dukes C colorectal cancer patients. Kaplan- Meier survival curves to 
illustrate the overall survival in patients coexpressing total IGF-IR (A and C) or 
membranous IGF-IR (mIGF-IR) (B and D) with the HER-2 and EGFR compared to 
patients without receptor coexpression. The expression of EGFR was determined using 
mAh ICR16 (A and B), or EGFR.113 (C and D). A log rank test value of P<0.05 was 
considered statistically significant.
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Figure 6.8 The impact of IGF-IR, EGFR (using mAh ICR16) and/or HER-2 
coexpression on overall survival in Dukes C patients receiving radiotherapy.
Kaplan-Meier survival curves for patients receiving radiotherapy who were found to 
coexpress the IGF-IR, EGFR, and HER-2 (A), IGF-IR and EGFR (B), or EGFR and 
HER-2 (C). A log rank test value of P<0.05 was considered statistically significant.
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was also seen with the anti-EGFR mAh EGFR.l 13 (data not shown). Indeed, while there 
was improved survival in patients receiving radiotherapy if they coexpressed the EGFR 
and HER-2 (Figure 6.8c), this was no longer significant in patients who also coexpressed 
the membranous form of the IGF-IR (Figure 6.9). However, on multivariate analysis, the 
coexpression of IGF-IR, EGFR, and HER-2, or EGFR and HER-2 were not significantly 
associated with patient survival, and T-stage was the most significant indicator of patient 
survival (P=0.002; data not shown).
However, in contrast to patients receiving radiotherapy, there were no significant 
associations between the coexpression of the IGF-IR, EGFR and/or HER-2 and overall 
survival in patients receiving chemotherapy (data not shown).
6.10 Discussion
In recent years, aberrant expression of growth factor receptors (e.g. EGFR, HER-2, IGF- 
IR) has been reported in many cancer cell lines and tissues, associated with the 
establishment and maintenance of the transformed phenotype, and in some cases has been 
associated with a poor prognosis and resistance to therapy (Nicholson et a l, 2001; 
LeRoith & Roberts, 2003; Normanno et a l, 2003; Baserga, 2004). In addition, the results 
of other experimental studies have indicated that the IGF-IR can interact with EGFR and 
HER-2 to enhance the malignant behaviour of tumours, and that IGF-IR signalling may 
be responsible for the poor response to therapy with EGFR specific inhibitors or the anti- 
HER-2 mAh trastuzumab (Lu et al, 2001; Camirand et al, 2002; Chakravarti et a l, 
2002; Wang et al, 2002). Consequently, the aim of this chapter was to determine the 
coexpression of IGF-IR, EGFR and HER-2 in tumour specimens of Dukes’ C colorectal
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Figure 6.9 The impact of membranous IGF-IR coexpression with the HER-2 and 
EGFR on overall survival in Dukes’C patients receiving radiotherapy. Kaplan- 
Meier survival curves for patients receiving radiotherapy who were found to coexpress 
membranous IGF-IR, HER-2 and EGFR. Coexpression analysis using anti-EGFR mAh 
ICR16 (A), and EGFR113 (B). A log rank test value of P<0.05 was considered 
statistically significant.
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cancer patients and to investigate their association with clinicopathological parameters, 
overall survival, and response to radiotherapy and chemotherapy.
The expression of IGF-IR has been reported previously in normal tissue and malignant 
tissues from a wide range of cancer patients, including cancer of the ovaiy, stomach, 
pancreas, lung, skin, endometrium, testicle, brain, breast (Peyrat et al.  ^1988; All-Ericsson 
et a/., 2002; Del Valle et al, 2002; Ouban et a l, 2003; Neuvians et a l, 2005), colon and 
rectum (Freier et al, 1999; Hakam et al, 1999; Weber et al, 2002; Ouban et al, 2003; 
Peters et a l, 2003). The IGF-IR has also been associated with the development of colon 
adenocarcinoma (Kulik et al, 1997; Werner, 1998; Freier et al, 1999; Weber et al, 
2002; Hakam et a l, 1999), angiogenesis and métastasés in experimental systems (Freier 
et al, 1999; Reinmuth et al, 2002a; Reinmuth et al, 2002b) as well as lung and liver 
métastasés in colorectal cancer patients (Hakam et a l, 1999).
The majority of immunohistochemical studies report the high expression of IGF-IR in 
colorectal cancer patients (Hakam et al, 1999; Weber et a l, 2002; Ouban et al, 2003; 
Peters et a l, 2003). For example, in one study, IGF-IR expression was detected in 91% 
of stage I-IV patients using a polyclonal chicken anti-IGF-IR antibody (Weber et a l,
2002). In another study, using a tissue microarray consisting of 713 stage I-III patients, 
IGF-IR expression was detected in 698 (99.6%) of tumours using anti-IGF-IR mAh 
3.G2.15D6 (Peters et al, 2003). However, in a recent study, also using a tissue 
microarray (2004), IGF-IR expression was detected in only 2/68 (3%) of colorectal 
adenocarcinomas using the anti-IGF-IR mAh Ab-1 clone 24-31 (Singer et a l, 2004). In 
this study, in common with other immunohistochemical studies (Hakam et a l, 1999; 
Weber et al, 2002; Ouban et al, 2003; Peters et al, 2003), tumour specimens from a
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high percentage (93%) of Dukes’ C (node positive) colorectal cancer patients were found 
to express the IGF-IR (Table 6.1). The use of different primary antibodies for IGF-IR 
detection, heterogeneous patient populations, and different numbers of colorectal cancer 
patients, among other factors makes the direct comparison of data in the literature 
difficult. In addition, studies examining the impact of IGF-IR expression on the overall 
survival of colorectal cancer patients are limited (Hakam et al, 1999). However, unlike 
other studies (Peyrat & Bonneterre, 1992; Bhatavdekar et al, 1995; All-Ericsson et al, 
2002; Weber et al, 2002; Peiro et a l, 2003) the expression of IGF-IR was not associated 
with clinicopathological parameters or overall survival in this study (Table 6.4 & Figure 
6.5).
While the expression of the IGF-IR did not have prognostic significance in this study, the 
frequent expression of IGF-IR among this series of patients may make them a suitable 
target for the new generation of receptor specific drugs. Indeed, receptor specific 
blocking mAbs, IGF-IR TKIs, antagonistic peptides and anti-sense oligonucleotides have 
been shown to inhibit the growth in-vitro and in-vivo of IGF-IR expressing breast, lung, 
prostate, glioma, and multiple myeloma cells (Perer et a l, 2000; Hailey et a l, 2002; 
Maloney et a l, 2003; Mitsiades et a l, 2004; Steinbach et al, 2004; Goetsch et a l, 2005; 
Min et a l, 2005; Miyamoto et a l, 2005). In particular, 60% of the patients in this study 
were found to express the membranous form of the IGF-IR (Table 6.1). The 
membranous IGF-IR expression in these patients would form an ideal target for therapy 
with antibodies (e.g. h7C10, MAB391, IR3) to the external domain of the IGF-IR (Hailey 
et al, 2002; Maloney et al, 2003; Goetsch et a l, 2005). For example, the anti-IGF-IR 
neutralising antibodies MAB391 and anti-IR3 have been shown to inhibit IGF-I induced 
IGF-IR phosphorylation and Akt activation, and downregulate IGF-IR expression in
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breast (MCF-7), prostate (DU-145), and colon (HT-29) tumour cells, and inhibit the 
growth of MCF-7 cells in-vitro (Hailey et a l, 2002).
A number of studies have shown that the IGF-IR is able to crosstalk with other receptor 
systems, including the HER-2, EGFR, and VEGFR, to enhance the malignant behaviour 
of tumours (Warren et al, 1996; Lu et al, 2001; Chakravarti et al, 2002; Wang et al, 
2002; Adams et al, 2004). Indeed, expression of IGF-IR has been associated with 
resistance to anti-EGFR and anti-HER-2 therapies in several experimental systems, and 
co-targeting the IGF-IR with the EGFR or HER-2 has been shown to reduce the 
malignant behaviour of tumour cells (Lu et a l, 2001 ; Camirand et a l, 2002; Jones et al, 
2004; Lu et a l, 2004b; Camirand et al, 2005). For example, in one study, continued 
IGF- IR signalling through the PI-3K pathway was shown to mediate resistance to the 
EGFR TKI AG1478, and simultaneous targeting the IGF-IR and EGFR enhanced 
apoptosis and reduced the invasiveness of glioblastoma tumour cells (Chakravarti et al,
2002). In another study, co-targeting the HER-2 with trastuzumab and the induction of 
dominant-negative IGF-IR expression resulted in potentiation of growth inhibition of 
transfected MCF7/herl8 breast cancer cells (Camirand et a l, 2002). However, there are 
no studies examining the expression pattern of IGF-IR, EGFR and HER-2 in patients 
with colorectal cancer and their association with clinicopathological parameters and 
overall survival.
Of the 87 Dukes’ C colorectal cancer cases examined in this study, 89% were found to 
express the HER-2 (Table 6.2). This is in common with a recent study by Essapen and 
colleagues (2004) who found that 87% of 170 patients with Dukes’ B and Dukes’ C 
colorectal cancer expressed the HER-2 (Essapen et al, 2004). In addition, 75% and 62%
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of the cases were found to coexpress the TGF-IR (total), EGFR and HER-2, using the 
anti-EGFR mAh ICR16 and EGFR.113 respectively. Interestingly, in a recent study, IGF- 
IR, EGFR, and HER-2 expression was detected in only 3% (2/68), 39% (27/69) and 4% 
(3/68) of colorectal cancer patients, respectively (Singer et ah, 2004). However, in that 
study, the immunohistochemical examination was performed on micro-dissected sections 
using tissue microarrays, which contain a small region of the heterogeneous tumour 
biopsy, and the impact of receptor coexpression on overall survival was not investigated 
in that study. In another study, the expression of EGFR and HER-2 was present in only 
8% and 3% of 244 stage I-IV colorectal carcinomas patients respectively (Goi et ah,
2004). However, in that study, cytoplasmic EGFR and HER-2 immunostaining were not 
considered positive for receptor expression. In the present study, there were no major 
associations between the coexpression of total IGF-IR, EGFR and HER-2 and 
clinicopathological parameters or overall survival (Table 6.5 and Figure 6.7).
As IGF-IR, EGFR, and HER-2 coexpression were found to occur in a high percentage of 
(>62%) Dukes’ C colorectal cancer patients, forther studies on the therapeutic advantages 
of simultaneous targeting of these receptors with a cocktail of receptor specific inhibitors 
and other forms of therapy (e.g. radiotherapy or chemotherapy) are warranted. For 
example, when combined with anti-EGFR mAb 225 or the chemotherapeutic agent 
Vinorelbine, a humanized anti-IGF-IR antibody was recently shown to inhibit more 
efficiently the growth of the human breast cancer cell line MCF-7 and non-small lung 
cancer cell line A549 in vivo (Goetsch et al, 2005).
The expression of the EGFR has been associated with resistance to radiotherapy, and 
inhibition of EGFR signalling by EGFR inhibitors has been shown to sensitise patients to
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radiotherapy (Dent et al, 1999; Giralt et a l, 2002). This may be mediated in part via the 
inhibition of EGFR induced activation of pro-survival and anti-apoptotic signalling, such 
as the PI3-K/Akt pathway (Giralt et al, 2002; Lammering et al, 2003; Herbst, 2004; 
Nyati et al, 2004). While the cytoplasmic expression of the EGFR and EGFRvIII was 
found to be associated with improved overall survival in Dukes’ C colorectal cancer 
patients receiving radiotherapy (please see chapter five), there was no significant 
association between the expression of IGF-IR alone or HER-2 alone and overall survival 
in patients receiving radiotherapy (Figure 6.6). However, there was improved survival in 
patients receiving radiotherapy if they were coexpressing the IGF-IR, EGFR and HER-2 
(Figure 6.8a) and further statistical analyses demonstrated that the coexpression of 
cytoplasmic EGFR and HER-2, rather than coexpression of the IGF-IR, EGFR and HER- 
2 is associated with improved survival in patients receiving radiotherapy (please see 
section 6.9 & Figure 6.8). Unlike membranous expression, cytoplasmic EGFR and HER- 
2 are unable to heterodimerise and activate pro-survival pathways, which may therefore 
explain why coexpression of predominantly cytoplasmic EGFR and HER-2 has greater 
significance than EGFR expression alone with respect to improved survival in patients 
receiving radiotherapy.
Like the EGFR, IGF-IR expression has been associated with resistance to chemotherapy 
and radiotherapy in several experimental studies (Perer et al, 2000; Goetsch et a l, 2005; 
Min et a l, 2005). For example, in one study the addition of lOOng/ml IGF-I to SW480 
colon cancer cells reduced the cytotoxicity of 5-FU (chemotherapy) and radiation therapy 
while the addition of the anti-IGF-IR blocking antibody a-IR3 increased the cytotoxicity 
of such treatment (Perer et al, 2000). The expression of a truncated IGF-IR in gastric 
cancer xenografts has been shown to block IGF-I and IGF-II induced Akt activation and
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increase chemotherapy and radiotherapy induced apoptosis in another study (Min et al, 
2005). Interestingly, 60% of the patients expressed membranous IGF-IR in this study, 
and there was no longer improved survival in EGFR and HER-2 expressing patients who 
received radiotherapy when they also co-expressed membranous IGF-IR (Figure 6.9). 
The overexpression of the IGF-IR in HCT116/IGF-IR colorectal cancer cells has been 
associated with IGF-IR induced activation of Akt and up-regulation of the anti-apoptotic 
protein B c 1-Xl , which in turn was associated with resistance to apoptosis (Sekharam et al,
2003). In another study, continued IGF-IR signalling through the PI-3K pathway was 
associated with resistance to the EGFR TKI AG1478 and radiation induced apoptosis in 
the GBMr glioblastoma cell line, and co-targeting the IGF-IR with the EGFR was shown 
to enhance radiation-induced apoptosis (Chakravarti et al, 2002). Since membranous 
IGF-IR can mediate IGF-I and IGF-II induced activation of the Akt pathway; this may 
explain why co-expression of predominantly cytoplasmic EGFR and HER-2 was not 
associated with improved survival in patients receiving radiotherapy when such patients 
also coexpressed membranous IGF-IR.
In summary, the results of clinical trials with the EGFR inhibitors have only resulted in a 
response of a short duration in a small subpopulation of patients, and there has been no 
clear correlation between EGFR levels and response to the EGFR inhibitors (Kris et a l, 
2003; Curmingham et a l, 2004; Saltz et al, 2004). In addition, expression of the IGF-IR 
has been associated with resistance to anti-EGFR and anti-HER-2 therapies in the 
experimental setting (Lu et al, 2001; Camirand et al, 2002). Unlike the low levels of 
EGFR, HER-2 and IGF-IR expression in colorectal tumour cell lines (Table 3.1), the 
results presented in this chapter indicate that coexpression of the IGF-IR, EGFR and 
HER-2 is common in patients with Dukes’ C colorectal cancer. Consequently, forther
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studies on prognostic significance, predictive value and the therapeutic benefit of co­
targeting the IGF-IR, EGFR and HER-2 with a cocktail of inhibitors in colorectal cancer 
patients are warranted.
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CHAPTER 7 
General Discussion
Colorectal cancer is the third most common cancer in the western world in terms of 
incidence and mortality (Edwards et a l, 2005). Despite improvements in conventional 
forms of therapy, the 5-year survival rates are less than 10% in the majority of patients 
with metastatic disease (Venook, 2005a). There is therefore the urgent need for 
identification of novel predictive and prognostic markers and more specific therapeutic 
targets in patients with colorectal cancer.
The EGFR is often aberrantly expressed in human malignancies, however, the expression 
levels and prognostic significance the EGFR reported for colorectal cancer varies 
between studies (Nicholson et a l, 2001). Since the 1980s a number of therapeutic 
strategies have been developed against the EGFR. Of these, the anti-EGFR mAb 
cetuximab and the EGFR TKIs gefitinib and erlotinib have now been approved for the 
treatment of patients with metastatic colorectal cancer and advanced NSCLC, 
respectively (Albanell & Gascon, 2005; Modjtahedi, 2005). However, a subpopulation of 
only approximately 10-20% of patients may respond to such treatment, and median 
overall survival in these patients may only be increased by several months (Fukuoka et 
al, 2003; Kris et al, 2003; Cunningham et a l, 2004; Saltz et al, 2004). In addition, 
there has been no clear association between the expression of EGFR and response to the 
EGFR inhibitors in pre-clinical and clinical studies (Albanell & Gascon, 2005; 
Modjtahedi, 2005). Since treatment with the EGFR inhibitors is expensive compared to 
conventional forms of therapy (Schrag, 2004), there is a need for the identification of
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factors which may aid in the selection of a more specific subpopulation of patients who 
respond to the EGFR inhibitors.
The aim of the present study was therefore to investigate the expression levels of the 
EGFR, HER-2, and IGF-IR in a panel of human colorectal tumour cell lines, and the 
association between receptor expression and response to the EGFR and/or IGF-IR 
inhibitors. In addition the expression pattern of the EGFR, pEGFR, EGFRvIII, HER-2, 
and IGF-IR was determined in the tumour biopsies from a series of 87 Dukes’ C 
colorectal cancer patients. The aim was to determine if there was any association 
between growth factor receptor expression and clinicopathological parameters, overall 
survival, and response to radiotherapy and chemotherapy.
7.1 Overexpression of the EGFR, HER-2, and IGF-IR is uncommon in human 
colorectal cancer cell lines
In this study, the cell surface expression of EGFR, HER-2, and IGF-IR was examined in 
a panel of 12 human colorectal cancer tumour cell lines. While EGFR, HER-2, or IGF- 
IR expression has been reported for some of the cell lines used in this study, no study has 
examined the expression of all three growth factor receptors in this panel of human 
colorectal cancer cell lines, which included the two newly established colorectal cancer 
cell lines, Colo2 and Colol3.
Of the colorectal tumour cell lines investigated, only DiFi was found to express high 
levels of the EGFR (Table 3.1), and none of the other cell lines were found to express 
high levels of the EGFR, HER-2 or IGF-IR. The majority of studies in the literature have 
not included growth factor receptor overexpressing cell lines as a positive reference.
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Consequently, it has been difficult to determine growth factor receptor levels from their 
data. However, in studies that have used a positive reference, or in studies that have 
quantified receptor levels, EGFR, HER-2, or IGF-IR expression was generally found to 
be low (Culouscou et al, 1988; Warren et a l, 1996; Boente et al, 1998; Ciardiello et al, 
2000; Half et al, 2004; Kuwada et a l, 2004; Moroni et a l, 2005; Shimizu et a l, 2005a; 
Shimizu et a l, 2005b). Interestingly, in this study, EGFR expression was found to be 
lower in the cell lines established from Dukes’ A (Colo2) and Dukes’ B (CCL228) 
tumours than the cell lines established from Dukes’ C tumours (Colo 13, CCL221, 225, 
227, 231; Table 3.1). This is of particular interest since, as shown in chapter five, EGFR 
expression was found to be common in tumour specimens from Dukes’ C colorectal 
cancer patients, and has been associated with advanced disease stage in a number of 
studies (Niikura et al, 1996; Ghaderi et al, 2002; Putti et al, 2002; Espinoza et al, 
2004; Spano et al, 2005).
7.2 Overexpression of the EGFR Is associated with response to the EGFR inhibitors
While the anti-EGFR mAbs 528 and cetuximab as well as the EGFR TKIs gefitinib and 
erlotinib have previously been shown to inhibit the growth of DiFi cells (Gross et al, 
1991; Wu et a l , 1995 ; Moyer et a l , 1997; Albanell et a l , 2001 ; Liu et ar/., 2001; Matar et 
al, 2004; Moroni et al, 2005), the effect of EGFR inhibitors on eveiy cell line used in 
this study has not been investigated. In addition, this is the first study to investigate the 
effects of anti-EGFR mAb ICR62 on a panel of human colorectal tumour cells lines.
Of the human colorectal cancer cell lines investigated in this study, only DiFi, which 
overexpresses the EGFR and contains a constitutively active EGFR, was highly sensitive 
to growth inhibition by mAb ICR62, gefitinib, and erlotinib (Figure 3.4). The other cell
204
lines, which were found to express low levels of the EGFR, HER-2 and IGF-TR, were 
relatively resistant to the EGFR inhibitors (Figure 3.4). The data herein would suggest 
that EGFR overexpression is associated with response to the EGFR inhibitors. In support 
of the present study, some of the low EGFR expressing cells (e.g. HCT-116, CCL218, 
and CCL228) have been shown to be resistant to the EGFR inhibitors in other studies 
(Prewett et a l, 2002; Xu et a l, 2003; Koizumi et al, 2004; Kuwada et a l, 2004; Matar et 
al, 2004; Skvortsov et a l, 2004; Moroni et a l, 2005; Yang et al, 2005). In addition, in a 
recent study, the anti-EGFR mAh cetuximab was shown to inhibit the growth of the DiFi 
cell line at concentrations that did not inhibit the growth of the low EGFR expressing 
CCL218, HCT-116, CCL221, CCL231 CCL228 and CCL227 colorectal cancer cells 
(Moroni et a l, 2005).
However, there has been no clear correlation between EGFR expression and response to 
the EGFR inhibitors in pre-clinical and clinical studies (Bos et a l, 1997; Ciardiello & 
Tortora, 2003; Campiglio et a l, 2004; Saltz et a l, 2004). Indeed, cells that were found to 
express relatively low levels of the EGFR but to overexpress the HER-2 (i.e. SKBR3 
cells) were inhibited by gefitinib in this study (Figure 3.4). In addition, some of the cell 
lines in the literature may contain unidentified mutations of regulatoiy molecules, which 
may uncouple the EGFR fi’om proliferative and pro-survival pathways. For example, 
MDA-468 breast cancer cells express high levels of the EGFR but are relatively 
insensitive to the EGFR inhibitors (Moasser et al, 2001; She et a l, 2003; Matar et a l,
2004). Resistance to gefitinib in MDA-468 cells has been attributed to EGFR 
independent constitutive Akt activation caused by loss of PTEN function (She et a l,
2003). Furthermore, a recent study has demonstrated that HER-3 may be a more useful 
biomarker for predicting response to erlotinib in human colorectal tumour cell lines
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(Buck et a l, 2005). Therefore, further studies investigating the expression of other ErbB 
molecules (i.e. HER-3 and HER-4) and the presence of mutations that may influence 
EGFR signalling (e.g. PTEN) in this panel of human colorectal tumour cells are 
warranted. In addition, as discussed in the introduction, activating mutations in exons 18 
to 21 of the EGFR have been associated with improved response to the EGFR TKIs in 
some patients with NSCLC (Lynch et a l, 2004; Paez et a l, 2004; Pao et a l, 2004; Pao et 
al, 2005). However, a recent study suggests that activating mutations may be less 
common and may not confer sensitivity to gefitinib in human colorectal cancer patients 
(Ogino et a l, 2005). It would therefore be of interest to investigate the presence of such 
mutations in the human colorectal cancer cell lines used in this study and to investigate 
their association with response to the EGFR inhibitors.
73 The anti-EGFR mAh ICR62, and the EGFR TKIs gefitinib and erlotinib have 
overlapping but not identical mechanisms of action
The anti-EGFR mAbs and EGFR TKIs have been shown to decrease EGFR 
phosphorylation, inhibit tumour cell growth via G1 arrest and up-regulation of the cell 
cycle inhibitor p27^P'^, and to induce terminal differentiation and apoptosis in some cell 
lines (Modjtahedi et al, 1994; Ciardiello et al, 2000; Moasser et a l, 2001; Li et al, 
2003; Matar et al, 2004; Albanell & Gascon, 2005). In this study, as shown in chapter 
four, treatment of DiFi cells with the EGFR inhibitors resulted in EGFR down regulation 
(Figure 4.1), G1 arrest (Figure 4.3), induction of apoptosis (Figure 4.3), and attenuation 
of EGFR and MAPK phosphorylation (Figure 4.5 & 4.6). However, there were key 
differences in the ability of mAb ICR62, gefitinib, and erlotinib to initiate these 
processes. The mAb ICR62 was more effective than gefitinib or erlotinib at inhibiting 
the growth of EGFR overexpressing DiFi and HN5 cells (Figure 3.4). This is probably
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attributable to the superior ability of mAb ICR62 to block EGFR ligand binding (Figure 
4.4). Interestingly, erlotinib was not as effective as gefitinib at inhibiting the growth of 
DiFi cells suggesting that although gefitinib and erlotinib are both aniliquinizoline 
derivatives that reversibly compete with ATP for binding to the EGFR tyrosine kinase 
domain (Wakeling, 2002), they do not have identical modes of action.
Indeed, in this study, the growth of HER-2 overexpressing SKBR3 cells was inhibited by 
gefitinib, in common with the findings of several previous studies (Anderson et a l, 2001 ; 
Moasser et al, 2001; Moulder et a l, 2001; Anido et a l, 2003). However, mAb ICR62 
and erlotinib did not inhibit the growth of SKBR3 cells (Figure 3.4). Recent studies 
suggest that gefitinib may inhibit the growth of HER-2 overexpressing breast cancer cells 
by inducing the formation of inactive EGFR/HER-2 and EGFR/HER-3 heterodimers and 
reducing the association of PI-3K with the HER-3 (Anido et al, 2003; Hirata et a l,
2005). It is therefore possible that gefitinib may be better at inducing the formation of 
inactive EGFR/HER-2 or EGFR/HER-3 containing heterodimers and reducing activation 
of the pro-survival PI-3K pathway than ICR62 or erlotinib in tumour cells coexpressing 
the ErbB receptors.
In this study, ICR62 and gefitinib were more effective than erlotinib at inducing G1 arrest 
and apoptosis in DiFi cells (Figure 4.3). This reflects the higher IC50 of erlotinib for DiFi 
cells (Figure 3.3). However, despite having a higher I C 5 0  than ICR62, gefitinib induced 
the most apoptosis in DiFi cells. As discussed above, this may be due, at least in part, to 
the ability of gefitinib to reduce HER-3 induced PI-3K signalling (Hirata et al, 2005), 
and this warrants forther investigation.
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Some of the anti-EGFR mAbs, most notably mAb225, have been shown cross-link cell 
surface EGFR molecules to induce receptor internalisation and attenuate EGFR signalling 
(Sunada et al, 1986; Fan et al, 1994; Friedman et al, 2005). In common with these, 
mAbs ICR16 and ICR62 were found to reduce membranous expression of the EGFR in 
DiFi cells (Figure 4.1). Interestingly, there was also a reduction in the expression of 
membranous EGFR in DiFi cells treated with gefitinib for 24 hours despite the fact that 
the EGFR TKIs do not target the ligand binding domain of the EGFR (Fan et al, 1994; 
Friedman et a l, 2005; Figure 4.1). It is therefore possible that attenuation of EGFR 
phosphorylation by the EGFR TKIs, as well as the formation of cross-linked EGFR 
lattices by anti-EGFR mAb, may lead to EGFR downregulation. Indeed, in DiFi cells 
treated with erlotinib for 24 hours, there was only moderate attenuation of EGFR 
phosphorylation, and no downregulation of EGFR expression in DiFi cells (Figure 4.1 & 
43^
Interestingly, reduction in EGFR phosphorylation in DiFi cells was greater for the EGFR 
TKIs than mAh ICR62, suggesting that inhibiting the tyrosine kinase domain of the 
EGFR may be advantageous over blocking ligand binding with regards to attenuation of 
EGFR activation (Figure 4.5 & 4.6). However, erlotinib only slightly reduced EGFR and 
MAPK phosphorylation following treatment of DiFi cells for 24 hours (Figure 4.5). 
Since DiFi cells are growth inhibited for up to 12 days by erlotinib at the concentrations 
used in Western blotting experiments (400nM), it is unlikely that DiFi cells are 
recovering fi-om treatment with erlotinib (Figure 3.4). Therefore, unlike mAh ICR62 and 
gefitinib, the anti-tumour actions of erlotinib in DiFi cells may not be directly related to 
attenuation of EGFR phosphorylation. In addition, unlike the anti-EGFR mAh ICR62, 
both gefitinib and erlotinib were able to attenuate EGFRvIII phosphorylation and
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EGFRvIII induced Akt activation in HC2 20 d2/c cells (Figure 4.11). This further 
highlights the differences between the different classes of EGFR inhibitors.
7.4 Co-targeting the EGFR with anti-EGFR mAh and EGFR TKI is not superior 
over the single-agent.
In two recent studies, the combination of the anti-EGFR cetuximab with gefitinib or 
erlotinib was found to synergistically enhance the growth inhibition of several cell lines 
when compared to the single-agent, and also synergistically inhibit MAPK and Akt 
activation (Huang et a l, 2004; Matar et a l, 2004). In the present study, in contrast to the 
above studies, the combination of anti-EGFR mAb ICR62 and gefitinib or erlotinib in a 
panel of 12 human colorectal tumour cell lines was not superior over treatment with the 
single-agent (Figure 3.5 to 3.7).
While the inhibition of EGF induced MAPK phosphorylation was enhanced in DiFi cells 
treated with the combination of anti-EGFR mAb and EGFR TKI (Figure 4.5 & 4.6), there 
was no synergistic inhibition of DiFi cell growth, even Wien using the same method as 
Matar and colleagues (2004) (Figure 3.8 & 3.9). The synergistic growth inhibition 
demonstrated in several cell lines by Matar and colleagues and Huang and colleagues 
(Huang et al, 2004; Matar et al, 2004) may therefore be a specific property of the anti- 
EGFR mAh cetuximab. In addition to studies in-vitro, more profound tumour regression 
and re-growth delay has been observed in mice treated with the combination of 
cetuximab and gefitinib or erlotinib (Huang et al, 2004). However, in another recent 
study, the combination of gefitinib and cetuximab was found to be antagonistic in the 
growth inhibition of two different cell lines (CAL33, CAL39). These results suggest that 
the anti-tumour effects of anti-EGFR mAh in combination with the EGFR TKIs may
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depend upon the properties of the inhibitor and also the cell line used (Fischel et al,
2005), and this warrants forther investigation with an additional panel of human tumour 
cell lines and anti-EGFR mAbs. In addition, since the anti-EGFR mAh ICR62 can inhibit 
the growth of tumour cells via immunological mechanisms, such as ADCC (Modjtahedi 
et al, 2003), forther studies investigating the effect of mAb ICR62 in combination with 
the EGFR TKIs in-vivo are also warranted.
7.5 Co-targeting the EGFR and IGF-IR has potential for synergistic growth 
inhibition of human colorectal tumour cell lines
The expression of the IGF-IR has been associated with resistance to anti- EGFR and anti- 
HER-2 therapies in several experimental systems, and co-targeting the IGF-IR with the 
EGFR or HER-2 may reduce the malignant behaviour of some tumours (Lu et a l, 2001; 
Camirand et a l, 2002; Jones et a l, 2004; Steinbach et a l, 2004). In this study, the 
combination of an IGF-IR TKI (NVP-AEW541) and the EGFR inhibitors synergistically 
enhanced the growth inhibition of several human colorectal cancer cell lines that were 
found to be EGFR and IGF-IR positive (i.e. Colol3, CCL 221, CCL 225, CCL 227, CCL 
231 or CCL 244 cells; Figure 3.13 to 3.15).
While the EGFR TKIs have been shown to inhibit IGF-I signalling via the MAPK 
pathway, they may not be as effective at inhibiting the activation of the IGF-IR associated 
molecule IRS-1 which can continue to activate the pro-survival PI-3K/Akt pathway 
(Roudabush et a l, 2000; Lu et al, 2004b; Camirand et a l, 2005). Indeed, it was shown 
that the EGFR inhibitors did not prevent IGF-I induced Akt phosphoiylation in the DiFi 
cell line (Figure 4.7). Since IGF-I induced Akt phosphorylation was only substantially 
reduced by the IGF-IR TKI (Figure 4.7), the results of this study therefore suggest that
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the combination of EGFR and IGF-IR inhibitors may lead to enhanced inhibition of 
signal transduction molecules in tumour cells. However, since combination of the EGFR 
and IGF-IR inhibitors did not completely inhibit the growth of any of the colorectal cell 
lines in this study (Figure 3.13 to 3.15), and there is no clear association between EGFR 
or IGF-IR expression and response to combination of the EGFR and IGF-IR inhibitors 
(Table 3.1), it is likely that other growth factor receptors may be mediating resistance to 
the EGFR and/or IGF-IR inhibitors.
Indeed, in this study, the growth of human colorectal tumour cells resistant to the EGFR 
and/or IGF-IR inhibitors could be inhibited using MAPK (U0126) and/or PI-3K 
(LY294002) inhibitors (Figure 3.16). This suggests that such cells may be dependent 
upon receptors other than the EGFR or IGF-IR for activation of the MAPK or PI-3K 
pathways and is in accordance with the low levels of EGFR, HER-2 and IGF-IR found in 
the cell lines examined in the present study (Table 3.1). However, the EGFR 
overexpressing DiFi and HN5 cells were found to be more sensitive to the EGFR 
inhibitors than the MAPK and PI-3K inhibitors (Figure 3.16). These data are consistent 
with a previous study in which gefitinib was shown to be more effective than the PI-3K 
and MAPK inhibitors at inhibiting the growth of EGFR overexpressing A431 cells 
(Janmaat et al, 2003). Therefore, these results suggest that in EGFR overexpressing cells 
(e.g. DiFi, HN5, A431) that are dependent upon the EGFR for survival, EGFR inhibition 
is more effective than PI-3K and MAPK inhibition for inhibiting their proliferation.
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7.6 Coexpression of the EGFR and EGFRvIII is common in Dukes’ C colorectal 
cancer patients
In colorectal cancer, the expression of EGFR reported in the literature ranges from 8% to 
100% of the cases examined (Moorghen et al, 1990; Coi et a l, 2004). As described in 
the introduction, the apparently conflicting evidence on the expression pattern of the 
EGFR may stem from the variety of methods used for determining receptor expression. 
However, while immunohistochemistiy is an ideal method for evaluating EGFR protein 
levels in clinical specimens the choice of antibody, fixative, storage time of tumour 
sections, scoring system, and patient population (e.g. Dukes’ stage) may contribute to the 
conflicting data on EGFR expression in human cancers (Ciardiello & Tortora, 2003; 
Atkins et a l, 2004). Indeed, the range of EGFR expression reported in the literature 
using immunohistochemistiy is summarised in Table 7.1. Consequently, in this study, for 
the first time, the expression pattern of the EGFR was determined in a single population 
of colorectal cancer patients using three different anti-EGFR antibodies.
Using three anti-EGFR antibodies, >76% of Dukes’ C colorectal cancer patients were 
found to express the EGFR suggesting that EGFR expression is common in Dukes’ C 
colorectal cancer. Using the rabbit pAb to the internal domain of the EGFR, 87 cases 
(100%) were found to be EGFR positive. In contrast, 72 cases (83%) and 66 cases (76%) 
were found to be EGFR positive using mAb ICR62 and mAb EGFR. 113 which are 
directed to the external domain of the EGFR (Table 5.2). In addition, there were more 
cases of 3+ intensity with the rabbit anti-EGFR polyclonal antibody, which is directed to 
the internal domain of the EGFR, than for mAb ICR16 or EGFR. 113 (Table 5.2).
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Table 7.1 Summary of the major studies investigating the expression pattern of 
the EGFR in colorectal cancer using immunohistochemistry. The variation in the 
number (n) and tumour stage of patients, and the different immunohistochemical 
antibodies used to determine EGFR expression are illustrated. The percentage of patients 
found to express the EGFR (% EGFR positive) and the reported statistical association 
with overall survival (OS) is indicated (P-Value for OS). NA: Not assessed; NI: Not 
indicated; (C) cytoplasmic immunostaining; (M); Membranous immunostaining.
Study Patients
(n)
Stage Antibody
(source)
% EGFR 
Positive
P-Value for OS
(Azriacf al, 
2005)
77 II-III mAb 2-18C9
(DAKO)
56 (M)
(C) not scored
NA
(Ceccarelli et 
a/., 2005)
205 II-IY mAb31G7
(Zymed)
83.4 (M/C NI) NA
(De Jong et al, 
1998)
33 IV mAb E-30 
(Biogenex)
30(M/CNI) NA
(Fric et al, 
2000)
53 I-IV mAbNI
(Sigma)
73.6 (C) NA
(Giralt et al, 
2002)
44 mAb MU 
207-UC 
(Biogenex)
64%
(M/CNI)
NA
(Goldstein & 
Armin, 2001)
102 IV mAb2-18C9
(DAKO).
75.5 (M+C) NS
2+/3+EGFR 
and poor 
survival 
(P=0.0252)
(Hemming et 
al, 1992)
62 I-IV mAbNI
(Price
Laboratories)
62
(M/CNI)
NA
(Italiano et al, 
2005)
80 I-IV mAb 2-18C9
(DAKO)
80 (M)
(C) not scored
NA
(Khorana et 
al, 2003)
131 i-m mAb2-18C9
(DAKO)
46 (M) NS
(Komuta et al, 
1995)
30 I-IV Rabbit pAb 
(Ni et al)
37 (M/CNI) NA
(Lee et al, 
2002)
125 I-IV mAbNI
(Triton
Diagnostics)
512 (M) 
(C) not scored
NS
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Table 7.1 Summary of the major studies investigating the expression pattern of 
the EGFR in colorectal cancer using immunohistochemistry. Continued from 
previous page.
Study Patients
(n)
Stage Antibody
(source)
% EGFR 
Positive
P-Value for 
OS
(Mayer et al, 
1993)
82 I-IV mAbF4
(Sigma)
97.6 (C) >50% EGFR 
and poor 
survival 
(P<0.01)
(McKay et 
a/., 2002b)
249 I-IV mAb
EGFR.113
(Novocastra)
72.7 (M+C) 
(Stage in= 
522)
NS
(Moorghen et 
al, 1990)
19 i-in mAb
EGFRl
(Amersham)
36 (M/CNI) 
Intracellular 
EGFR observed
NA
(Nakae et al, 
1993)
41 i-in mAbNI
(Oncogene
Science)
53.7 (M+C) 
(Stage in= 
55.6)
NA
(Ooi et al, 
2004)
244 I-IV mAbNI
(Novocastra)
8 (M+C) 
(C) not scored
NA
(Porschen et 
al, 1993)
69 I-IV mAb
EGFRl
(Amersham)
68.1
(M+C)
NA
(Resnick et 
a/., 2004)
126 II mAh 2- 
18C9 
(DAKO)
80 (M)
(C) not scored
2+/3+EGFR 
and poor 
survival 
(P=0.04)
(Saeki et al, 
1995)
45 i-m mAb Ab-4 
(Uniondale)
51.1 (M/CNI) 
(Stage in = 57)
NA
(Singer et al, 
2004)
69 NI mAb31G7
(Zymed)
39% (M) 
(C) not scored
NA
(Spano et al, 
2005)
148 I-IV mAb
EGFR.113
(Novocastra)
97 (M+C) NS
(Steele et al, 
1990a)
50 I-m EGFRl
(Amersham)
100 (C) NA
(Steele et al, 
1990b)
30 NI EGFRl
(Amersham)
90(C) NA
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The results of this study confirm that the choice of antibody may have contributed to the 
variation in EGFR expression reported in the literature. Indeed, as was shown in Table 
5.2, the higher levels of the EGFR detected using the rabbit polyclonal was attributed to 
the fact that, unlike mAbs ICR16 and EGFR.113, this antibody is directed to an epitope 
on the internal domain of the EGFR and should therefore bind to various form of the 
EGFR, including tumours containing the EGFR with extracellular deletions and tumours 
that proteolytically shed the extracellular domain (ECD) of the EGFR (Modjtahedi et a l, 
2003; Jacot et a l, 2004). The cross-reactivity of the anti-EGFR mAbs with the EGFR 
and EGFRvin may also have contributed to the lack of association between EGFR 
expression and response to the EGFR inhibitors in the literature (Campiglio et a l, 2004; 
Cunningham et al, 2004; Saltz et a l, 2004). Consequently, fiirther 
immunohistochemical studies using wild-type EGFR specific antibodies (e.g. mAb 
ICRIO; Figure 5.1) are warranted so that the true expression of the wild-type EGFR in 
colorectal cancer can be determined together with its association with overall survival, 
clinicopathological parameters, and response to radiotherapy and chemotherapy.
The results of this study also suggest that the variation of EGFR expression in the 
literature may also depend on additional factors. For example, a similar percentage of 
cases were EGFR positive in this study (76%) and in the study by Mckay and colleagues
(2002) using EGFR.113 (72.9%). However, while EGFR expression was predominmtly 
cytoplasmic in the Dukes’ C (stage III) patients in this study (Figure 5.4), 92.3% of 
EGFR positive patients expressed membranous EGFR in the study by McKay and 
colleagues (McKay et al, 2002b). These differences in EGFR expression may be due to 
the inclusion of patients with stage I-IV (Dukes’A-C) disease or different tissue 
processing in the study by McKay and colleagues (2002). In another study, only 8% of
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stage T-IV (Dukes A-D) patients were found to express the EGFR also using an antibody 
to the external domain of the receptor. The lower number of EGFR positive cases 
detected in that study when compared to the present study and the study by McKay and 
colleagues (2002) may however, be due to differences in scoring systems as cytoplasmic 
EGFR immunostaining was not considered positive in that study (Ooi et a l, 2004).
The EGFRvin is a ligand-independent, constitutively active, deletion mutant form of the 
EGFR (Figure 4.10 & 4.11 ; Pedersen et al, 2001). Expression of the EGFRvIII has been 
associated with cell transformation, increased motility and invasion, and resistance to 
radiotherapy (Haley et a l, 1989; Yamazaki et al, 1990; Ekstrand et a l, 1995; Pedersen 
et al, 2001; Lammering et a l, 2003). Interestingly, the majority of anti-EGFR 
antibodies that are commonly used in immunohistochemistiy (e.g. mAb 113, 2-18C9, or 
antibodies against internal domain) can also interact with EGFRvin, and in many studies 
it has been difficult to assess the relative contribution and prognostic significance of 
EGFRvIII in EGFR positive cases. In addition, EGFR phosphorylation, but not 
overexpression, has been associated with a poor prognosis and the pathogenesis of 
NSCLC in one study (Kanematsu et a l, 2003). Consequently, in this study, for the first 
time, the relative contribution of the EGFRvIII and pEGFR in EGFR positive colorectal 
cancer was investigated. It was found that while 76% of cases were EGFR positive with 
three different anti-EGFR antibodies, 34% of such cases were EGFRvIII positive (Table 
5.3). In addition, phosphoiylated EGFR (residue tyrosine 1068) was only present in 8% 
of specimens and was never present in more than 10% of tumour cells (please see section 
5.6).
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The frequent expression of cytoplasmic EGFR, the coexpression of EGFRvTTI, and low 
expression of pEGFR may have important clinical implications. Indeed, as discussed 
above, there has been no clear correlation between EGFR expression and response to the 
EGFR inhibitors in clinical trials and the response rates have generally been between 
10% and 20% (Fukuoka et a l, 2003; Kris et a l, 2003; Cunningham et al, 2004). As 
summarised in Table 7.1, while some studies have found the predominant pattern of 
EGFR immunostaining to be cytoplasmic, other studies have reported the expression of 
both membranous and cytoplasmic EGFR or scored only the membranous EGFR as 
membranous EGFR forms an ideal target for monoclonal antibody based therapy. 
However, in this study EGFR expression was predominantly cytoplasmic. Recently, 
EGFR expression has been demonstrated in the nuclei of many cell lines and tissues, and 
nuclear localisation of the EGFR has also been associated with a highly proliferative state 
of these tissues (Lin et a l, 2001; Lo et al, 2005). In this study, while there was no 
distinctive nuclear EGFR or EGFRvIII immunostaining, pEGFR nuclear staining in 
greater than 10% of cells was present in 9% of the cases (data not shown). Further 
studies are therefore needed to address the association between the location of EGFR 
immunostaining and response to the EGFR inhibitors, in particular the EGFR TKIs, since 
they target the intracellular domain of the EGFR.
In several studies, cells expressing the EGFRvIII were found to be more resistant to 
gefitinib than cells which do not express the EGFRvIII (Lammering et a l, 2003; 
Pedersen et al, 2005). In the present study, the EGFR TKIs were shown to attenuate 
EGFRvIII phosphorylation and EGFRvIII induced Akt phosphorylation in HC2 20 d2/c 
cells but not substantially inhibit the growth of such cells (Figure 4.11 ; data not shown). 
Therefore, further studies on the relative contribution of the EGFRvIII and pEGFR in
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EGFR expressing patients who are treated with the EGFR inhibitors are warranted. Such 
studies may also aid in the selection of the subpopulation of patients Wio benefit fi*om 
therapy with the EGFR inhibitors (Modjtahedi, 2005).
7.7 Coexpression of the IGF-IR, EGFR, and HER-2 is common in Dukes C 
colorectal cancer patients
A number of recent studies have shown that the IGF-IR can crosstalk with other receptor 
systems, such as the EGFR, VEGFR, and HER-2, to enhance the malignant behaviour of 
tumour cells (Warren et al., 1996; Lu et a l, 2001; Wang et al, 2002; Adams et al, 
2004). Several studies in the experimental setting have shown that continuous activation 
of the IGF-IR pathway may be one of the factors responsible for the development of 
tumour cells resistant to therapy with the anti-HER-2 mAb trastuzumab as well as the 
EGFR inhibitors (Lu et a l, 2001; Camirand et al, 2002; Chakravarti et a l, 2002; Jones 
et al, 2004; Camirand et a l, 2005). Since there has been no clear association between 
EGFR expression and response to the EGFR inhibitors in pre-clinical and clinical studies, 
these studies therefore provide a rationale for investigating the coexpression pattern and 
clinical significance of the IGF-IR, EGFR and HER-2 in human malignancies.
The reported expression of IGF-IR in the literature in colorectal cancer patients ranges 
fix)m 3% to 100% of patients (Peters et al, 2003; Singer et a l, 2004). However, as 
summarised in Table 7.2, the majority of immunohistochemical studies report IGF-IR 
expression in more than 90% of colorectal cancer patients (Hakam et a l, 1999; Weber et 
al, 2002; Ouban et a l, 2003). In common with these studies, tumour specimens fi*om a 
high percentage (93%) of Dukes’ C (node positive) colorectal cancer patients were found 
to express the IGF-IR in the present study (Table 6.1). Of the 87 Dukes’ C colorectal
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cancer cases examined in this study, 89% were also found to express the HER-2 (Table 
6.2). This is in common with a recent study by Essapen and colleagues (2004) who 
found that 87% of 170 patients with Dukes’ B and Dukes’ C colorectal cancer expressed 
the EGFR (Essapen et a l, 2004). Importantly, the patients used in this study consisted of 
a selection of the 105 Dukes’ C patients used by Essapen and colleagues, and in that 
study 84% of Dukes’ C patients were found to express the HER- 2 (Essapen et a l, 2004).
Interestingly, coexpression of the IGF-IR, EGFR, and HER-2 was found to be common in 
the Dukes’ C colorectal cancer patients in this study, with coexpression in >62% of 
patients (please see section 6.8). This is much higher than the coexpression of these 
receptors reported in two recent studies. In one study, IGF-IR, EGFR, and HER-2 
expression was detected in only 3% (2/68), 39% (27/69) and 4% (3/68) of colorectal 
cancer patients, respectively (Singer et a l, 2004). However, in that study, the 
immunohistochemical examination was performed on micro-dissected sections using 
tissue microarrays, which contain a small region of the heterogeneous tumour biopsy. In 
another study, the expression of EGFR and HER-2 was present in only 8% and 3% of 
244 stage I-IV colorectal carcinomas patients respectively (Ooi et a l, 2004). However, 
in that study, cytoplasmic EGFR and HER-2 immunostaining were not considered 
positive for receptor expression. Therefore, since the expression of IGF-IR has been 
associated with resistance to anti-EGFR and anti-HER-2 therapies in the experimental 
setting (Lu et a l, 2004b; Camirand et a l, 2005), and the results herein indicate that 
coexpression of the IGF-IR, EGFR and HER-2 is common in patients with Dukes’ C 
colorectal cancer, further studies on therapeutic benefit of co-targeting such receptors in 
colorectal cancer patients are warranted.
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Table 12 Summary of the major studies investigating the expression pattern of 
the IGF-IR in colorectal cancer using immunohistochemistry. The variation in the 
number (n) and tumour stage of patients, the different immunohistochemical antibodies 
used to determine IGF-IR expression are illustrated. The percentage of patients found to 
express the IGF-IR (% IGF-IR positive) and the reported statistical association with 
overall survival (OS) is indicated (P-Value for OS). NA: Not assessed; NI: Not 
indicated; (C) cytoplasmic immunostaining; (M); Membranous immunostaining.
Study Patients
(n)
Stage Antibody
(source)
% IGF-IR 
Positive
P-Value 
for OS
(Hakam et 
al, 1999)
36 I-IV Rabbit pAb 
(Santa Cruz)
96 (M+C) NS
(Ouban et 
a/., 2003)
10 I-IV mAb C20 
(Santa Cruz)
90 (M) NA
(Peters et 
a/., 2003)
713 I-m mAb 3.G2.15D6 (Roche) 99.6 (C) NA
(Singer et 
a/., 2004)
68 NI mAh Abl (NeoMarkers) 3(M)
(C) not scored
NA
(Weber et
üf/.,2002)
33 i-rv Chicken pAb 
(Biozol)
91 (M4C) NA
7.8 The expression of EGFR, pEGFR, and EGFRvIII are not associated with overall 
survival in Dukes’ C colorectal cancer patients
The expression of the EGFR in colorectal cancer patients has been associated with a poor 
prognosis in some studies (Mayer et al, 1993; Kopp et al, 2003), while there has been 
no such association in other studies (Magnusson et a l, 1989; Goldstein & Armin, 2001; 
Lee et al, 2002; McKay et al, 2002b; Khorana et al, 2003; Spano et al, 2005). As 
described above, the apparently conflicting evidence on the prognostic significance of the 
EGFR may stem from the choice of antibody, fixative, storage time of tumour sections, 
scoring system, or patient population (e.g. Dukes’ stage) used to determine EGFR
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expression (Ciardiello & Tortora, 2003; Atkins é ta l, 2004). However, in this study there 
were no significant associations between EGFR expression and overall survival using the 
three different anti-EGFR antibodies (please see section 5.8).
Cytoplasmic EGFR is unable to bind ligand or homodimerise or heterodimerise with 
other ErbB molecules to mediate cellular responses (e.g. MAPK, Akt activation; Figure 
1.5) associated with human malignancy (Hackel et a l, 1999; Schlessinger, 2000). Since 
the predominant expression of the EGFR was cytoplasmic in this study, it may explain 
why there was no association between EGFR expression and overall survival (Figure 5.4 
& 5.8). However, while cytoplasmic EGFR expression has been associated with a poor 
prognosis in colorectal cancer patients in one study (Mayer et al, 1993), no significant 
association has been reported between EGFR expression and overall survival in 
colorectal cancer patients with predominantly membranous (Lee et a l, 2002; Khorana et 
al, 2003), predominantly cytoplasmic (Mawdsley et al, 2004), or membranous and 
cytoplasmic EGFR expression (Goldstein & Armin, 2001 ; McKay et a l, 2002b; Spano et 
al, 2005). Therefore, further investigation on the location of EGFR immunostaining, 
including nuclear immunostaining, and its association with patient prognosis in a larger 
series of patients are warranted.
The lack of association between EGFR expression and overall survival may be 
attributable to frequent expression of EGFRvIII in this series of patients (Table 5.3). 
While no significant associations were found between the expression of EGFRvIII and 
overall survival (Figure 5.8c), the antibodies used to detect EGFR expression in the 
present study were found to cross-react with the EGFRvIII (Figure 5.3) and the true 
prognostic significance of the wild-type EGFR in these patients remains unclear.
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Therefore, further immunohistochemical studies using wild-type EGFR specific 
antibodies, such as mAh ICRIO (Figure 5.1), should determine the true prognostic 
significance of the wild-type EGFR in colorectal cancer patients.
In addition, phosphoiylation, but not overexpression of the EGFR, has been associated 
with poor prognosis in NSCLC patients in one study (Kanematsu et al, 2003). No 
association was found between total or nuclear pEGFR (at tyrosine 1068) expression and 
patient survival in this study. However, as shown in Figure 4.5 and 4.10, the EGFR and 
EGFRvIII were found to be phosphoiylated at multiple tyrosine residues (i.e. 1173,1148, 
1086, 1068, 845). Therefore it may be possible that phosphorylation of other sites on the 
EGFR may be more fi*equent in colorectal cancer patients (Kanematsu et a l, 2003; 
Okamoto et al, 2003), and this warrants further investigation. In addition, since 
coexpression of the IGF-IR, EGFR and HER-2 was common in this series of patients, and 
such patients may also express other growth factor receptors, further studies investigating 
the phosphoiylation status of multiple receptors or total phospho-tyrosine containing 
proteins are also warranted. These studies may reveal their full potential as prognostic or 
predictive marker in patients with colorectal cancer.
7.9 Coexpression of IGF-IR, EGFR, and HER-2 is not associated with overall 
survival in Dukes’ C colorectal cancer patients
While the expression of IGF-IR has been associated with poor prognosis in some studies 
(All-Ericsson et a l, 2002; Peiro et a l, 2003); in other studies it has been associated with 
improved prognosis (Peyrat & Bonneterre, 1992; Bhatavdekar et al, 1995) or there has 
been no association between IGF-IR expression and survival (Hakam et a l, 1999). As 
shown in Table 7.2, the number of studies examining the impact of IGF-IR expression on
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the survival of colorectal cancer patients is limited. However, like Hakam and colleagues 
(1999), no significant association was found between the expression of IGF-IR (total or 
membranous) and overall survival in the 87 Dukes’ C colorectal cancer patients in the 
present study (Figure 6.5). The membranous expression of IGF-IR, however, was more 
frequent in patients with tumours less than or equal to 5cm (P = 0.001), and in patients 
older than 70 years (P = 0.025), and such patients may therefore form ideal candidates for 
therapy with antibodies to the external domain of the IGF-IR (Table 6.4; Maloney et al, 
2003; Goetsch et al, 2005). Clinical trials with the new generation of human anti-IGF-IR 
antibodies should unravel the full potential of such agents in cancer patients (Maloney et 
al, 2003; Lu eta l, 2004a; Goetsch eta l, 2005).
In the recent study by Essapen and colleagues (2002), cytoplasmic HER-2 expression was 
associated with improved survival in Dukes’ C colorectal cancer patients (Essapen et a l, 
2004). Interestingly, although the 87 Dukes’ C patients used in this study were a 
selection of the 105 Dukes’ C patients used by Essapen and colleagues, no association 
was found between HER-2 expression and overall survival (Figure 6.5). Furthermore, 
when the 87 Dukes’ C patients used in the present study were analysed from the 
immunostaining determined previously with anti-HER-2 mAh HM.64.13 by Dr. Essapen 
(Essapen et al, 2004), cytoplasmic HER-2 expression was found to be associated with 
significantly improved survival (6.02 ± 0.46 versus 3.58 ± 0.79 years, P= 0.021; data not 
shown).
In the study by Press and colleagues (1994), immunohistochemical staining with 7 
polyclonal and 21 monoclonal anti-HER-2 antibodies differed in their ability to detect 
HER-2 overexpression in 187 archival breast cancer patients, which was concluded to
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explain the variable expression rate of HER-2 in the literature (Press et al., 1994). The 
present study demonstrates that the prognostic significance of the HER-2 may also 
depend on the anti-HER-2 antibody used for immunohistochemistiy. Alternatively, the 
differences between the present study and the study by Essapen and colleagues (2004) 
may be due to intra-observer differences in the scoring of tumour sections.
There is currently no study in colorectal cancer or any other cancer that has investigated 
the association between EGFR, HER-2 and IGF-IR coexpression and overall survival. In 
this study, there was no significant association between the coexpression of IGF-IR, 
EGFR, and HER-2 and clinicopathological parameters and overall survival (Table 6.5 & 
Figure 6.7). However, as IGF-IR, EGFR, and HER-2 coexpression were found to occur 
in a high percentage of (>62%) Dukes’ C colorectal cancer patients, these results provide 
a rationale for further studies on the therapeutic advantages of simultaneously targeting 
these receptors with a cocktail of receptor specific inhibitors and other forms of therapy 
(e.g. radiotherapy or chemotherapy; Modjtahedi, 2005).
7.10 Coexpression of cytoplasmic EGFR and HER-2 and expression of the 
EGFRvHl are associated with improved response to radiotherapy in Dukes’ C 
colorectal cancer patients
The expression of the EGFR has been associated with resistance to radiotherapy, and 
inhibition of EGFR signalling by the EGFR inhibitors has been shown to sensitise 
patients to radiotherapy (Dent et a l, 1999; Giralt et a l, 2002). This may be mediated in 
part via the inhibition of EGFR induced activation of pro-survival and anti-apoptotic 
signalling, such as the MAPK and PI3-K/Akt pathways (Giralt et a l, 2002; Lammering et 
al, 2003; Herbst, 2004; Nyati et al, 2004). However, in a recent study, mainly
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cytoplasmic EGFR expression has been associated with improved disease free survival in 
60 patients with locally advanced rectal carcinoma treated with neoadjuvant 
chemoradiation (Mawdsley et al, 2004).
Interestingly, in this study the expression of EGFR was also associated with improved 
survival in Dukes’ C colorectal patients receiving radiotherapy (Figure 5.9). While HER- 
2 expression alone was not associated with overall survival, coexpression of 
predominantly cytoplasmic EGFR and HER-2 has greater significance than EGFR 
expression alone with respect to improved survival in patients receiving radiotherapy 
(Figure 6.8). This could be attributable to the localisation of EGFR and HER-2 
immunostaining, which was predominantly cytoplasmic. Cytoplasmic EGFR should not 
transmit the action of the EGF-like ligands (e.g. TGFa), which can initiate activation of 
the MAPK or PI-3K pathways and subsequently protect from radiation induced cell 
death. Similarly, unlike membranous expression, cytoplasmic EGFR and HER-2 are 
unable to heterodimerise to activate pro-survival pathways (Dent et a l, 1999; Harari & 
Huang, 2004).
Interestingly, Lammering and colleagues (2003) have shown that radiation may increase 
the tyrosine phosphorylation of EGFR and EGFRvIII, and EGFRvIII expression has been 
shown to confer a stronger cytoprotective response to radiation than wild type EGFR 
(Lammering et al, 2003). However, in this study, expression of the EGFRvIII was 
associated with improved survival in patients receiving radiotherapy (Figure 5.9). In 
contrast to HC2 20 d2/c cells which contained high levels of constitutively active and 
membranous EGFRvIII (Figure 5.2), EGFRvIII expression in the Dukes’C patients was 
predominantly cytoplasmic and was only phosphorylated at tyrosine residue 1068 in 8%
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of patients (Figure 5.6). Consequently, the cytoplasmic location of EGFR, HER-2 and 
EGFRvIII, together with the low level of pEGFR may have contributed to an improved 
overall survival in this group of patients receiving radiotherapy (Herbst, 2004; Mawdsley 
et al, 2004). Interestingly, there was no longer improved survival in EGFR and HER-2 
coexpressing patients who received radiotherapy when they also co-expressed the 
membranous form of the IGF-IR (Figure 6.9). Since membranous IGF-IR can mediate 
IGF-I and IGF-II induced activation of the anti-apoptotic PI-3K/Akt pathway (Figure 4.7; 
Liu et al, 2001; Ahmad et a l, 2004; Min et al, 2005); this may explain why co­
expression of EGFR and HER-2 was not associated with improved survival in patients 
receiving radiotherapy when such patients also coexpressed membranous IGF-IR 
(Chakravarti et a l, 2002; Sekharam et al, 2003; Min et al, 2005).
7.11 Concluding remarks and future considerations
In this study, of the 12 human colorectal tumour cell lines, DiFi was found to express 
high levels of the EGFR, but the expression of EGFR, HER-2, and IGF-IR was found to 
be much lower in the other 11 colorectal tumour cell lines. The EGFR inhibitors were 
found to inhibit the growth of EGFR overexpressing cells; however, cells with lower 
levels of EGFR expression were relatively resistant to the EGFR inhibitors. While the 
combination of anti-EGFR mAb and EGFR TKI was not superior over treatment with the 
single agent, the combination of the IGF-IR TKI with the EGFR inhibitors synergistically 
inhibited the growth of a number of colorectal tumour cell lines. In addition, the results 
of this study have also demonstrated that studies in tumour cell lines may not reflect the 
biological situation in human colorectal cancer tumour specimens.
226
Indeed, while overexpression of the EGFR was uncommon in human colorectal cancer 
cells, using three different anti-EGFR antibodies >76% of Dukes’ C colorectal cancer 
patients were found to express the EGFR, with up to 37% of patients demonstrating 
immunostaining of 3+ intensity. Interestingly, 34% and 8% of patients were also found 
to express the EGFRvIII and pEGFR, respectively. In addition, coexpression of the IGF- 
IR, EGFR, and HER-2 was found to be common (>62% of patients) in the 87 Dukes’ C 
patients in this study. While no significant associations were found between patient 
survival and the expression of EGFR, EGFRvIII, pEGFR, IGF-IR, or HER-2, the 
cytoplasmic expression of EGFRvIII, coexpression of the EGFR and HER-2, and 
coexpression of the EGFR, HER-2, and IGF-IR was associated with improved response 
to radiotherapy. Interestingly, there was no such association in patients who also 
coexpressed the membranous form of the IGF-IR.
Since there has been no clear association between the expression of EGFR and response 
to EGFR inhibitors (Ciardiello & Tortora, 2003; Cohen et a l, 2005; Modjtahedi, 2005), 
further studies investigating the phosphorylation status of EGFR, the location of the 
EGFR, and relative expression of EGFRvIII in EGFR positive tumours are warranted. In 
addition, since expression of IGF-IR has been associated with resistance to anti-EGFR 
and anti-HER-2 therapies in the experimental setting (Lu et a l, 2001; Jones et a l, 2004; 
Camirand et al, 2005), and the results of this study demonstrate that IGF-IR, EGFR, and 
HER-2 coexpression is common in colorectal cancer patients, these studies provide a 
rationale for investigating the therapeutic benefit of co-targeting the IGF-IR, EGFR, and 
HER-2 in colorectal cancer patients.
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Futhermore, it would be interesting to determine the expression of other ErbB molecules 
(i.e. HER-3 and HER-4) and EGFR mutations (e.g. exon 18-21) in the panel of colorectal 
tumour cell lines and a larger population of colorectal cancer patients, together with their 
association with patient prognosis and response to therapy with the EGFR and/or IGF-IR 
inhibitors, radiotherapy, and chemotherapy. Further studies using additional cell lines 
and anti-EGFR antibodies are also warranted to elucidate whether superior growth 
inhibition of tumour cells with combination of anti-EGFR mAb and EGFR TKI is a 
specific property of the anti-EGFR mAh cetuximab, and whether combination of the anti- 
EGFR mAh ICR62 with the EGFR TKIs produces superior anti-tumour activity in-vivo.
As the IGF-IR did not affect attenuation of EGFR or MAPK signalling by the EGFR 
inhibitors in DiFi cells, fiirther studies in additional cell lines are warranted to investigate 
the role of EGFR/IGF-IR crosstalk in mediating response to the EGFR inhibitors. In 
addition, since only 8% of patients were found to express pEGFR at tyrosine 1068 in this 
study, further studies investigating the expression pattern, prognostic significance, and 
predictive value of other EGFR autophosphoiylation sites (e.g. 1173,1148, 1086,992) in 
colorectal cancer patients are warranted.
Finally, the majority of antibodies used in the literature cross-react with the wild-type 
EGFR and EGFRvHl, which may have contributed to the lack of association between 
EGFR expression and response to the EGFR inhibitors (Campiglio et a l, 2004; 
Cunningham et al, 2004; Saltz et al, 2004). Further studies using wild-type EGFR 
specific antibodies, such as mAblCRlO, should elucidate the true expression pattern and 
prognostic significance of the wild-type EGFR in colorectal cancer.
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T h e  e x p r e s s i o n  o f  I G F - I R  ( a t  m R N A  o r  p r o t e i n  l e v e l )  h a s  
b e e n  r e p o r t e d  i n  t h e  t u m o u r s  f r o m  a  n u m b e r  o f  d i f f e r e n t  t i s s u e s  
i n c l u d i n g  c o l o r e c t a l  c a n c e r  ( 1 6 - 2 2 ) .  W h i l e  s o m e  s t u d i e s  h a v e  
r e p o r t e d  n o  d i f f e r e n c e  i n  I G F - I R  e x p r e s s i o n  b e t w e e n  m a l i g n a n t  
a n d  n o r m a l  c o l o r e c t a l  t i s s u e s  ( 1 7 , 2 2 ) ,  o t h e r  s t u d i e s  h a v e  f o u n d  
a  s i g n i f i c a n t l y  h i g h e r  l e v e l  o f  I G F - I R  i n  m a l i g n a n t  c o l o r e c t a l  
t i s s u e s  b u t  n o  c l e a r  a s s o c i a t i o n  w i t h  c l i n i c o p a t h o l o g i c a l  
p a r a m e t e r s  o r  p r o g n o s i s  ( 1 8 - 2 0 ) .  T h e s e  s t u d i e s  t h e r e f o r e
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p r o v i d e  a  r a t i o n a l e  f o r  i n v e s t i g a t i n g  t h e  c o e x p r e s s i o n  o f  t h e  
I G F - I R ,  E G F R  a n d  H E R - 2  i n  h u m a n  m a l i g n a n c i e s ,  a n d  t h e i r  
a s s o c i a t i o n  w i t h  c l i n i c o p a t h o l o g i c a l  p a r a m e t e r s ,  p a t i e n t  
s u r v i v a l  a n d  r e s p o n s e  t o  t h e r a p y .
W e  h a v e  s h o w n  p r e v i o u s l y  t h a t  o v e r e x p r e s s i o n  o f  t h e  
H E R - 2  i s  c o m m o n  i n  p a t i e n t s  w i t h  D u k e s '  B  a n d  C  c o l o r e e t a l  
c a n c e r  ( 2 3 ) .  I n  t h i s  s t u d y ,  w e  t h e r e f o r e  d e t e r m i n e d  t h e  
e o e x p r e s s i o n  o f  I G F - I R ,  E G F R  a n d  H E R - 2  i n  t u m o u r  
s p e e i m e n s  f r o m  D u k e s '  C  ( n o d e  p o s i t i v e )  c o l o r e c t a l  c a n c e r  
p a t i e n t s  u s i n g  i m m u n o h i s t o c h e m i s t r y .  W e  a l s o  i n v e s t i g a t e d  
t h e  a s s o c i a t i o n  b e t w e e n  t h e  c o e x p r e s s i o n  o f  I G F - I R ,  E G F R  
a n d  H E R - 2  a n d  c l i n i c o p a t h o l o g i c a l  p a r a m e t e r s  a n d  o v e r a l l  
s u r v i v a l .
Materials and methods
Patient inform ation. E i g h t y - s e v e n  p a t i e n t s  w i t h  D u k e s '  C  
c o l o r e c t a l  c a n c e r  w e r e  i n c l u d e d  i n  t h i s  r e t r o s p e c t i v e  s t u d y .  T h i s  
g r o u p  c o n s i s t e d  o f  c o n s e c i i t i v e  p a t i e n t s  w h o  u n d e r w e n t  r a d i c a l  
s u r g e r y  a t  t h e  R o y a l  S u r r e y  C o u n t y  H o s p i t a l  ( G u i l d f o r d ,  U K )  
b e t w e e n  J a n u a r y  1 9 9 0  a n d  D e c e m b e r  1 9 9 8 ,  e x c l u d i n g  t h o s e  
w i t h  n o  f o l l o w - u p  i n f o r m a t i o n ,  m i s - d i a g n o s i s ,  a n d  i n e o m p l e t e  
h i s t o l o g y .  C a s e s  o f  p e r i -  a n d  p o s t - o p e r a t i v e  d e a t h  ( i . e .  w i t h i n  
3 0  d a y s  a f t e r  s u r g e r y )  w e r e  e x c l u d e d  f r o m  t h i s  s t u d y ,  a s  w e r e  
t h o s e  w i t h  p o s i t i v e  t u m o u r  r e s e c t i o n  m a r g i n s  o n  m i c r o s c o p y ,  
a n d  t h o s e  w i t h  t u m o u r  b l o c k s  i n  a  c o n d i t i o n  t o o  p o o r  f o r  
i m m u n o h i s t o c h e m i c a l  u s e .  E t h i c a l  a p p r o v a l  w a s  o b t a i n e d  f r o m  
t h e  R e s e a r c h  a n d  D e v e l o p m e n t  C o m m i t t e e  o f  t h e  R o y a l  S u r r e y  
C o u n t y  H o s p i t a l .  D e t a i l e d  c l i n i c o p a t h o l o g i c a l  i n f o r m a t i o n ,  
i n c l u d i n g  p a t i e n t  a g e  a n d  g e n d e r  a s  w e l l  a s  t u m o u r  s i z e ,  w a s  
a v a i l a b l e  f o r  e a c h  p a t i e n t .
Tumour cell lines and antibodies. T h e  h u m a n  b r e a s t  ( M C F - 7  
a n d  S K B R 3 )  a n d  h e a d  a n d  n e c k  c a r c i n o m a  ( H N 5 )  c e l l  p e l l e t s  
w e r e  u s e d  a s  p o s i t i v e  c o n t r o l s  f o r  I G F - I R ,  H E R - 2  a n d  E G F R  
s t a i n i n g ,  r e s p e c t i v e l y .  T h e  I G F - I R  n e g a t i v e  R -  c e l l  l i n e  w a s  a  
k i n d  g i f t  f r o m  D r  R e n a t o  B a s e r g a  ( K i m m e l  C a n c e r  I n s t i t u t e ,  
P h i l a d e l p h i a ,  P A )  a n d  w a s  u s e d  a s  a  n e g a t i v e  c o n t r o l  f o r  
I G F - I R  s t a i n i n g  ( 1 1 ) .  A l l  c e l l  l i n e s  w e r e  c u l t u r e d  r o u t i n e l y  i n  
D u l b e c c o ' s  m o d i f i e d  E a g l e ' s  m e d i u m  s u p p l e m e n t e d  w i t h  
1 0 %  P C S  a n d  t h e  a n t i b i o t i c s  p e n i c i l l i n ,  s t r e p t o m y c i n ,  a n d  
n e o m y c i n .  F o r  R -  c e l l s ,  t h e  m e d i u m  a l s o  c o n t a i n e d  5 0  pg/m l 
o f  h y g r o m y c i n  B .
T h e  e x p r e s s i o n  o f  I G F - I R  i n  t h e  t u m o u r  s p e c i m e n s  w a s  
d e t e r m i n e d  u s i n g  a  m o u s e  m o n o c l o n a l  a n t i b o d y  ( m A b )  
d i r e c t e d  a g a i n s t  t h e  a - s u b u n i t  ( e x t r a c e l l u l a r  d o m a i n )  o f  t h e  
h u m a n  I G F - I R  ( C a l b i o c h e m ) .  T h e  e x p r e s s i o n  o f  E G F R  a n d  
H E R - 2  w a s  d e t e r m i n e d  u s i n g  t h e  r a t  m A b s  I C R  1 6  a n d  I C R  1 2  
w h i c h  a r e  d i r e c t e d  a g a i n s t  t h e  e x t e r n a l  d o m a i n  o f  t h e  h u m a n  
E G F R  a n d  H E R - 2 ,  r e s p e c t i v e l y  ( 2 4 , 2 5 ) .
Immunohistochemistry. P a r a f f i n - e m b e d d e d  s e c t i o n s  o f  t u m o u r  
s p e c i m e n s  ( 3  p m )  a n d  c o n t r o l  c e l l  p e l l e t s  w e r e  c u t  f r o m  
p a r a f f i n - e m b e d d e d  b l o c k s .  S e c t i o n s  w e r e  d e - w a x e d  i n  x y l e n e ,  
w a s h e d  t h r e e  t i m e s  i n  i n d u s t r i a l  m e t h y l a t e d  s p i r i t ,  a n d  
r e h y d r a t e d  t o  w a t e r ,  a s  d e s c r i b e d  p r e v i o u s l y  ( 2 3 ) .  F o l l o w i n g  
d e p a r a f f i n i s a t i o n  a n d  r e h y d r a t i o n ,  s e c t i o n s  w e r e  w a s h e d  i n  
T r i s - b u f f e r e d  s a l i n e  ( T B S )  f o r  5  m i n ,  a n d  u n m a s k e d  i n  c i t r a t e  
a n t i g e n  u n m a s k i n g  s o l u t i o n  ( V e c t o r  l a b o r a t o r i e s ,  P e t e r b o r o u g h ,  
U K ) ,  i n  a  p r e s s u r e  c o o k e r  a t  o p e r a t i n g  t e m p e r a t u r e  f o r  1 m i n .
S l i d e s  w e r e  t h e n  i m m e r s e d  i n  t a p  w a t e r  a n d  w a s h e d  i n  T B S  
f o r  5  m i n ,  p r i o r  t o  t h e  b l o c k a d e  o f  e n d o g e n o u s  p e r o x i d a s e  
a n d  b i o t i n  ( Z y m e d )  a n d  i n c u b a t i o n  w i t h  r a b b i t  s e r u m  f o r  
2 0  m i n .  E a c h  s e c t i o n  w a s  i n c u b a t e d  f o r  1 h  a t  r o o m  t e m p e r a t u r e  
w i t h  m o u s e  a n t i - h u m a n  I G F - I R  a n t i b o d y  ( 1 / 5 0  i n  T B S ) .  T h e  
b o u n d  p r i m a r y  a n t i b o d y  w a s  t h e n  d e t e c t e d  b y  a d d i t i o n  o f  
b i o t i n y l a t e d  r a b b i t  a n t i - m o u s e  s e c o n d a r y  a n t i b o d y  ( D a k o ,  
C A ,  U S A )  f o l l o w e d  b y  a v i d i n / b i o t i n / h o r s e r a d i s h  p e r o x i d a s e  
c o m p l e x  ( D a k o )  f o r  3 0  m i n  e a c h  a t  r o o m  t e m p e r a t u r e .  T h e  
i m m u n o s t a i n i n g  w a s  t h e n  v i s u a l i s e d  u s i n g  l i q u i d  d i a m i n o -  
b e n z i d i n e  d i l u t e d  1 / 5 0  i n  H R P  s u b s t r a t e  b u f f e r  ( D a k o ) ,  a n d  
s e c t i o n s  w e r e  c o u n t e r s t a i n e d  w i t h  M a y e r ' s  h a e m a t o x y l i n  
b e f o r e  m o u n t i n g .
N o  a n t i g e n  r e t r i e v a l  w a s  n e c e s s a r y  i n  t h e  s t a i n i n g  o f  
t u m o u r  s e c t i o n s  w i t h  a n t i - E G F R  m A b  I C R  1 6  a n d  a n t i - H E R - 2  
m A b  I C R 1 2 .  F o l l o w i n g  d e p a r a f f i n i s a t i o n  a n d  r e h y d r a t i o n ,  
s e c t i o n s  w e r e  w a s h e d  i n  T B S  f o r  5  m i n ,  p r i o r  t o  t h e  b l o c k a d e  
o f  e n d o g e n o u s  p e r o x i d a s e  a n d  i n c u b a t i o n  w i t h  r a b b i t  s e r u m  
f o r  2 0  m i n .  A f t e r  b l o t t i n g  o f f  e x c e s s  s e r u m ,  e a c h  s e c t i o n  w a s  
i n c u b a t e d  w i t h  2 0 0  p \  o f  h y b r i d o m a  c u l t u r e  s u p e r n a t a n t  
( d i l u t e d  1 / 4  i n  T B S  f o r  I C R  1 2  a n d  1 / 2  f o r  I C R  1 6 )  o v e r n i g h t  
a t  4 ° C .  T h e  b o u n d  p r i m a r y  a n t i b o d y  w a s  t h e n  d e t e e t e d  b y  
a d d i t i o n  o f  b i o t i n y l a t e d  r a b b i t  a n t i - r a t  s e c o n d a r y  a n t i b o d y  
( D a k o )  f o r  3 0  m i n  a t  r o o m  t e m p e r a t u r e  ( 1 / 3 0 0  i n  T B S ) .  
F i n a l l y ,  t h e  v i s u a l i s a t i o n ,  c o u n t e r s t a i n i n g  a n d  m o u n t i n g  o f  
t h e  s e c t i o n s  w e r e  p e r f o r m e d  a s  d e s c r i b e d  a b o v e .
S e c t i o n s  w e r e  s c o r e d  b y  t h e  p e r c e n t a g e  o f  p o s i t i v e  c e l l s  
( m e m b r a n o u s  a n d  c y t o p l a s m i c )  a n d  t h e  i n t e n s i t y  o f  i m m u n o ­
s t a i n i n g  [ i . e .  n e g a t i v e  ( 0 ) ,  w e a k  ( 1 + ) ,  i n t e r m e d i a t e  ( 2 + ) ,  a n d  
s t r o n g  ( 3 + ) ] .  I m m u n o s t a i n i n g  i n  > 1 0 %  o f  t u m o u r  c e l l s  w a s  
c o n s i d e r e d  p o s i t i v e .  T h e  i m m u n o s t a i n i n g  w a s  s c o r e d  b y  t w o  
i n d e p e n d e n t  o b s e r v e r s  w i t h o u t  p r i o r  k n o w l e d g e  o f  c l i n i c o ­
p a t h o l o g i c a l  p a r a m e t e r s .  A n y  d i s p a r i t y  i n  s c o r i n g  w a s  r e s o l v e d  
b y  s i m u l t a n e o u s  r e a s s e s s m e n t  b y  b o t h  o b s e r v e r s .
Statistical analysis. T h e  a s s o c i a t i o n  b e t w e e n  i m m u n o h i s t o ­
c h e m i s t r y  s c o r e s  a n d  p a t i e n t  c l i n i c o p a t h o l o g i c a l  d a t a  w a s  
a s s e s s e d  u s i n g  t h e  C h i - S q u a r e d  t e s t  ( P e a r s o n  C h i - S q u a r e ) .  
U n i v a r i a t e  a n a l y s i s  o f  s u r v i v a l  w a s  p e r f o r m e d  u s i n g  K a p l a n -  
M e i e r  s u r v i v a l  p l o t s ,  a n d  e v a l u a t i o n  o f  d i f f e r e n c e s  b e t w e e n  
g r o u p s  w a s  p e r f o r m e d  w i t h  t h e  l o g  r a n k - t e s t .  F o r  m u l t i v a r i a t e  
a n a l y s i s ,  t h e  C o x  p r o p o r t i o n a l  h a z a r d s  r e g r e s s i o n  m o d e l  w a s  
u s e d  t o  d e t e c t  t h e  i m p a c t  o f  p a t i e n t  c l i n i c o p a t h o l o g i c a l  p a r a ­
m e t e r s  a n d  r e c e p t o r  e x p r e s s i o n  o n  o v e r a l l  s u r v i v a l .  U s i n g  a  
s t e p w i s e  f o r w a r d  s e l e c t i o n  m e t h o d ,  t h e  c o v a r i â t e s  c o n s i d e r e d  
f o r  i n c l u s i o n  i n  t h e  m o d e l  w e r e  s i t e  a n d  s i z e  o f  t u m o u r ,  d e p t h  
o f  t u m o u r  i n v a s i o n  ( i . e .  T  s t a g e ) ,  g r a d e ,  l y m p h o v a s c u l a r  
i n v a s i o n ,  n o d e  s t a g e ,  ( N 1  o r  N 2 ) ,  a n d  t h e  p r e s e n c e  o f  a p i c a l  
n o d e  m é t a s t a s é s .  P a t i e n t  t r e a t m e n t  w i t h  c h e m o t h e r a p y  o r  
r a d i o t h e r a p y  w a s  a l s o  i n c l u d e d  i n  t h e  m o d e l .  S i g n i f i e a n c e  
l e v e l s  w e r e  s e t  a t  P < 0 . 0 5 ,  a n d  a l l  s t a t i s t i c a l  a n a l y s e s  w e r e  
c a r r i e d  o u t  u s i n g  t h e  S t a t i s t i c a l  P a c k a g e  f o r  t h e  S o c i a l  S c i e n c e s  
( S P S S )  v e r s i o n s  1 1 . 5 . 1  a n d  v e r s i o n  1 2 . 0  f o r  W i n d o w s  ( S P S S  
U K  L t d . ,  W o k i n g ,  S u r r e y ,  U K ) .
Results
C lin icopath ologica l fea tu res .  P a t i e n t  c l i n i c o p a t h o l o g i c a l  
c h a r a c t e r i s t i c s  a r e  d e t a i l e d  i n  T a b l e  I .  A l l  8 7  p a t i e n t s  w e r e  
d i a g n o s e d  w i t h  n o d e  p o s i t i v e  ( D u k e s '  C ,  N 1 / N 2 )  c o l o r e c t a l
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T a b l e  I .  A s s o c i a t i o n  b e t w e e n  c l i n i c o p a t h o l o g i c a l  p a r a m e t e r s  a n d  o v e r a l l  s u r v i v a l  u s i n g  K a p l a n - M e i e r  s u r v i v a l  c u r v e s  a n d  t h e  
l o g - r a n k  t e s t ,  a n d  b e t w e e n  e l i n i c o p a t h o l o g i c a l  p a r a m e t e r s  a n d  e x p r e s s i o n  o f  I G F - I R ,  H E R - 2  o r  E G F R ,  a n d  c o e x p r e s s i o n  o f  
I G F - I R ,  H E R - 2  a n d  E G F R  d e t e r m i n e d  u s i n g  t h e  c h i - s q u a r e d  t e s t .
C h a r a c t e r i s t i c  (n) P - v a l u e  f o r  
o v e r a l l
N u m b e r  o f  p a t i e n t s  w i t h  > 1 0 %  r e c e p t o r  e x p r e s s i o n  
( P - v a l u e  f o r  a s s o c i a t i o n  w i t h  p a t i e n t  c h a r a c t e r i s t i c s )
I G F - I R H E R - 2 E G F R A l l  t h r e e
S e x
M a l e  ( 4 7 ) 4 3 4 0 3 6 3 1
F e m a l e  ( 4 0 ) N S 3 8 N S 3 7 N S 3 6 N S 3 4 N S
A g e  i n  y e a r
< 7 0  ( 4 7 ) 4 3 4 2 4 1 3 7
> 7 0  ( 4 0 ) 0 . 0 1 4 3 8 N S 3 5 N S 3 1 N S 2 8 N S
T u m o u r  s i t e
R i g h t  c o l o n  ( 2 6 ) 2 3 2 3 2 0 1 7
L e f t  e o l o n  ( 2 4 ) 2 4 2 0 2 1 2 0
R e c t u m  ( 3 7 ) N S 2 4 N S 3 4 N S 3 1 N S 2 8 N S
S i z e
< 5  c m  ( 5 6 ) 5 3 5 0 4 5 4 1
> 5  c m  ( 3 1 ) N S 2 8 N S 2 7 N S 2 7 N S 2 4 N S
G r a d e
1 ( 3 ) 3 2 3 2
2 ( 4 8 ) 4 6 4 2 3 9 3 7
3 ( 3 2 ) 2 9 3 0 2 7 2 4
M u c i n o u s  ( 4 ) N S 3 N S 3 N S 3 N S 2 N S
L y m p h o v a s c u l a r
i n v a s i o n
A b s e n t  ( 6 5 ) 6 0 5 6 5 4 4 8
P r e s e n t  ( 2 2 ) N S 2 1 N S 2 1 N S 1 8 N S 1 7 N S
T  s t a g e
T 2  ( 1 0 ) 9 9 9 8
T 3  ( 5 6 ) 5 4 4 9 4 8 4 4
T 4  ( 2 1 ) 0 . 0 0 1 2 1 8 N S 1 9 N S 1 5 N S 1 3 N S
A p i c a l  n o d e
N e g a t i v e  ( 4 5 ) 4 3 4 0 3 8 3 5
P o s i t i v e  ( 1 1 ) 1 1 1 1 1 0 1 0
U n k n o w n  ( 3 1 ) 0 . 0 0 6 8 2 7 N S 2 6 N S 2 4 N S 2 0 N S
P o s i t i v e  n o d e s
1 - 3  n o d e s  ( 5 7 ) 5 1 4 9 4 7 4 0
4 +  n o d e s  ( 3 0 ) N S 3 0 N S 2 8 N S 2 5 N S 2 5 N S
N S ,  n o t  s i g n i f i c a n t  ( P  > 0 .0 5 ) .
c a n c e r .  T h e  m e d i a n  p a t i e n t  f o l l o w - u p  t i m e  w a s  4 . 1  y e a r s .  
F i f t y  p a t i e n t s  h a d  a  c a n c e r  o f  t h e  c o l o n  ( i n c l u d i n g  6  r e c t o ­
s i g m o i d  c a n c e r s )  a n d  3 7  p a t i e n t s  h a d  a  c a n c e r  o f  t h e  r e c t u m .  
T w e n t y - s i x  p a t i e n t s  r e c e i v e d  p o s t - o p e r a t i v e  r a d i o t h e r a p y ,  
a n d  o f  t h e s e ,  2 0  h a d  a  c a n c e r  o f  t h e  r e c t u m  a n d  6  h a d  a  r e c t o ­
s i g m o i d  c a n c e r .  F o r t y - n i n e  p a t i e n t s  r e c e i v e d  p o s t - o p e r a t i v e
c h e m o t h e r a p y .  N o n e  o f  t h e  p a t i e n t s  h a d  r e c e i v e d  r a d i o t h e r a p y  
o r  c h e m o t h e r a p y  b e f o r e  s u r g e r y .  T h e r e  w a s  a  p o o r e r  s u r v i v a l  
i n  p a t i e n t s  w i t h  T  s t a g e  4  d i s e a s e  ( P = 0 . 0 0 1 ) ,  t h o s e  w i t h  a p i c a l  
n o d e  m é t a s t a s é s  ( P = 0 . 0 0 7 ) ,  a n d  i n  p a t i e n t s  > 7 0  y e a r s  o l d  
( P = 0 . 0 1 4 ) .  N o  s i g n i f i c a n t  a s s o c i a t i o n  w a s  f o u n d  b e t w e e n  
s u r v i v a l  a n d  t h e  o t h e r  f a c t o r s  ( T a b l e  I ) .
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Figure 1. Im m unohistochemical staining o f  the IGF-IR positive MCF-7 cell pellet (A ), and the IGF-IR negative R- cell pellet (B). Predominantly membranous 
(C) and cytoplasm ic (D ) IGF-IR staining o f  two different colorectal cancer cases. Predominantly cytoplasm ic 3+ HER-2 staining (E) and cytoplasm ic 2+ 
EGFR staining (F) in a selected colorectal cancer case.
The expression o f IGF-IR, EGFR and HER-2 in colorectal 
tum ours. T h e  a n t i - I G F - I R  a n t i b o d y  u s e d  i n  t h i s  s t u d y  i s  
s p e c i f i c  f o r  t h e  I G F - I R  ( F i g .  1 ) .  T h i s  a n t i b o d y  s t a i n e d  t h e  
m e m b r a n e  o f  t h e  I G F - I R  e x p r e s s i n g  c e l l  l i n e  M C F - 7  w i t h  
s t r o n g  i n t e n s i t y ,  b u t  d i d  n o t  s t a i n  t h e  c e l l  p e l l e t  o f  t h e  n o n -  
I G F - I R  e x p r e s s i n g  c e l l  l i n e  R -  ( F i g .  1 A  a n d  B ) .  I G F - I R  
e x p r e s s i o n  w a s  f o u n d  t o  b e  p o s i t i v e  i n  8 1  ( 9 3 % )  o f  8 7  D u k e s '  
C  c o l o r e c t a l  c a n c e r  c a s e s  ( T a b l e  1 1 ) . T h e  p a t t e r n  o f  I G F - I R  
i m m u n o s t a i n i n g  w a s  b o t h  m e m b r a n o u s  a n d  c y t o p l a s m i c  
( F i g .  1 C  a n d  D ) .  W h e r e  m e m b r a n e  I G F - I R  w a s  p r e s e n t ,  t h e  
i n t e n s i t y  o f  s t a i n i n g  w a s  o f  a b u n d a n t l y  s t r o n g  ( 3 + )  i n t e n s i t y
( F i g .  1 C ) .  M e m b r a n o u s  I G F - I R  w a s  p r e s e n t  i n  5 2  ( 6 0 % )  o f  
t h e  c a s e s  ( T a b l e  I I ) .
O f  8 7  c a s e s  e x a m i n e d ,  7 7  ( 8 9 % )  a n d  7 2  ( 8 3 % )  w e r e  H E R - 2  
o r  E G F R  p o s i t i v e ,  r e s p e c t i v e l y  ( T a b l e  I I ;  F i g .  I E  a n d  F )  
U n l i k e  s t a i n i n g  o f  t h e  I G F - I R ,  m e m b r a n e  e x p r e s s i o n  o f  
H E R - 2  a n d  E G F R  w a s  t y p i c a l l y  c o n f i n e d  t o  a  l o w  p e r c e n t a g e  
o f  c a s e s  a n d  t u m o u r  c e l l s  ( T a b l e  I I ) .  T h e  i n t e n s i t y  o f  H E R - 2  
a n d  E G F R  i m m u n o s t a i n i n g  w a s  s i m i l a r  w i t h  r e s p e c t  t o  t h e  
n u m b e r  o f  c a s e s  w i t h  1+ a n d  2+  i m m u n o s t a i n i n g ;  h o w e v e r ,  
t h e r e  w e r e  m o r e  c a s e s  w i t h  3 +  i n t e n s i t y  i m m u n o s t a i n i n g  f o r  
H E R - 2  t h a n  f o r  E G F R  ( T a b l e  I I ) .  S t a i n i n g  f o r  E G F R  a n d
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Figure 2. Kaplan M eier survival curves for Dukes' C colorectal cancer patients expressing >10%  IGF-IR, EGFR, and HER-2. Overall survival in patients 
expressing membranous IGF-IR (A ), total HER-2 (B ), total EGFR (C ), and patients with IGF-IR, EGFR and HER-2 coexpression (D ).
H E R - 2  w a s  n o t i c e a b l e  i n  s t r u c t u r a l l y  b e n i g n  g l a n d s  a n d  a l s o  
t h e  s t r o m a  o f  c o l o r e c t a l  c a n c e r  t i s s u e s ,  w h e r e a s  I G F - I R  w a s  
n o t  e x p r e s s e d  i n  t h e  s t r o m a  o f  a n y  b i o p s i e s .
The association between IGF-IR, EGFR and HER-2 expression 
and clinicopathological param eters and overall survival. T h e  
e x p r e s s i o n  o f  I G F - I R ,  E G F R  a n d  H E R - 2  w a s  e v a l u a t e d  w i t h  
r e s p e c t  t o  c l i n i c o p a t h o l o g i c a l  f e a t u r e s  ( T a b l e  I )  a n d  o v e r a l l  
s u r v i v a l  ( F i g .  2 ) .  N o  a s s o c i a t i o n s  w e r e  f o u n d  b e t w e e n  t o t a l  
I G F - I R  e x p r e s s i o n  ( m e m b r a n o u s  a n d  c y t o p l a s m i c )  a n d  c l i n i c o ­
p a t h o l o g i c a l  p a r a m e t e r s  o r  o v e r a l l  s u r v i v a l  ( T a b l e  I ,  d a t a  n o t  
s h o w n ) .  H o w e v e r ,  s i g n i f i c a n t  a s s o c i a t i o n s  w e r e  f o u n d  b e t w e e n  
t h e  e x p r e s s i o n  o f  m e m b r a n o u s  I G F - I R  i n  > 1 0 %  o f  t u m o u r  
c e l l s  a n d  t u m o u r  s i z e ,  w i t h  m o r e  e x p r e s s i o n  i n  t u m o u r s  < 5  c m  
( P = 0 . 0 0 1 ) ,  p a t i e n t  a g e ,  w i t h  m o r e  e x p r e s s i o n  i n  p a t i e n t s  
> 7 0  y e a r s  ( P = 0 . 0 2 5 )  ( d a t a  n o t  s h o w n ) ,  b u t  n o t  o v e r a l l  s u r v i v a l  
( F i g .  2 A ) .  S i m i l a r l y  t o  t o t a l  I G F - I R  e x p r e s s i o n ,  t h e r e  w e r e  n o  
s i g n i f i c a n t  a s s o c i a t i o n s  b e t w e e n  H E R - 2  e x p r e s s i o n ,  E G F R  
e x p r e s s i o n ,  a n d  t h e  c o e x p r e s s i o n  o f  t h e  I G F - I R ,  H E R - 2  a n d  
E G F R  a n d  c l i n i c o p a t h o l o g i c a l  p a r a m e t e r s  ( T a b l e  I )  o r  o v e r a l l  
s u r v i v a l  ( F i g .  2 B - D ) .
Discussion
I n  r e c e n t  y e a r s ,  a b e r r a n t  e x p r e s s i o n  o f  g r o w t h  f a c t o r  r e c e p t o r s  
( e . g .  E G F R ,  H E R - 2 ,  I G F - I R )  h a s  b e e n  r e p o r t e d  i n  m a n y  c a n c e r  
c e l l  l i n e s  a n d  t i s s u e s ,  a s s o c i a t e d  w i t h  t h e  e s t a b l i s h m e n t  a n d
m a i n t e n a n c e  o f  t h e  t r a n s f o r m e d  p h e n o t y p e ,  a n d  i n  s o m e  c a s e s  
h a s  b e e n  a s s o c i a t e d  w i t h  a  p o o r  p r o g n o s i s  a n d  r e s i s t a n c e  
t o  t h e r a p y  ( 3 , 4 , 2 6 , 2 7 ) .  I n  a d d i t i o n ,  t h e  r e s u l t s  o f  o t h e r  
e x p e r i m e n t a l  s t u d i e s  h a v e  i n d i c a t e d  t h a t  t h e  I G F - I R  c a n  
i n t e r a c t  w i t h  E G F R  a n d  H E R - 2  t o  e n h a n c e  t h e  m a l i g n a n t  
b e h a v i o u r  o f  t u m o u r s ,  a n d  t h a t  I G F - I R  s i g n a l l i n g  m a y  b e  
r e s p o n s i b l e  f o r  t h e  p o o r  r e s p o n s e  t o  t h e r a p y  w i t h  E G F R -  
s p e c i f i c  i n h i b i t o r s  o r  t h e  a n t i - H E R - 2  m A h  t r a t s u z u m a b  
( 1 0 , 1 2 - 1 5 ) .  C o n s e q u e n t l y ,  i n  t h i s  s t u d y  w e  i n v e s t i g a t e d  t h e  
c o e x p r e s s i o n  o f  I G F - I R ,  E G F R  a n d  H E R - 2  i n  D u k e s '  C  
c o l o r e c t a l  c a n c e r  s p e c i m e n s  a n d  d e t e r m i n e d  t h e i r  a s s o c i a t i o n  
w i t h  c l i n i c o p a t h o l o g i c a l  p a r a m e t e r s  a n d  o v e r a l l  s u r v i v a l .
W e  h a v e  f o u n d  t h a t  a  h i g h  p e r c e n t a g e  ( 9 3 % )  o f  D u k e s '  C  
( n o d e  p o s i t i v e )  c o l o r e c t a l  c a n c e r  p a t i e n t s  a r e  I G F - I R  p o s i t i v e  
( T a b l e  I  a n d  I I ) .  T h e  e x p r e s s i o n  o f  I G F - I R  h a s  b e e n  r e p o r t e d  
p r e v i o u s l y  i n  b o t h  n o r m a l  a n d  m a l i g n a n t  t i s s u e s  f r o m  a  w i d e  
r a n g e  o f  c a n c e r  p a t i e n t s  i n c l u d i n g  c o l o r e c t a l  c a n c e r  ( 1 6 - 2 2 ) .  
T h e  g r e a t  m a j o r i t y  o f  s t u d i e s  h a v e  f o u n d  n o  s i g n i f i c a n t  
d i f f e r e n c e  i n  t h e  l e v e l s  o f  I G F - I R  m R N A  b e t w e e n  n o r m a l  
a n d  m a l i g n a n t  c o l o r e c t a l  t i s s u e s  ( 1 7 , 2 2 ) .  H o w e v e r ,  l i k e  o t h e r  
i m m u n o h i s t o c h e m i c a l  s t u d i e s ,  w e  f o u n d  t h a t  I G F - I R  o v e r ­
e x p r e s s i o n  i s  c o m m o n  i n  t u m o u r  s p e c i m e n s  f r o m  c o l o r e c t a l  
c a n c e r  p a t i e n t s  ( 1 8 - 2 0 )  b u t  t h e  e x p r e s s i o n  o f  I G F - I R  i s  n o t  
a s s o c i a t e d  w i t h  c l i n i c o p a t h o l o g i c a l  p a r a m e t e r s  ( T a b l e  I )  
( 1 9 , 2 0 , 2 2 ) .  W h e n  o u r  d a t a  w a s  a n a l y s e d  u s i n g  p a t i e n t s  w i t h  
> 1 0 %  m e m b r a n o u s  I G F - I R  e x p r e s s i o n ,  6 0 %  o f  t h e  c a s e s  
w e r e  I G F - I R  p o s i t i v e  ( T a b l e  I I )  a n d  t h e r e  w e r e  s i g n i f i c a n t
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T a b l e  I I .  D i s t r i b u t i o n  o f  I G F - I R ,  H E R - 2  a n d  E G F R  p r o t e i n  
e x p r e s s i o n  i n  c o l o r e c t a l  c a n c e r  ( n = 8 7 ) ,  u s i n g  t h e  a n t i - h u m a n -  
I G F - I R  m A h , m A b  I C R  1 6 ,  o r  m A b  I C R  1 2 . “
P e r c e n t a g e  N u m b e r  o f  c a s e s  w i t h  r e c e p t o r  e x p r e s s i o n  
o f  p o s i t i v e  [ c y t o p l a s m i c  +  m e m b r a n e  ( m e m b r a n e  o n l y ) ]
I G F - I R H E R - 2 E G F R
N e g a t i v e 6 ( 3 5 ) 1 0  ( 8 2 ) 1 5  ( 8 6 )
> 1 0 8 1  ( 5 2 ) 7 7 ( 5 ) 7 2 ( 1 )
> 5 0 6 2  ( 1 2 ) 6 6 ( 0 ) 5 5 ( 0 )
A n t i b o d y  t o : O v e r a l l  i n t e n s i t y  o f  s t a i n i n g
0 1 + 2 + 3 +
I G F - I R 4 4 1 3 5 7
H E R - 2 6 4 3 1 6 2 2
E G F R 1 1 5 1 1 7 8
“Data are shown according to the percentage of reactive cells and 
overall intensity of staining. 0 , negative; I+, weak staining; 2+, 
moderate staining, 3+, strong staining.
a s s o c i a t i o n s  w i t h  t u m o u r  s i z e  ( P = 0 . 0 0 1 ) ,  w i t h  h i g h e r  e x p r e s s i o n  
i n  t u m o u r s  < 5  c m .  T h e  l i m i t e d  n u m b e r  o f  s t u d i e s  i n v e s t i g a t i n g  
t h e  a s s o c i a t i o n  b e t w e e n  I G F - I R  a n d  c l i n i c o p a t h o l o g i c a l  p a r a ­
m e t e r s ,  t h e  u s e  o f  d i f f e r e n t  c u t - o f f  v a l u e s  f o r  I G F - I R  p o s i t i v e  
t u m o u r s ,  t o g e t h e r  w i t h  t h e  u s e  o f  d i f f e r e n t  p r i m a r y  a n t i b o d i e s ,  
h e t e r o g e n e o u s  p o p u l a t i o n s  o f  c o l o r e c t a l  c a n c e r  p a t i e n t s  a n d  
p a t i e n t  n u m b e r s ,  a m o n g  o t h e r  f a c t o r s  m a k e s  t h e  d i r e c t  c o m ­
p a r i s o n  o f  d a t a  i n  t h e  l i t e r a t u r e  d i f f i c u l t .  I n  a d d i t i o n ,  t h e  
n u m b e r  o f  s t u d i e s  e x a m i n i n g  t h e  i m p a c t  o f  I G F - I R  e x p r e s s i o n  
o n  t h e  s u r v i v a l  o f  c o l o r e c t a l  c a n c e r  p a t i e n t s  i s  l i m i t e d .  L i k e  
H a k a m  a n d  c o l l e a g u e s  ( 1 8 )  w e  d i d  n o t  f i n d  a n y  s i g n i f i c a n t  
a s s o c i a t i o n  b e t w e e n  t h e  e x p r e s s i o n  o f  I G F - I R  a n d  o v e r a l l  
s u r v i v a l  i n  c o l o r e c t a l  c a n c e r  p a t i e n t s  ( F i g .  2 A ) .  I n  a d d i t i o n ,  w e  
f o u n d  n o  s i g n i f i c a n t  c o r r e l a t i o n  b e t w e e n  I G F - I R  e x p r e s s i o n  
a n d  o v e r a l l  s u r v i v a l  u s i n g  d i f f e r e n t  c u t - o f f  v a l u e s  o f  > 1 %  a n d  
> 5 0 %  e x p r e s s i o n  ( d a t a  n o t  s h o w n ) .  W h i l e  t h e  e x p r e s s i o n  o f  
t h e  I G F - I R  d i d  n o t  h a v e  p r o g n o s t i c  s i g n i f i c a n c e  i n  t h i s  s t u d y ,  
t h e  f r e q u e n t  e x p r e s s i o n  o f  I G F - I R  a m o n g  t h i s  s e r i e s  o f  p a t i e n t s  
m a k e s  i t  a  s u i t a b l e  t a r g e t  f o r  t h e  n e w  g e n e r a t i o n  o f  r e c e p t o r -  
s p e c i f i c  d r u g s  ( 8 - 1 0 , 1 5 ) .  I n  t h i s  s t u d y ,  6 0 %  o f  D u k e s '  C  c o l o ­
r e c t a l  c a n c e r  c a s e s  e x p r e s s e d  t h e  m e m b r a n o u s  I G F - I R  i n  > 1 0 %  
o f  t u m o u r  c e l l s  ( T a b l e  I I ) .  T h e  m e m b r a n o u s  I G F - I R  i n  s u c h  
p a t i e n t s  w o u l d  f o r m  a  g o o d  t a r g e t  f o r  t h e r a p y  w i t h  a n t i b o d i e s  
t o  t h e  e x t e r n a l  d o m a i n  o f  t h e  r e c e p t o r  ( 1 5 ) .
A  n u m b e r  o f  s t u d i e s  h a v e  s h o w n  t h a t  t h e  I G F - I R  i s  a b l e  t o  
c r o s s t a l k  w i t h  o t h e r  r e c e p t o r  s y s t e m s  t o  e n h a n c e  t h e  m a l i g n a n t  
b e h a v i o u r  o f  t u m o u r s .  F o r  e x a m p l e ,  I G F - I R  a c t i v a t i o n  h a s  
b e e n  f o u n d  t o  u p - r e g u l a t e  t h e  e x p r e s s i o n  o f  t h e  E G F R  l i g a n d  
T G F a  a n d  r e s u l t  i n  E G F R  a c t i v a t i o n  a n d  r e - e n t r y  i n t o  t h e  c e l l  
c y c l e  ( 1 3 ) .  T h e  e x p r e s s i o n  o f  I G F - I R  h a s  b e e n  a s s o c i a t e d  
w i t h  r e s i s t a n c e  t o  a n t i - E G F R  a n d  a n t i - H E R - 2  t h e r a p i e s  i n  
s e v e r a l  e x p e r i m e n t a l  s y s t e m s ,  a n d  c o - t a r g e t i n g  t h e  I G F - I R  
w i t h  t h e  E G F R  o r  H E R - 2  h a s  b e e n  s h o w n  t o  r e d u c e  t h e  
m a l i g n a n t  b e h a v i o u r  o f  t u m o u r  c e l l s  ( 7 , 1 4 ) .  M o r e  r e c e n t l y .
w h e n  c o m b i n e d  w i t h  a n t i - E G F R  m A h  2 2 5  o r  t h e  c h e m o ­
t h e r a p e u t i c  a g e n t  v i n o r e l b i n e ,  a  h u m a n i z e d  a n t i - I G F - I R  
a n t i b o d y  h a s  b e e n  s h o w n  t o  i n h i b i t  m o r e  e f f i c i e n t l y  t h e  
g r o w t h  o f  t h e  h u m a n  b r e a s t  c a n c e r  c e l l  l i n e  M C F - 7  a n d  n o n ­
s m a l l  l u n g  c a n c e r  c e l l  l i n e  A 5 4 9  in vivo  ( 1 5 ) .  W h e n  t h e  8 7  
D u k e s '  C  c o l o r e c t a l  c a n c e r  c a s e s  w e r e  e x a m i n e d  f o r  E G F R  
a n d  H E R - 2  e x p r e s s i o n ,  w e  f o u n d  t h a t  8 3  a n d  8 9 %  o f  t h e  c a s e s  
w e r e  p o s i t i v e ,  r e s p e c t i v e l y  ( T a b l e  I I ) .  I n  a d d i t i o n ,  c o e x p r e s s i o n  
o f  t h e  t h r e e  r e c e p t o r s  w a s  p r e s e n t  i n  7 5 %  o f  t h e  c a s e s .  
I n t e r e s t i n g l y ,  i n  a  r e c e n t  s t u d y  b y  S i n g e r  a n d  c o l l e a g u e s  ( 2 1 )  
I G F - I R ,  E G F R  a n d  H E R - 2  w a s  d e t e c t e d  i n  o n l y  3 %  ( 2 / 6 8  
p a t i e n t s ) ,  3 9 %  ( 2 7 / 6 9  p a t i e n t s )  a n d  4 %  ( 3 / 6 8  p a t i e n t s )  o f  a  
s e r i e s  o f  7 5  c o l o r e c t a l  c a n c e r  p a t i e n t s ,  r e s p e c t i v e l y .  H o w e v e r ,  
t h e  l o w e r  l e v e l s  o f  r e c e p t o r s  d e t e c t e d  i n  t h a t  s t u d y  m a y  b e  
a t t r i b u t a b l e  t o  t h e  u s e  o f  t i s s u e  m i c r o a r r a y ,  w h i c h  a n a l y s e s  a  
s m a l l e r  r e g i o n  o f  t h e  h e t e r o g e n e o u s  t u m o u r  b i o p s y .  I n  a d d i t i o n ,  
t h e r e  w a s  n o  i n v e s t i g a t i o n  o n  t h e  a s s o c i a t i o n  b e t w e e n  r e c e p t o r  
e x p r e s s i o n  a n d  o v e r a l l  s u r v i v a l  i n  t h a t  s t u d y .  I n  o u r  p r e s e n t  
s t u d y ,  w e  f o u n d  n o  s i g n i f i c a n t  a s s o c i a t i o n  b e t w e e n  t h e  
e x p r e s s i o n  o f  E G F R ,  H E R - 2 ,  o r  r e c e p t o r  c o e x p r e s s i o n  a n d  
c l i n i c o p a t h o l o g i c a l  p a r a m e t e r s  o r  w i t h  o v e r a l l  s u r v i v a l  
( T a b l e  I  a n d  F i g .  2 ) .  W e  h a v e  r e p o r t e d  r e c e n t l y  t h a t  c y t o ­
p l a s m i c  e x p r e s s i o n  o f  E G F R  a n d  t h e  t y p e - H I  d e l e t i o n  m u t a n t  
E G F R  ( E G F R v i n )  i s  a s s o c i a t e d  w i t h  i m p r o v e d  o v e r a l l  s u r v i v a l  
i n  D u k e s '  C  c o l o r e c t a l  c a n c e r  p a t i e n t s  r e c e i v i n g  r a d i o t h e r a p y  
( 2 8 ) .  H e r e i n ,  t h e  e x p r e s s i o n  o f  E G F R  a n d  i t s  c o e x p r e s s i o n  
w i t h  H E R - 2 ,  o r  H E R - 2  a n d  I G F - I R  w a s  a l s o  a s s o c i a t e d  w i t h  
i m p r o v e d  o v e r a l l  s u r v i v a l  i n  p a t i e n t s  r e c e i v i n g  r a d i o t h e r a p y  
( d a t a  n o t  s h o w n ) .
I n  t h e  p a s t  s e v e n  y e a r s ,  s e v e r a l  g r o w t h  f a c t o r  r e c e p t o r -  
s p e c i f i c  p r o d u c t s ,  i n c l u d i n g  t h e  a n t i - H E R - 2  a n t i b o d y  
t r a s t u z u m a b ,  t h e  a n t i - E G F R  a n t i b o d y  c e t u x i m a b ,  a n t i - V E G F  
a n t i b o d y  a v a s t i n ,  a n d  t y r o s i n e  k i n a s e  i n h i b i t o r s  g e f i t i n i b  a n d  
e r l o t i n i b ,  h a v e  b e e n  a p p r o v e d  f o r  t h e  t r e a t m e n t  o f  c a n c e r  
p a t i e n t s  ( 2 6 , 2 7 ) .  H o w e v e r ,  t h e  r e s u l t s  o f  c l i n i c a l  t r i a l s  w i t h  
t h e  E G F R  i n h i b i t o r s  h a v e  o n l y  r e s u l t e d  i n  a  r e s p o n s e  o f  a  
s h o r t  d u r a t i o n  i n  a  s m a l l  s u b p o p u l a t i o n  o f  p a t i e n t s ,  a n d  t h e r e  
h a s  b e e n  n o  c l e a r  c o r r e l a t i o n  b e t w e e n  E G F R  l e v e l s  a n d  
r e s p o n s e  t o  t h e  E G F R  i n h i b i t o r s  ( 2 6 , 2 7 , 2 9 , 3 0 ) .  I n  a d d i t i o n ,  
s i n c e  t h e  e x p r e s s i o n  o f  I G F - I R  h a s  b e e n  a s s o c i a t e d  w i t h  
r e s i s t a n c e  t o  a n t i - E G F R  a n d  a n t i - H E R - 2  t h e r a p i e s  i n  t h e  
e x p e r i m e n t a l  s e t t i n g  ( 1 2 - 1 5 )  a n d  o u r  r e s u l t s  h e r e i n  i n d i c a t e  
t h a t  c o e x p r e s s i o n  o f  t h e  I G F - I R ,  E G F R  a n d  H E R - 2  i s  
c o m m o n  i n  p a t i e n t s  w i t h  D u k e s '  C  c o l o r e c t a l  c a n c e r ,  f u r t h e r  
i n v e s t i g a t i o n  o n  t h e  t h e r a p e u t i c  b e n e f i t  o f  c o - t a r g e t i n g  s u c h  
r e c e p t o r s  i n  c o l o r e c t a l  c a n c e r  p a t i e n t s  i s  w a r r a n t e d .
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